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Voorwoord 
 
Beste lezer, dit proefschrift behandelt verschillende aspecten van “dyspepsie”, 
vandaar het eerste stuk van de titel. Het “et al.” in de titel is een knipoog naar het “et 
al.” (=“en anderen”), zoals dat vaak gebruikt wordt bij verwijzingen naar 
publicaties. Echter in dit geval symboliseert het de diversiteit van dit proefschrift 
(=“en andere dingen”). Het verwijst niet alleen naar de veelvormigheid van het 
ziektebeeld dyspepsie (dyspepsie is immers geen duidelijk afgebakende ziekte, maar 
veel meer een complex van klachten waarvan wordt aangenomen dat ze uit het 
bovenste deel van het spijsverteringsstelsel komen), maar ook naar de diversiteit aan 
thema’s (van etiologie, patientenselectie en effectiviteit van interventies tot 
behandelstrategieën) en de diversiteit aan methoden (van simpele prevalentiestudies 
en ongecontroleerde interventiestudies, via meta-analyses, tot gerandomiseerde 
trials). Ik wens u veel leesplezier! 
 
 
 
 
 
Marcel Janssen 
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Dyspepsia 
 
The term “dyspepsia” does not refer to a well-defined disease, but merely to a 
cluster of symptoms thought to arise in the upper gastrointestinal tract.1 It comprises 
symptoms such as epigastric pain, heartburn, regurgitation, pain before/after meals, 
belching, bloating, burping, abdominal fullness, early satiety, nausea, and vomiting. 
The often cited Rome II definition excludes patients with predominant heartburn, as 
these patients are considered to suffer from gastro-oesophageal reflux disease.2 
However, many others consider heartburn to be an integral symptom of dyspepsia 
because in clinical practice predominant reflux symptoms and upper abdominal 
symptoms often can not reliably be distinguished. This broader definition which 
better reflects clinical practice, especially in primary care, will be used in this thesis. 
 
 
Disease burden 
 
Regardless of the definition used, dyspeptic symptoms are very common. It is 
estimated that in Western countries some 20-40% of the general population suffer 
from dyspeptic symptoms each year.3,4 Although most of these people do not seek 
medical attention, half of them regularly use over-the-counter medication.5 About 
one in four consult their general practitioners and these visits account for 2-5% of all 
consultations in primary care. Moreover, about 25% of primary care patients are 
referred for further investigation or to a secondary care physician within the same 
year.6-8 Furthermore, drugs for treatment of dyspeptic symptoms are among the most 
frequently used drugs. In 2001 in The Netherlands more than €400,000,000 (13% of 
the pharmaceutical budget) was spent on these drugs and this sum had increased by 
40% during the previous 5 years.9 Thus, dyspepsia is an important health issue.10 
 
 
Upper gastrointestinal pathology 
 
The aetiology of dyspeptic symptoms is a complex interplay of a variety of 
mechanisms, such as mucosal damage, mucosal defence, mucosal sensitivity, 
gastrointestinal motility, acid production, lower oesophageal sphincter function, etc. 
These mechanisms may in turn be influenced by certain genetic predispositions, 
stress, viral or bacterial infections, medication, and lifestyle factors. 
Traditionally, the underlying pathology is divided into four major entities: gastro-
oesophageal reflux disease, peptic ulcer disease, gastro-oesophageal malignancy, 
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and by exclusion of (detectable) organic pathology “functional (or non-ulcer) 
dyspepsia”. Of course there are other organic diagnoses, but these are either rare 
(e.g. achalasia, oesophageal webs, etc.) or of little clinical importance (e.g. hiatal 
hernia, gastritis, etc.). 
The relative distribution of upper gastrointestinal pathology varies geographically 
and in time. Usually, oesophagitis is the most common organic diagnosis at 
endoscopy (10-30%), followed by peptic ulcer disease (5-15%), while gastro-
oesophageal malignancy is rare (0-2%).11-14 A further 10% will have non-erosive 
reflux disease detected by oesophageal pH monitoring.2 Therefore, the majority of 
patients (50-70%) will have normal or insignificant findings and will be diagnosed 
with “functional dyspepsia”.11,14 
Furthermore, the incidence of underlying disease seems to be changing in time, with 
a decreasing prevalence of peptic ulcer disease and an increasing prevalence of 
gastro-oesophageal reflux disease.15 The former is probably associated with the 
decreasing prevalence of H. pylori infection, while the latter may be associated with 
the increasing body mass index and the changes in lifestyle seen in many Western 
populations.16,17 
This decrease in the prevalence of peptic ulcer disease has also been described in 
The Netherlands.18 In a population of 861 patients studied between 1986 and 1988 
the prevalence of peptic ulcer disease was 19.8%, while in a population of 1,286 
primary care patients referred for upper gastrointestinal endoscopy in 2004 the 
prevalence of peptic ulcer disease was 5.7%. In the latter population, the prevalence 
of gastro-oesophageal reflux disease was 22% and of gastro-oesophageal 
malignancy was 1.8%. 
 
 
Symptoms vs. endoscopic diagnosis 
 
Ideally, therapy should focus on correcting the underlying pathophysiological 
mechanism, but unfortunately symptoms are notoriously unreliable for identifying 
this mechanism, firstly because most patients have a variety of symptoms and these 
symptoms may vary in time, secondly because these symptoms poorly discriminate 
between the various endoscopic diagnoses, and thirdly because the severity of the 
symptoms hardly correlates with the degree of mucosal damage. 
Regarding the first argument, a Canadian study (by Thomson et al.) investigating 
1,040 primary care patients with uninvestigated dyspepsia showed that nearly all 
patients had at least three dyspeptic symptoms at baseline, and more than 80% had 
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at least 6.13 Our own results of a population of almost 200 primary care patients 
show that nearly all patients reported more than one symptom, on average nine 
symptoms.21 (chapter 9 of this thesis) Furthermore, the pattern and severity of symptoms may 
vary in time. 
Regarding the second argument, it has been suggested that it would be better to 
cluster the symptoms into subgroups: ulcer-like, dismotility-like, or reflux-like 
dyspepsia.22 However, this proved difficult in practice since there is considerable 
overlap between these subgroups. Again Thomson et al. showed that the prevalence 
of gastric/duodenal findings was similar in all subgroups: most patients had 
functional dyspepsia, while oesophagitis was the most common organic diagnosis, 
followed by peptic ulcer disease.13 Only the prevalence of gastro-oesophageal reflux 
disease was somewhat higher in the reflux-like subgroup. Therefore, there is some 
association between the presence of heartburn and gastro-oesophageal reflux 
disease, but even in patients with heartburn as the only dyspeptic symptom peptic 
ulcer disease can not be excluded. Cadet studie: % ulcera bij mensen met reflux. 
Indeed peptic ulcer disease can present with heartburn as the sole or predominant 
complaint.23 Others have suggested predictive scoring systems combining multiple 
patient factors in order to predict findings at endoscopy, but these results proved 
difficult to repeat in other populations and these scoring systems are too complicated 
for use in routine clinical practice.24,25 
Regarding the third argument, in patients with severe symptoms often no mucosal 
pathology can be detected at upper gastrointestinal endoscopy, while many erosions 
or ulcers are found during routine endoscopy of asymptomatic individuals. For 
example Lu et al. showed that of all peptic ulcers found during endoscopy for a 
routine health maintenance program, as many as two thirds were asymptomatic.26 
Therefore, symptoms are poor indicators of the underlying pathology. This was 
recently demonstrated by Van Kerkhoven et al.27 This is further supported by several 
studies showing no differences in the prevalence of endoscopic pathology between 
primary and secondary care patients, even though the latter are more selected.11 
 
 
Therapy for dyspepsia 
 
Patients with mild symptoms or symptoms of short duration can often be managed 
with supportive care or with simple antacids, and have a good prognosis. Regardless 
of therapy some 70% of patients with uninvestigated dyspeptic symptoms will 
experience symptom improvement or resolution within one year.28 For patients with 
more severe symptoms or with persisting/recurrent symptoms there are several 
therapeutic options: acid suppression, H. pylori eradication (if infected), and 
prokinetic therapy. 
 
Acid suppression 
With the H2-receptor antagonists the first 
effective acid-suppressive medication 
became available. These drugs block the 
histamine-2 receptor which regulates 
histamine stimulated acid production, but 
unfortunately they are hampered by 
pharmacological tolerance.29 The more 
recently introduced proton pump 
inhibitors directly block the acid pumps in the stomach and provide much more 
powerful acid suppression. They proved to be very effective for treatment of gastro-
oesophageal reflux disease and peptic ulcer disease.29-31 However, in the majority of 
patients the disease relapses after cessation of therapy. Moreover, for patients with 
functional dyspepsia acid suppression is only slightly more effective than placebo.32 
Figure 1 
 
H. pylori eradication 
In 1984 Warren and Marshall radically changed the 
view of the aetiology of peptic ulcer disease by their 
rediscovery of H. pylori (Figure 2).33 They showed 
that H. pylori was able to survive in the stomach and 
that almost all patients with peptic ulcer disease 
were infected with H. pylori. Since then, much 
research has been dedicated to the role of H. pylori 
(and H. pylori eradication) in patients with dyspeptic 
symptoms. It became clear that infection with H. 
pylori invariably caused chronic gastritis (which 
may be asymptomatic), and could progress to more 
serious disease, such as peptic ulcer disease and 
complications or gastric cancer, in susceptible 
patients. Furthermore, it became clear that nearly all duodenal ulcers and the 
majority of gastric ulcers were associated with H. pylori infection, and that H. pylori 
eradication cured the ulcers and prevented ulcer relapse.34 But for H. pylori positive 
Figure 2 
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functional dyspepsia, H. pylori eradication proved to provide long term 
improvement only in some 10% of patients.35 Moreover, it was shown that chronic 
corpus gastritis due to H. pylori is associated with the development of atrophic 
gastritis and eventually gastric cancer, a process which probably can be halted by 
timely (i.e. before the development of mucosal atrophy) H. pylori eradication.36-38 
 
Prokinetics 
Prokinetics proved to be of some value, especially for patients with functional 
dyspepsia. However, the majority of studies regarding prokinetics are of low quality, 
which makes the results difficult to interpret.39 Furthermore, research focused on 
cisapride, which has been withdrawn from the market because of its cardiac side 
effects. There are only limited data available for other prokinetics, such as 
domperidone.39 But new prokinetics are being developed and some promising agents 
such as itopride may soon reach the market. 
 
 
How to treat patients with dyspeptic symptoms? 
 
Ideally, therapy should correct the underlying pathophysiological mechanism. 
Unfortunately, as described above, symptoms poorly correlate with upper 
gastrointestinal pathology. Endoscopy provides more information, but is 
troublesome to the patient and associated with considerable costs, while in two 
thirds of patients no organic abnormalities are found.9,10 Therefore, strategies were 
designed in which patients are managed without prior endoscopy. Several studies 
showed that such strategies were as effective as prompt endoscopy followed by 
targeted treatment, but cost less.40 
The most widely used strategies without endoscopy are empirical acid-suppressive 
treatment and the H. pylori test-and-treat strategy, which will only briefly be 
introduced in this chapter. Empirical acid inhibition is attractive because it is simple 
and provides immediate symptom relief in many patients, although symptoms often 
relapse after cessation of therapy.40,41 Unfortunately, there are few prospective 
studies comparing empirical acid suppression with other treatment strategies. In the 
H. pylori test-and-treat strategy all patients have a non-invasive H. pylori test. Those 
testing infected receive antibiotics to eliminate the infection, those not infected 
usually receive a course of acid suppressive medication.42 These treatment strategies 
will be elaborately discussed in the other chapters of this thesis. 
 
Dyspepsia guidelines 
 
During the past fifteen years, many different guidelines for treatment of patients 
with dyspeptic symptoms have been developed.42-48 Most of these guidelines have a 
similar structure. Firstly, nearly all guidelines single out patients with alarm 
symptoms such as weight loss, disturbed food passage, signs or symptoms of upper 
gastrointestinal bleeding, and persistent vomiting for direct endoscopy. Secondly, 
they usually specify a certain age above which prompt endoscopy is advised in order 
not to miss patients with gastrooesophageal cancer, the prevalence of which 
increases with age. Finally, treatment without endoscopy (usually H. pylori test-and-
treat) is advised for young patients without alarm symptoms. 
 
Reflux-predominant 
symptoms 
H2-RA 
Prompt 
endoscopy 
Persisting or 
recurrent? 
Dyspeptic symptoms 
Alarm 
symptoms? 
Other symptoms 
Need for diagnostic 
evaluation 
Hp eradication 
Hp-test 
Prompt 
endoscopy Oesophagitis 
Referral 
Ulcer 
Cancer 
Normal 
PPI-trial 
H2-RA 
PPI-trial 
Hp eradication 
PPI-trial 
Yes 
No 
Yes 
- 
+ 
No 
 
Figure 3. Schematic of the Dutch dyspepsia Guideline 
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The Dutch Dyspepsia guideline, published in 2004, uses a more individualized 
approach (figure 3). Again patients with alarm symptoms are referred for immediate 
endoscopy, but there is no specific age cut-off. Furthermore, there is no uniform 
treatment strategy for all patients: the decision whether to use empirical acid 
suppression, H. pylori test-and-treat, or direct endoscopy is left to the general 
practitioner and the patient.47,48 
 
 
Questions remain 
 
Despite the enormous amount of research regarding dyspepsia and despite all 
guidelines many questions remain unanswered. This is caused by several problems. 
Firstly, because there are inconsistencies in the current evidence often caused by the 
abundance of small, underpowered studies on the same subject reaching 
contradictory conclusions. Secondly, because the study outcome may be so rare (e.g. 
gastro-oesophageal cancer) that very large cohorts need to be investigated for 
definite conclusions to be drawn, which may not be feasible in clinical practice. In 
these cases systematic reviews and, if possible, meta-analyses may be helpful. 
Thirdly, because there are large differences in the studied populations with regard to 
age, prevalence of H. pylori infection, use of NSAIDs, etc. And fourthly, because 
randomized head-to-head comparisons of management strategies are lacking, which 
makes it impossible to draw evidence-based conclusions. And finally, because 
several factors vary geographically or in time, recent regional data are necessary (but 
not always available) for the development of adequate guidelines. Therefore, many 
aspects of the current guidelines are not fully evidence-based: on many topic they 
merely reflect the consensus reached among their authors, rather than evidence. 
 
 
Aims and outline of this thesis 
 
The aim of this thesis was to investigate various aspects of dyspepsia in The 
Netherlands in order to improve treatment of Dutch patients with dyspeptic 
symptoms. 
In chapter 2 the use of the widely accepted alarm symptoms for selection of patients 
for endoscopy in order to detect gastro-oesophageal malignancy is questioned in a 
meta-analysis using individual patient data. In chapter 3 the role of genetic 
polymorphisms in gastric mucins for susceptibility to H. pylori infection is studied. 
In chapter 4 the prevalence of antibiotic resistant H. pylori is described for two 
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Dutch regions. In chapter 5 several aspects of H. pylori eradication are studied. 
Firstly, the effectiveness of two widely used regimens for treatment of H. pylori 
infection is compared by means of a meta-analysis. Then the issue of proton pump 
inhibitor pre-treatment as a cause of failure of H. pylori eradication is addressed 
both by means of a randomized pilot study and a meta-analysis, and finally the 
effectiveness of H. pylori eradication and the influence of a H. pylori test-and-treat 
strategy in routine daily practice in The Netherlands are evaluated. In chapter 7 the 
effectiveness of proton pump inhibitor therapy in primary care patients and the 
influence of acetyl salicylic acid or non-steroidal anti-inflammatory drugs on proton 
pump inhibitor effectiveness are investigated. In chapter 8 the benefits of H. pylori 
test-an-treat and proton pump inhibitor therapy are combined into two multi-step 
treatment strategies (one starting with H. pylori test-and-treat followed by proton 
pump inhibitor therapy in case of persisting/recurrent symptoms, the other starting 
with proton pump inhibitor therapy followed by H. pylori test-and-treat in case of 
persisting/recurrent symptoms) which are compared in a randomized clinical trial. 
Finally, in chapter 9 a personal view on dyspepsia management is presented, based 
on data from the literature as well as data from this thesis. 
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Abstract 
 
Background: Alarm symptoms are widely used for selection of patients with a high 
risk of having gastro-oesophageal cancer, but the supporting evidence is not 
consistent. Therefore, we performed a meta-analysis using individual patient data. 
Methods: Medline was searched for studies measuring alarm symptoms in 
primary/secondary care patients having upper gastrointestinal endoscopy. If 
possible, the original databases from all selected papers were retrieved, recoded, and 
combined. 
Results: Of the 10 selected papers, patient data could be retrieved from 7, resulting 
in a combined database of 13,377 patients (mean age 52 years (SD: 17), 48% male). 
Overall, there were 166 (1.2%) patients with cancer: 133 gastric and 33 oesophageal 
cancers. Of these patients, 103 had alarm symptoms (weight loss, disturbed food 
passage, signs/symptoms of upper gastrointestinal bleeding, or persistent vomiting). 
Overall 3,927 (29.9%) patients had alarm symptoms and 9,205 patients had no alarm 
symptoms. This resulted in a sensitivity of 62.0%, a specificity of 70.5%, a positive 
predictive value of 2.6%, and a negative predictive value of 99.3% for having “any 
alarm symptom”. Of the 166 patients with cancer, 19 (11.4%) were younger than 50 
years, of which 11 (57.9%) reported alarm symptoms. 
Conclusions: More than a third of patients with gastro-oesophageal cancer had no 
alarm symptoms, while only few of the patients with alarm symptoms had cancer. 
Therefore, alarm symptoms are far from ideal for selection of patients at risk. Other 
factors such as age, H. pylori status, gender, and presence of heartburn should also 
be taken into account when estimating each individual’s risk. 
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Introduction 
 
Dyspeptic symptoms are common in the general population.1 They may be 
associated with gastric or oesophageal pathology such as gastro-oesophageal reflux 
disease, peptic ulcer disease and, rarely, gastro-oesophageal malignancy.2 Upper 
gastrointestinal endoscopy provides most information about the underlying cause 
but is expensive, troublesome to the patient, and in more than 50% of endoscopic 
examinations no organic disease can be identified. Therefore, non-invasive treatment 
strategies such as H. pylori test-and-treat or empirical treatment with acid 
suppressants have been proposed, and it has become clear that these are as effective 
as upper gastrointestinal endoscopy followed by targeted treatment.3-6 Thus, a 
growing number of patients are treated without upper gastrointestinal endoscopy. 
However, it is important not to delay diagnosis in patients with gastro-oesophageal 
malignancy. Therefore, it has become increasingly important to be able to select 
patients with a high risk of gastro-oesophageal cancer for immediate endoscopy. For 
this selection alarm symptoms such as weight loss, disturbed food passage, signs and 
symptoms of upper gastrointestinal bleeding, and persistent vomiting are generally 
accepted; most guidelines recommend immediate endoscopy in all patients with 
alarm symptoms.7-9 
However, the evidence supporting the use of alarm symptoms as a selection criterion 
for endoscopy is inconsistent. Although several retrospective case series reported 
that most patients with gastro-oesophageal cancer had one or more alarm symptoms, 
some studies investigating cohorts of patients with dyspeptic symptoms were less 
conclusive.10,11 Therefore, more research is necessary to definitely establish the 
value of alarm symptoms. 
Due to the low prevalence of gastric and oesophageal cancer, large populations are 
needed for such research. This can be overcome by performing meta-analysis, 
although traditional meta-analysis is hampered by several drawbacks. In particular, 
only outcomes reported in the original papers can be analyzed, and various 
investigators may use different definitions and analyses which may make it 
impossible to combine the results. 
These problems can be overcome by going back to the source: the individual patient. 
In a meta-analysis of individual patient data, the original databases are combined 
and reanalyzed. Furthermore, outcomes and subgroups can be re-defined and all 
registered variables can be used in the analysis. Therefore, the aim of this study was 
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to investigate the value of alarm symptoms for selection of patients with gastric or 
oesophageal malignancy by means of a meta-analysis using individual patient data. 
 
 
Methods 
 
Search strategy 
A bibliographical search was performed in the Medline database (to September 
2004) in order to identify studies investigating alarm symptoms and upper 
gastrointestinal malignancy. The search was based on the key words “alarm” or 
“sinister” and “malignancy”. Furthermore, reference lists of all identified trials and 
reviews were searched to identify other relevant studies. All abstracts were 
examined for eligibility by two independent reviewers. Disagreements were resolved 
by consulting a third independent reviewer. 
 
Inclusion criteria 
Population: adult primary and/or secondary care patients 
Diagnosis: upper gastrointestinal endoscopy (in all patients) 
Directionality: prospective, alarm symptoms had to be registered before the 
endoscopy 
 
Data recoding 
The original databases of the selected papers were retrieved. From each database 
data regarding age, gender, presence of alarm symptoms, and diagnosis at upper 
gastrointestinal endoscopy were retrieved. Alarm symptoms were defined as: weight 
loss, disturbed food passage, symptoms indicating upper gastrointestinal bleeding 
(haemathemesis, melena) and/or anaemia, and persistent vomiting. Diagnoses were 
categorized as: gastric cancer, oesophageal cancer, oesophagitis, gastric ulcer, 
duodenal ulcer, and Barrett’s oesophagus. Malignancy had to be confirmed by 
histology. Additionally, if available, data regarding smoking behaviour, alcohol 
consumption, use of acetylsalicylic acid (ASA) and/or non-steroidal anti-
inflammatory drugs (NSAIDs), presence of heartburn, epigastric pain, and H. pylori 
status were retrieved. Due to limitations of the source data, all variables (except age) 
were dichotomized (being either present or absent). Patients without endoscopy 
results were excluded. In case of multiple endoscopic examinations of the same 
patient, only the first examination was included in the final database. 
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Analysis 
The prevalence of alarm symptoms was compared for patients with and without 
gastro-oesophageal cancer, both for the individual alarm symptoms mentioned 
above and for having any of these alarm symptoms. Sensitivity, specificity, positive 
and negative predictive values (PPV/NPV) of having “any alarm symptom” for 
gastro-oesophageal cancer were calculated. Furthermore, other patient 
characteristics such as age, gender, H. pylori status, smoking, alcohol consumption 
and use of ASA/NSAIDs were compared for patients with and without gastro-
oesophageal cancer. Additionally, all variables were included in adjusted logistic 
regression analysis. Because only alarm symptoms, age, and gender were available 
for all patients, dummy variables were constructed for the missing values of the 
other patient characteristics. All analyses were performed with the SAS® statistical 
software package (SAS Institute Inc., Minneapolis, Minnesota, USA). Statistical 
significance was defined as a p-value<0.05. 
 
 
Results 
 
Selection of studies 
The bibliographical search resulted in 340 hits in Medline. Only 10 of these studies 
fulfilled the predefined inclusion criteria and the authors of these papers were 
invited to participate. For three studies, investigating a total of 4,829 patients, the 
original data were not available any more.12-14 The remaining 7 papers (table 1) were 
included in this meta-analysis.15-21 
 
Table 1. Characteristics of the included studies 
Study Study period Region N Gastro-
oesoph. 
cancer 
Manes, et al.15 1998 Italy 697 0.9% 
Adang, et al.16 1988-1990 The Netherlands 2,842 2.4% 
Voutilainen, et al.17 1996 Finland 3,665 0.9% 
Hammer, et al.18 1994-1998 Australia 526 0.0% 
Sung, et al.19 1998-1999 China (Hong Kong) 2,626 0.9% 
Numans, et al.20 1986-1994 The Netherlands 1,982 1.8% 
Thomson, et al.21 1999-2000 Canada 1,039 0.2% 
 
Combined study population 
The combined database included 13,377 patients (mean age 52 years (SD: 17), 6,085 
(45.6%) patients under 50 years, 6,295 (47.6%) males). In 8,992 (67.2%) patients no 
organic disease was found at upper gastrointestinal endoscopy. For the remaining 
patients, figure 1 shows the prevalence of the various diagnoses. There were 166 
patients (1.2%) with upper gastrointestinal cancers (133 (1.0%) gastric, 33 (0.2%) 
oesophageal). 
 
Figure 1. Endoscopic diagnoses (% of study population) 
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Alarm symptoms for gastro-oesophageal cancer 
Table 2 shows that patients with gastro-oesophageal cancer more often had alarm 
symptoms than patients without cancer, but that the sensitivity of each individual 
alarm symptom was low: it ranged from 12% for persistent vomiting to 29% for 
weight loss.  
 
Table 2. Prevalence of individual alarm symptoms in patients with and without 
gastro-oesophageal cancer. 
  Gastro-oesophageal cancer 
  Yes (N=166) 
n (%) 
No (N=13,211) 
n (%) 
Weight loss* 48 (28.9%) 780 (6.0%)) 
Disturbed food passage* 41 (24.7%) 1,213 (9.4%) 
Anaemia and/or bleeding* 35 (21.1%) 1,649 (12.6%) 
Persistent vomiting* 20 (12.1%)11 954 (7.3%)6 
*p<0.05 
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Sensitivity increased when the alarm symptoms were combined into the outcome 
“any alarm symptom”. Figure 2 shows that of the 166 patients with gastro-
oesophageal cancer 103 had one or more alarm symptoms. Therefore, the sensitivity 
of having “any alarm symptom” was 62.0% (95%CI: 54.7%-69.4%). Of the 12,966 
patients without gastro-oesophageal cancer 9,142 did not have any alarm symptom, 
yielding a specificity of 70.5% (95%CI: 69.7%-71.3%). Furthermore, of the 3,927 
(29.9%) with an alarm symptom 103 had gastro-oesophageal cancer, yielding a 
positive predictive value of 2.6% (95%CI: 2.1%-3.1%). Analogously, the negative 
predictive value was 99.3% (95%CI: 99.1%-99.5%) because 9,142 of the 9,205 
patients without any alarm symptom did not have gastr0-oesophageal cancer. If 
“persistent vomiting” was not used as an alarm symptom the results were 
comparable: sensitivity 60.8% (95%CI: 53.4%-68.3%), specificity 74.4% (95%CI: 
73.6%-75.1%), PPV 3.0% (95%CI: 2.4%-3.5%), NPV 99.3% (95%CI: 99.2%-
99.5%), while 3,419 (26.1%) patients had one or more alarm symptoms. 
When looking at the relationship between the number of alarm symptoms and the 
presence of gastro-oesophageal cancer it could be calculated that of the 2,740 
patients with 1 alarm symptom 56 (2.0%) had gastro-oesophageal cancer, of the 994 
with 2 alarm symptoms 39 (3.9%) had gastro-oesophageal cancer, of the 78 with 3 
alarm symptoms 7 (9.0%), and ironically of the 4 with all four alarm symptoms none 
had gastro-oesophageal cancer. 
 
Figure 2. Alarm symptoms for selection of patients with gastro-oesophageal cancer. 
  
Gastro-
oesophageal cancer 
 
  
  Yes No    
Y
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s 
103 3,824 3,927 Any 
alarm 
symptom* N
o 
63 9,142 9,205 
Sensitivity: 
Specificity: 
PPV: 
NPV: 
62.0% (54.7%-69.4%) 
70.5% (69.7%-71.3%) 
2.6% (2.1%-3.1%) 
99.3% (99.1%-99.5%) 
  166 12,966 13,132   
       
*weight loss, disturbed food passage, symptoms indicating upper gastrointestinal bleeding and/or 
anaemia, persistent vomiting 
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Alarm symptoms for any organic diagnosis 
Figure 3 shows that the value of alarm symptoms for selection of patients with any 
organic diagnosis (i.e. oesophagitis, peptic ulcer disease, Barrett’s oesophagus, 
gastro-oesophageal malignancy, or other rare pathology such as Schatzki’s rings, 
etc.) is disappointing. Although the prevalence of organic disease is slightly higher 
in patients with alarm symptoms (37.6% vs. 30.7%, p<0.0001), in 2,451 (62.4%) of 
the 3,927 patients with alarm symptoms no organic pathology was detected. 
 
Figure 3. Alarm symptoms for organic disease 
  Organic disease    
  Yes No    
Y
e
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1,476 2,451 3,927 Any 
alarm 
symptom* N
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2,827 6,378 9,205 
Sensitivity: 
Specificity: 
PPV: 
NPV: 
34.3% (32.9%-35.7%) 
72.2% (71.3%-73.2%) 
37.6% (36.1%-39.1%) 
69.3% (68.3%-70.2%) 
  4,303 8,829 13,132   
       
*weight loss, disturbed food passage, symptoms indicating upper gastrointestinal bleeding and/or 
anaemia, persistent vomiting 
 
Age cut-off 
Figure 4 shows that there was no clear age cut-off for gastro-oesophageal cancer 
since the angle of inclination of the graph showing the cumulative number of 
patients with gastro-oesophageal cancer slowly increased between the ages of 30 
and 60, reaching a maximum at the age of 70 years. Nine-teen of 166 patients 
(11.4%) with gastro-oesophageal cancer were less than 50 years of age. Eight of 
these patients (42.1%) did not have any alarm symptom, while 1,532 (25.6%) of 
patients <50 years reported alarm symptoms. Therefore, in patients under 50 years 
of age the sensitivity of alarm symptoms was 57.9% (95%CI: 35.7-80.0%), the 
specificity was 74.5% (95%CI: 73.4-75.6%), the PPV was 0.7% (95%CI: 0.3-1.1%), 
and the NPV was 99.8% (95%CI: 99.7-99.9%), with a 0.3% prevalence of gastro-
oesophageal cancer. 
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Figure 4. Cumulative number of patients with gastro-oesophageal cancer vs. age 
with the cumulative number of endoscopies vs. age as a reference. 
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Of the 147 patients with gastro-oesophageal cancer over 50 years of age 55 (37.4%) 
did not report any alarm symptom, while 2,377 (33.4%) of patients in this age group 
reported alarm symptoms. Therefore, in patients over 50 years of age the sensitivity 
was 62.6% (95%CI: 54.8-70.4%), the specificity was 67.3% (95%CI: 66.2-68.4%), 
the PPV was 3.9% (95%CI: 3.1-4.6%) and the NPV was 98.8% (95%CI: 98.5-
99.1%), for a 2.1% prevalence of gastro-oesophageal cancer. 
Because the majority of patients with gastro-oesophageal cancer were over 50 years 
of age the sensitivity and NPV can be increased to 95.2% (95%CI: 91.9-98.4%) and 
99.8% (95%CI: 99.7-99.9%) resp. by adding “age over 50” to the alarm symptoms. 
However, at the cost of the specificity and PPV (34.0% (95%CI: 33.1-34.8%) and 
1.8% (95%CI: 1.5-2.1%), resp.) since 8,811 (66.4%) of all patients had an alarm 
symptom or were older than 50 years. 
The importance of age can be illustrated by using age ≥50 as sole selection criterion 
which had a sensitivity of 88.6% (95%CI: 83.7-93.4%), a specificity of 46.0% 
(95%CI: 45.2-46.9%), a PPV of 2.0% (95%CI: 1.7-2.3%), and a NPV of 99.7% 
(95%CI: 99.5%-99.8%), while 7,261 patients (54.4%) were 50 years of age or older. 
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Other patient factors 
In table 3 the prevalence of other patient characteristics are compared for patients 
with and without gastro-oesophageal cancer. Unfortunately, besides age, gender, and 
the four alarm symptoms, none of the other characteristics were registered in all 
studies. Therefore, in the second column of this table is described for how many 
patients each variable was available. Male gender and H. pylori infection were 
associated with gastro-oesophageal cancer, while current symptoms of heartburn and 
a history of peptic ulcer disease were associated with a lower risk of having gastro-
oesophageal cancer. Additionally, current use of ASA/NSAIDs was associated with 
a lower chance of a diagnosis of gastro-oesophageal cancer. 
 
Table 3. Prevalence of other characteristics in patients with and without gastro-
oesophageal cancer. 
  Navailable Gastro-oesophageal cancer 
   Yes (N=166) 
n (%) 
No (N=13,211) 
n (%) 
Male gender* 13,214 96 (58.2%) 6,199 (47.5%) 
Current smoking 5,130 22 (40.7%) 1,952 (38.5%) 
Current alcohol consumption 5,106 15 (29.4%) 1,777 (35.2%) 
Use of ASA/NSAIDs* 8,814 5 (4.4%) 896 (10.3%) 
H. pylori infection* 7,789 31 (50.8%) 2,790 (36.1%) 
History of peptic ulcer disease* 5,270 9 (8.6%) 827 (16.0%) 
Heartburn* 7,696 19 (22.6%) 2,977 (39.1%) 
Epigastric pain 7,212 32 (40.0%) 3,389 (47.5%) 
*p<0.05 
 
Adjusted analysis 
Table 4 shows both the unadjusted and adjusted odds ratios for all aforementioned 
variables. The results of the adjusted analysis are comparable with the results of the 
unadjusted analysis. However, the results for persistent vomiting and history of 
peptic ulcer disease were not statistically significant after adjustment. 
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Table 4. Factors associated with gastro-oesophageal cancer. 
Factor Unadjusted analysis Adjusted analysis** 
 Odds 
ratio 
(95% CI) Odds 
ratio 
(95% CI) 
Weight loss 6.35* (4.5-9.0) 5.84* (4.0-8.5) 
Disturbed food passage 3.17* (2.2-4.5) 3.40* (2.3-5.1) 
Anaemia and/or bleeding 1.85* (1.3-2.7) 1.65* (1.1-2.5) 
Persistent vomiting 1.73* (1.1-2.8) 1.63 (0.9-2.8) 
Age ≥50 years 6.60* (4.1-10.7) 5.56* (3.4-9.2) 
Male gender 1.54* (1.1-2.1) 1.59* (1.2-2.2) 
Smoking 1.10 (0.6-1.9) 0.98 (0.5-1.8) 
Alcohol consumption 0.77 (0.4-1.4) 0.90 (0.5-1.7) 
H. pylori infection 1.83* (1.1-3.0) 1.78* (1.1-3.0) 
Use of ASA/NSAIDs 0.40* (0.2-1.0) 0.32* (0.1-0.8) 
History of peptic ulcer disease 0.49* (0.2-1.0) 0.56 (0.3-1.2) 
Heartburn 0.46* (0.3-0.8) 0.49* (0.3-0.9) 
Epigastric pain 0.74 (0.5-1.2) 0.67 (0.4-1.1) 
*p<0.05 
**adjusted for weight loss, disturbed food passage, anaemia and/or bleeding, persistent vomiting, age 
group, gender, smoking, alcohol consumption, H. pylori infection, use of ASA/NSAIDs, history of peptic 
ulcer disease, heartburn, epigastric pain. 
 
 
Discussion 
 
The aim of this meta-analysis was to investigate the use of alarm symptoms for 
selection of patients with gastro-oesophageal malignancy. Individual patient data 
from 7 studies were combined. In the combined population of more than thirteen 
thousand patients the prevalence of gastro-oesophageal malignancy was 1.2%. In 
patients with alarm symptoms this was only moderately higher (2.6%). The results 
show that alarm symptoms are far from ideal for selection of patients with gastro-
oesophageal cancer: firstly, because they are not adequately sensitive; and secondly, 
because the overall prevalence of alarm symptoms is high, while the prevalence of 
gastro-oesophageal cancer is low. 
 
Although the prevalence of alarm symptoms (weight loss, disturbed food passage, 
signs and symptoms of upper gastrointestinal bleeding or anaemia, and persistent 
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vomiting) was higher in patients with gastro-oesophageal cancer, especially for 
weight loss and disturbed food passage, none of the individual alarm symptoms 
identified more than 30% of patients with gastro-oesophageal cancer. When used in 
combination (“having any alarm symptom”) sensitivity increased, but still more than 
a third of all patients with gastro-oesophageal cancer would have been missed. This 
is contradictory to the results of several retrospective case series reporting that more 
than 90% of patients with gastro-oesophageal cancer had alarm symptoms.10 This 
discrepancy may be explained by the fact that the latter patients may have had more 
advanced cancers which are less often asymptomatic,22 as well as by recall bias 
leading to an overestimation of the prevalence of alarm symptoms before 
endoscopy. 
The low sensitivity of alarm symptoms is supported by several other studies. 
Lieberman et al.23 who studied a very large database of endoscopy reports and 
showed that only 56% of patients with gastro-oesophageal cancer had alarm 
symptoms. In that study disturbed food passage was not used as an alarm symptom 
because this was an exclusion criterion. Marmo et al.24 studied over six thousand 
patients (of whom 58 with gastro-oesophageal cancer) and found a sensitivity of 
alarm symptoms of 62%. However, a recent study by Bowrey et al.25 found a 
sensitivity of 85% in a population of four thousand patients (3% prevalence of 
gastro-oesophageal cancer), although they stated that especially patients with 
curable cancers were not found when using alarm symptoms. 
Our results are in concordance with another recent meta-analysis (not using 
individual patient data). Vakil et al.26 found a pooled sensitivity of 67% and a pooled 
specificity of 66% in a large population in which 19% of the patients reported one or 
more alarm symptoms. 
 
Additionally, our data show that many patients, almost a third of the study 
population, reported one or more alarm symptoms. However, if vomiting was not 
taken into account this could be reduced to a quarter of the patients. This still is 
higher than the 11% prevalence of alarm symptoms in primary care patients with 
dyspeptic symptoms reported by Meineche-Schmidt et al.11 This difference can be 
explained by the fact that all patients in our meta-analysis were referred for 
endoscopy, while Meineche-Schmidt studied patient files of primary care patients, 
irrespective of endoscopy. Because having alarm symptoms is one of the indications 
to refer a patient for endoscopy, it seems plausible that the prevalence of alarm 
symptoms was higher in our study population than in the general population. Some 
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degree of selection is also reflected by the relatively high prevalence of gastro-
oesophageal cancer in our study compared to the 0.5% prevalence of gastro-
oesophageal cancers reported by Meineche-Schmidt et al. 
Furthermore, the high prevalence of alarm symptoms may have been caused by the 
special focus on alarm symptoms. Most of the studies included in this meta-analysis 
used questionnaires asking specifically about alarm symptoms which may have led 
to the detection of a higher number of patients with relatively mild alarm symptoms. 
The same phenomenon may explain that Vakil et al.26 also found a high prevalence 
of alarm symptoms in a meta-analysis (19%, not including vomiting as an alarm 
symptom). Notably, Lieberman et al.23 found a lower prevalence of alarm symptoms 
(14.5%) when using routine endoscopy reports. Furthermore, the type of 
questionnaire may also play a role since Marmo et al.24 found a lower prevalence of 
alarm symptoms (7%) even although they also used patient questionnaires and not 
referral indications. Unfortunately, the severity of the alarm symptoms (such as the 
amount of weight loss) could not be taken into account in our analyses because all 
included studies used different definitions of alarm symptoms. However, the relative 
over-reporting of alarm symptoms in our study would not have decreased sensitivity. 
In fact, it would rather have led to an overestimation of the sensitivity (and 
specificity). Therefore, given the high prevalence of alarm symptoms in our study it 
may be deduced that the sensitivity and specificity of alarm symptoms in routine 
clinical practice may be even lower. 
 
Additionally, alarm symptoms may have other causes besides gastro-oesophageal 
cancer, such as peptic ulcer disease. However, in more than 60% of patients with 
alarm symptoms, no organic disease was found at upper gastrointestinal endoscopy, 
and the prevalence of organic disease was only marginally higher than in patients 
without alarm symptoms. Therefore, in the majority of patients the alarm symptoms 
could not be explained by pathology in the upper gastrointestinal tract. 
 
Thus, if of all patients in our database only those with alarm symptoms would have 
had endoscopy, this would have saved about three quarters of all endoscopies, but 
more than a third of all patients with gastro-oesophageal cancer would have been 
missed. And even though the prevalence of gastro-oesophageal cancer was twice as 
high in patients with alarm symptoms as in the study population as a whole, still 
only few of these patients had gastro-oesophageal cancer. In fact, the majority of 
these patients did not even have organic pathology detected at endoscopy. 
 28 
Therefore, besides alarm symptoms, other factors should be taken into account when 
selecting patients for endoscopy. 
 
Our results show that age is an important factor. Unfortunately, there is a gradual 
increase in the risk of gastro-oesophageal cancer without a clear age cut-off, but 
nonetheless, in this population almost 90% of patients with gastro-oesophageal 
cancer were over 50 years of age. Endoscoping all patients over 50 in addition to 
those with alarm symptoms would have increased sensitivity and negative predictive 
value, but at the cost of specificity and positive predictive value. Applying this 
strategy would have saved a third of all endoscopies, while missing 5% of gastro-
oesophageal cancers. In comparison, if only age over 50 would have been used to 
select patients for endoscopy irrespective of the presence of alarm symptoms, this 
would have saved 46% of endoscopies, while 11% of patients with gastro-
oesophageal cancer would have been missed. This emphasizes the important role for 
age. 
Ideally, the exact age cut-off for each setting should be determined using data from 
the local population, since the age distribution of gastro-oesophageal cancer may 
vary. For example Boldys et al.27 showed that in a high-risk tertiary care population 
in Poland as many as 24% of patients with gastric cancer were under 45 years. 
 
Moreover, there were other factors associated with gastro-oesophageal cancer. H. 
pylori infection and male gender were associated with a higher risk of gastro-
oesophageal cancer, while heartburn and current use of ASA/NSAIDs were 
associated with a lower risk. H. pylori infection is a known risk factor for gastric 
cancer and is associated with a 6-8 times higher risk of developing gastric (but not 
oesophageal) cancer.28 The higher risk for males has been confirmed by several 
other studies, but the aetiology is not clear.12,27 Possibly, gender is associated with 
other risk factors. It seemed somewhat surprising that the presence of heartburn was 
associated with a lower risk of gastro-oesophageal cancer, because several studies 
found an association of heartburn with Barrett’s oesophagus and oesophageal 
cancer. However, Lieberman et al.23 found the same protective effect of heartburn 
for gastro-oesophageal cancer. This observation may be explained by the 
predominance of gastric malignancies in our population. And gastric cancer often 
arises from gastric atrophy which is associated with low acid production.29 
Therefore, patients with heartburn symptoms probably have a lower risk of having 
gastric cancer. 
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Interestingly, the use of ASA/NSAIDs was associated with a lower risk of gastro-
oesophageal cancer. Maybe, this can be explained by the role of ASA/NSAIDs in 
several cellular processes such as the induction of cell-cycle arrest, restoration of 
apoptosis and inhibition of angiogenesis.30 The chemo-preventive effect of 
ASA/NSAIDs has been studied most thoroughly for colon cancer, and regular intake 
of ASA/NSAIDs is associated with a decreased risk of developing colon adenomas 
and adenocarcinomas.31 The same mechanism is probably also important for the 
development of other malignancies. Several case-control studies suggest that 
ASA/NSAIDs may have a chemo-preventive effect for oesophageal and gastric 
cancer as well.32-34 Our data further support this hypothesis. Unfortunately, we had 
no data regarding the duration of ASA/NSAID therapy. Therefore, it could not be 
determined whether this effect was limited to long-term users. 
 
In conclusion, more than a third of patients with gastro-oesophageal cancer had no 
alarm symptoms, while only few of the patients with alarm symptoms had gastro-
oesophageal cancer. Therefore, alarm symptoms are far from ideal for selection of 
patients at risk. Other factors such as age, H. pylori infection, gender, use of 
ASA/NSAIDs, and presence of heartburn symptoms should be taken into account 
when estimating each individual’s risk. 
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Abstract 
 
Background: The mucus gel layer provides protection against acid, mechanical 
trauma, and pathogens. The most important components of this layer are large 
glycoproteins named mucins. The genes encoding for these mucins show a variable 
number tandem repeat (VNTR) polymorphism resulting in mucins that substantially 
differ in length and glycosylation. These differences may influence their protective 
properties and may therefore be related to susceptibility to H. pylori infection. 
Therefore the aim of this study was to investigate the relationship between mucin 6 
(MUC6) VNTR length and H. pylori infection. 
Methods: Blood samples were collected from patients visiting the Can Tho General 
Hospital for upper gastrointestinal endoscopy. DNA was isolated from whole blood, 
the repeated section was cut out with a restriction enzyme (PvuII) and the length of 
the allele fragments was determined by Southern blotting. H. pylori infection was 
diagnosed by 14C urea breath test. For analysis, MUC6 allele fragment length was 
dichotomized as being either long (>13.5 kbp) or short (≤13.5 kbp) and patients 
were classified according to genotype (long-long (LL), long-short (LS), short-short 
(SS). 
Results: 160 patients were studied (mean age 43 years, 36% male, 58% H. pylori 
infected). MUC6 PvuII-restricted allele fragment lengths ranged from 7 to 19kbp. Of 
the patients with the LL, LS, SS MUC6 genotype 43% (24/56), 57% (25/58) and 
76% (11/46) were infected with H. pylori, resp. (p=0.003). 
Conclusion: Short MUC6 alleles are associated with H. pylori infection. 
 
Introduction 
 
Helicobacter pylori has the unique ability to colonize the human stomach. Infection 
with H. pylori invariably leads to gastritis and in many instances to peptic ulcer 
disease1 or even gastric cancer.2 It is a common infection throughout the world, with 
prevalences ranging from below 20% in developed countries to over 80% in 
developing countries. Some risk factors for H. pylori infection have been identified, 
such as low socio-economic status or poor hygiene.3 However, there is remarkable 
inter-individual variability in susceptibility to the infection that can not be explained 
by differences in environmental factors. 
Another factor that may be related to susceptibility to H. pylori infection is the 
composition of the mucus gel layer in the stomach, in which H. pylori resides. This 
layer protects the underlying epithelium from acid, proteases, mechanical trauma, 
and pathogenic micro-organisms and its main constituents are high molecular weight 
glycoproteins named mucins. These mucins consist of a polypeptide backbone with 
O-linked oligosaccharide side chains, which largely determine the properties of the 
mucins (Figure 1).4 Interestingly, there is substantial inter-individual variation in the 
number of these side chains. This is caused by a variable number tandem repeat 
(VNTR) polymorphism in the genes encoding for the mucins. VNTRs consist of 
repeated DNA sequences and the number of repeats is highly variable. The resulting 
repeated amino acid sequences are located in the central part of the mucin 
polypeptide backbone, to which the oligosaccharide side chains are attached.5 
Therefore this polymorphism leads to the production of mucin polypeptides that 
substantially differ in both length and glycosylation.6,7 Thus, this VNTR 
polymorphism may affect the protective properties of the mucins and consequently 
susceptibility to H. pylori infection. 
 
Figure 1. Model of a mucin molecule 
 
Normal gastric mucosa is characterized by expression of the mucins MUC1, 
MUC5AC, and MUC6. MUC1 is of the membrane bound type, whereas MUC5AC 
and MUC6 are of the secreted, gel forming type.8 MUC6 and MUC1 show extensive 
VNTR variation, MUC5AC only moderate.6,9 Furthermore, the length of the 
Repeat 1 Repeat 3 Repeat 4 Repeat nRepeat 2
507 kbp 
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repeated sequence differs: a single MUC6 tandem repeat sequence consists of 507 
base pairs whereas single MUC1 and MUC5AC tandem repeat sequences consist of 
only 60 and 24 base pairs, respectively.6 Therefore the VNTR polymorphism has the 
most profound impact on allele length and protein structure of MUC6. 
Despite the significant structural consequences of these VNTR polymorphisms, few 
studies investigated their pathophysiological consequences. In a study comparing 
gastric cancer patients with healthy blood donors, shorter VNTR sections were 
associated with gastric cancer for MUC610 and MUC1.11 This effect may be 
mediated by an altered susceptibility to H. pylori infection which is an important 
factor in gastric carcinogenesis, since Vinall et al.9 showed that short VNTR sections 
were associated with H. pylori infection for MUC1. However, there are no data 
available regarding the relationship between H. pylori infection and VNTR 
polymorphism in MUC6, which is abundant in the stomach and has the most 
extensive VNTR variation.12 
Therefore the aim of this study was to investigate the hypothesis that susceptibility 
to H. pylori infection is related to MUC6 VNTR length. We studied a sample of 160 
patients referred for upper gastrointestinal endoscopy and found that patients with 
short MUC6 allele fragments have a significantly higher risk of being infected with 
H. pylori which suggests that mucin 6 protein length modifies susceptibility to H. 
pylori. 
 
 
Methods 
 
Study population 
From September to December 2003 all patients with upper gastrointestinal 
symptoms visiting the Gastroenterology Outpatient Clinic of the Can Tho General 
Hospital for upper gastrointestinal endoscopy were asked to participate in this study. 
Patients who had not been treated for H. pylori infection in the past and who gave 
written informed-consent were included in the study. At baseline, data regarding 
age, gender, smoking habits, and alcohol consumption were registered. 
 
Diagnosis of H. pylori infection 
All patients had a 14C urea breath test (HeliprobeTM, Noster system AB, Stockholm, 
Sweden). Patients were not allowed to use proton pump inhibitors/H2-receptor 
antagonists or antibiotics during 2 weeks preceding breath testing. After an 
overnight fast patients took a HeliCapTM capsule (containing 1 µCi of 14C urea) with 
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50ml of water. Ten minutes later a breath sample was collected (BreathCardTM) and 
analyzed during 4 minutes. Measuring more than 50 counts was regarded as prove of 
H. pylori infection, measuring fewer than 25 counts was regarded as prove of 
absence of H. pylori infection.13 
 
Determination of MUC6 allele length 
Blood samples were collected for DNA isolation (PuregeneTM kit, Gentra systems, 
Minneapolis, USA). MUC6 allele fragment length was measured using Southern 
blot analysis. The DNA samples were digested with the PvuII restriction enzyme as 
described previously by Vinall et al.6 This enzyme cuts just outside the tandem 
repeat domain and clearly reveals the MUC6 VNTR polymorphism. The resulting 
DNA fragments were separated by agarose gel electrophoresis (0.7% agarose in 
0.04M Tris, 0.001M EDTA, pH 8.0) at 35V for 18 hours. We used λ-hind III digest 
as a marker of DNA fragment length. DNA fragments were then transferred onto 
nylon membranes (Gene Screen PlusTM hybridization transfer membrane, Boston, 
USA). Afterwards, the nylon membranes were treated with ultraviolet radiation and 
prepared for hybridization by Church buffer. The probe, which consisted of two 
MUC6 tandem repeats, was produced by polymerase chain reaction with forward 
primer 5’-ACCTCTTTGGTGACTCCAATTA-3’ and reverse primer 5’-
AACGTGAGTGGGAAGTGTGGT-3’ and randomly labelled with α-32PdCTP. The 
resulting PCR product was verified by sequencing. After 18 hours of hybridization 
of the probe in 0.5M phosphate buffer containing 7% SDS and 0.001M EDTA, 
SSPE/SDS-solutions were used to remove unspecifically bound probe. Using the λ-
hind III digest as a reference, the individual MUC6 allele fragment lengths were 
calculated. 
 
Data analysis 
The primary outcome of this study was presence or absence of H. pylori infection. 
For analysis, MUC6 allele fragment length was dichotomized as being either short 
(≤13.5 kbp) or long (>13.5 kbp) and patients were classified according to genotype 
(long-long (LL), long-short (LS), short-short (SS)). Baseline characteristics for H. 
pylori positive and negative patients were compared. MUC6 genotype and baseline 
characteristics were related to H. pylori infection by means of unadjusted and 
adjusted logistic regression analyses, using the SAS® statistical software package 
(SAS Institute Inc., USA). Statistical significance was defined as a p-value<0.05. 
Missing values were excluded from analyses. 
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Results 
 
Population 
During the study period 160 patients (mean age 43 years, 36% male, 58% H. pylori 
infected) were included. Table 1 shows that H. pylori positive and negative patients 
were comparable for all baseline characteristics except age. 
 
Table 1. Baseline characteristics of H. pylori positive and negative patients. 
  Number (%) of 
H. pylori positives 
(n=92) 
Number (%) of 
H. pylori negatives 
(n=68) 
Mean age (SD)* 46 (12) 39 (13) 
Gender   
 Male 29 (50%) 29 (50%) 
 Female 63 (62%) 39 (38%) 
Current smoking   
 Yes 22 (56%) 17 (44%) 
 No 70 (58%) 51 (42%) 
Current alcohol consumption   
 Yes 16 (55%) 13 (45%) 
 No 76 (58%) 55 (42%) 
*p<0.05 
 
MUC6 allele fragment length 
Using the restriction enzyme PvuII, a clear length polymorphism was detected. 
Minimum fragment length difference was 0.5 kbp, reflecting the length of a single 
MUC6 tandem repeat that consists of 507 base pairs. MUC6 was found to be highly 
polymorphic with PvuII-restricted fragment lengths ranging from 7 to 19 kbp (mean 
13.8kbp (SD: 2)) (Figure 1). 
 
Figure 1. Distribution of MUC6 allele fragment lengths after PvuII restriction 
enzyme digestion. 
0
5
10
15
20
25
30
35
40
45
7 8 9 10 11 12 13 14 15 16 17 18 19
MUC6 allele fragment length
N
um
be
r o
f f
ra
gm
en
ts
 
Factors associated with H. pylori infection 
Mean MUC6 allele fragment length was shorter for H. pylori positive patients than 
for H. pylori negative patients (13.4 vs. 14.2, p=0.001). Because there were too 
many different allele fragment lengths to analyse separately, MUC6 allele fragment 
length was dichotomized as being either short (≤13.5 kbp) or long (>13.5 kbp). 
Furthermore patients were grouped according to genotype (long-long (LL), long-
short (LS), short-short (SS)). 
Patients with two short allele fragments were more often infected with H. pylori than 
patients with one long and one short allele fragment (Odds ratio (95%CI): 2.41 (1.0-
5.7)) or patients with two long allele fragments (4.24 (1.8-10.0)). Figure 2 shows 
that there seems to be a gradual increase in prevalence of H. pylori infection from 
43% (24/56) for patients with two long allele fragments, through 57% (25/58) for 
patients with one long and one short allele fragment, to 76% (11/46) for patients 
with two short allele fragments. 
Additionally, table 2 shows that of the other patient characteristics measured, only 
age was associated with H. pylori infection, and that the influence of MUC6 
genotype remained virtually unchanged after adjustment for age group, gender, 
smoking, and alcohol consumption. 
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Figure 2. Percentage of H. pylori infected patients according to MUC6 genotype. 
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Table 2. Factors associated with H. pylori infection. 
Factor Unadjusted analysis Adjusted analysis* 
 Odds 
ratio 
(95% CI) Odds 
ratio 
(95% CI) 
MUC6 genotype (SS vs. LS/LL)** 3.18 (1.5-6.9) 2.93 (1.3-6.5) 
Age group (>45 vs. ≤45 years)** 2.11 (1.1-4.1) 2.11 (1.0-4.3) 
Gender (male vs. female) 0.62 (0.3-1.2) 0.47 (0.2-1.9) 
Current smoking 0.94 (0.5-2.0) 1.46 (0.5-4.3) 
Current alcohol consumption 0.89 (0.4-2.0) 1.39 (0.5-3.9) 
*adjusted for MUC6 genotype, age group, gender, current smoking, and current alcohol consumption. 
**p<0.05 
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Discussion 
 
The aim of this study was to investigate the relationship between MUC6 VNTR 
polymorphism and H. pylori infection. We were able to confirm that MUC6 VNTR 
length is highly polymorphic and our data suggest that H. pylori infection is more 
frequent in patients with short MUC6 alleles. 
 
Few other studies investigated the MUC6 VNTR polymorphism. Vinall et al.6 found 
11 different allele fragment lengths for MUC6, ranging from 8 to 13.5 kbp. This 
degree of variation is considerably lower than in our study. It is not likely that this 
difference in VNTR length variation is inherent to the Southern blotting technique, 
as we used the same restriction enzyme. However, the aforementioned study used 
the Centre d’Étude du Polymorphisme Humain (CEPH) series of families in France 
and these may be much more homogeneous than our study population. 
 
The relationship between H. pylori infection and mucin VNTR length has been 
investigated for another mucin gene, MUC1, and the results were similar to our 
results. Like other mucins, MUC1 lubricates epithelial structures and constitutes a 
barrier against acid, proteases, and pathogenic organisms. Vinall et al.9 showed that 
short MUC1 alleles were associated with H. pylori induced gastritis. Therefore 
MUC1 and MUC6, although arising from different families of mucins, may be 
involved in the same mechanism regarding H. pylori infection.14 
 
Our results are also compatible with research focusing on the relationship between 
mucin allele length and gastric cancer. In a study investigating 157 gastric cancer 
patients it was found that short MUC6 alleles were more frequent in patients with 
gastric cancer than in healthy blood donors.10 This seems to be in line with our 
results that short MUC6 alleles are associated with H. pylori infection. In fact, 
because H. pylori has been classified as a class I carcinogen, the higher prevalence 
of H. pylori infection among patients with short MUC6 alleles may (partly) explain 
the higher prevalence of gastric cancer in these patients. Again, the same goes for 
MUC1 since Carvalho et al. stated that short MUC1 alleles were associated with 
gastric cancer.11 More research is necessary to determine whether these relationships 
are independent. 
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However, other researchers claimed that MUC5AC, and not MUC6, is important in 
H. pylori infection: Van den Brink et al.15 stated that H. pylori colocalised with 
MUC5AC but not with MUC6, and Van de Bovenkamp et al.16 stated that 
MUC5AC, and not MUC6, was the most important receptor for H. pylori. However, 
in the study by Van den Brink et al. antibodies recognizing MUC6 precursor rather 
than mature MUC6 were used. Therefore it seems plausible that the precursor 
MUC6 is only found in neck and gland cells, where MUC6 is synthesized. However, 
the mature MUC6, which is secreted, may be found in a much larger area. In fact, 
Ho et al.17 recently confirmed that the mucin within the glands consisted entirely of 
MUC6, but they also showed that, although the mucus layer on the gastric surface 
consisted primarily of MUC5AC, layers of MUC6 were interspersed between the 
layers of MUC5AC. 
Regarding the receptor function of the mucins, MUC5AC is the primary source of 
Lewis B (Leb), a terminal carbohydrate chain that acts as a ligand for the bacterial 
adhesion molecule BabA 16,18 However, although other receptor sites may be present 
on MUC6,19 mucins may be involved in many other processes besides bacterial 
binding. 
 
In fact, recently Kawakubo et al.20 showed that secretions from the glands 
(consisting of MUC6) may have an antibiotic effect on H. pylori while secretions 
from the superficial epithelium (primarily consisting of MUC5AC) may have a pro-
biotic effect, thereby limiting H. pylori infection to the superficial epithelium and 
protecting the deeper layers of the gastric mucosa. This is consistent with the 
geographical distribution of H. pylori described by Van de Brink et al.15 The 
antibiotic effect was mediated by terminal α1,4-linked N-acetylglucosamine 
(α1,4GlcNAc) residues, which are present on the variable region of MUC6. 
Furthermore, the presentation of multiple terminal α1,4GlcNAc residues as a cluster 
may be important for achieving optimal activity. This may explain our finding that 
shorter MUC6 molecules, which have fewer α1,4GlcNAc residues and therefore less 
antimicrobial activity, are associated with H. pylori infection. More research is 
necessary to further elucidate the functions of the mucins. 
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Abstract 
 
Background: Mucin 5AC (MUC5AC) has been reported to be the primary receptor 
for binding H. pylori in the gastric mucus gel layer. Interestingly, the MUC5AC 
gene shows a variable number tandem repeat (VNTR) polymorphism. However, it is 
not clear whether this polymorphism is associated with H. pylori infection. 
Methods: Blood samples were collected from patients visiting the Can Tho General 
Hospital (Vietnam) for upper gastrointestinal endoscopy. MUC5AC SacI restricted 
allele length was determined by Southern blotting. H. pylori infection was diagnosed 
by 14C UBT. MUC5AC allele fragment length distributions were compared for H. 
pylori positive and negative patients.  
Results: 170 patients were studied (mean age 43 years, 35% male, 52% H. pylori 
infected). MUC5AC SacI-restricted allele fragment lengths ranged from 6.2 to 11.2 
kbp (mean 7.9 (SD: 0.7)). Accordingly, the (calculated) number of repeats ranged 
from 170 to 380 (mean 243 (SD: 30)). However, the vast majority of observations 
(92%) were in a much narrower range: 7.0-9.0 kbp. Mean allele length was identical 
for H. pylori positive and negative patients (7.9 vs. 7.9 kbp) and the distribution of 
allele fragment lengths was also similar for both groups (p=0.7). Moreover, the 
scatter plot showed a similar distribution of MUC5AC genotypes for H. pylori 
positive and negative patients. 
Conclusion: The number of repeats in the MUC5AC gene was highly polymorphic, 
but the variation in allele length was limited. MUC5AC VNTR polymorphism was 
not associated with H. pylori infection. 
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Introduction 
 
The gastric mucus gel layer protects the underlying epithelium from gastric acid, 
proteases, mechanical trauma, and pathogenic micro-organisms.1-3 The main 
constituents of this mucus gel layer are large glycoproteins named mucins. There are 
many different mucins, but in the stomach only mucins 1, 5AC, and 6 are 
expressed.4 These mucins all consist of a polypeptide backbone with O-linked 
oligosaccharide side chains. These side chains largely determine the chemical and 
physical properties of the molecules.5 
Interestingly, there is substantial inter-individual variation in the number of side 
chains. This is caused by a variable number tandem repeat (VNTR) polymorphism 
in the genes encoding for the mucins. VNTRs consist of repeated DNA sequences 
and the number of repeats is highly variable. The resulting repeated amino acid 
sequences are located in the central part of the mucin polypeptide backbone, to 
which the oligosaccharide side chains are attached.6 Therefore, this polymorphism 
leads to the production of mucin polypeptides that substantially differ in both length 
and glycosylation.7,8 Thus, this polymorphism may affect the protective properties of 
the mucins. 
Despite the significant structural consequences of VNTR polymorphism, few studies 
investigated its pathophysiological consequences. In a study comparing gastric 
cancer patients with healthy blood donors, shorter VNTR sections were associated 
with gastric cancer for MUC110 and MUC69. This effect may (partially) be caused 
by an altered susceptibility to H. pylori infection, since H. pylori is an important 
factor in the aetiology of gastric cancer.11 Indeed, Vinall et al.12 stated that short 
alleles for MUC1 were associated with H. pylori infection, and recently the same 
was reported for MUC6.13 
However, there is no published research regarding the influence of MUC5AC 
VNTR polymorphism on susceptibility to H. pylori infection. MUC5AC may be 
important since Van den Brink et al. showed that H. pylori and MUC5AC co-
localized geographically.14 Furthermore, MUC5AC is the primary receptor for H. 
pylori.15,16 Therefore, the aim of this study was to investigate the influence of 
MUC5AC VNTR polymorphism on susceptibility to H. pylori infection. 
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Methods 
 
Study population 
From September to December 2003 all patients with upper gastrointestinal 
symptoms visiting the Gastroenterology Outpatient Clinic of the Can Tho General 
Hospital for upper gastrointestinal endoscopy were asked to participate in this study. 
Patients who had not been treated for H. pylori infection in the past and who gave 
written informed-consent were included in the study. At baseline, data regarding 
age, gender, smoking habits, and alcohol consumption were registered. 
 
Diagnosis of H. pylori infection 
All patients had a 14C urea breath test (HeliprobeTM, Noster system AB, Stockholm, 
Sweden). Patients were not allowed to use proton pump inhibitors/H2-receptor 
antagonists or antibiotics during 2 weeks preceding breath testing. After an 
overnight fast patients took a HeliCapTM capsule (containing 1 µCi of 14C urea) with 
50ml of water. Ten minutes later a breath sample was collected (BreathCardTM) and 
analyzed during 4 minutes. Measuring more than 50 counts was regarded as prove of 
H. pylori infection, measuring fewer than 25 counts was regarded as prove of 
absence of H. pylori infection.17 
 
Determination of MUC5AC allele length 
Blood samples were collected for DNA isolation (PuregeneTM kit, Gentra systems, 
Minneapolis, USA). MUC5AC allele fragment length was measured using Southern 
blot analysis. The DNA samples were digested with the SacI restriction enzyme as 
described previously by Escande et al.18 This enzyme cuts just outside the tandem 
repeat domain and clearly reveals the MUC5AC VNTR polymorphism. The 
resulting DNA fragments were separated by agarose gel electrophoresis (0.7% 
agarose in 0.04M Tris, 0.001M EDTA, pH 8.0) at 35V for at least 18 hours. We 
used λ-HindIII digest as a marker of DNA fragment length. DNA fragments were 
then transferred onto nylon membranes (Gene Screen PlusTM hybridization transfer 
membrane, Boston, USA). Afterwards, the nylon membranes were treated with 
ultraviolet radiation and prepared for hybridization by Church buffer. The probe, 
which consisted of a part of cysteine-rich domain 9, was produced by polymerase 
chain reaction with forward primer 5’-ACCAGCACAAGCCATCTTTC-3’ and 
reverse primer 5’-CAGGGAAGGATACAGAGCATTG-3’ and randomly labelled 
with α-32PdCTP. The resulting PCR product was verified by sequencing. After 18 
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hours of hybridization of the probe in 0.5M phosphate buffer containing 7% SDS 
and 0.001M EDTA at 60 oC, SSPE/SDS-solutions were used to remove 
unspecifically bound probe. Using the λ-hind III digest as a reference, the individual 
MUC5AC allele fragment lengths were calculated using TotallabTM (Nonlinear 
Dynamics, Great Britain). 
 
Data analysis 
The primary outcome of this study was presence or absence of H. pylori infection. 
Baseline characteristics of H. pylori positive and negative patients were compared 
using χ2 test and t-test were appropriate. MUC5AC allele fragment length 
distributions were compared for H. pylori positive and negative patients. 
Furthermore, a scatter plot of the various combinations (i.e. genotypes) of MUC5AC 
allele fragment lengths was constructed in order to graphically detect different 
patterns for H. pylori positive and negative patients. For construction of these 
figures, MUC5AC allele fragment lengths were divided in groups of 250bp. 
Statistical significance was defined as a p-value<0.05. Missing values were excluded 
from analyses. All analyses were performed using the SAS® statistical software 
package (SAS Institute Inc., USA). 
 
Table 1. Baseline characteristics of H. pylori positive and negative patients. 
  Number (%) of 
H. pylori positives 
(n=89) 
Number (%) of 
H. pylori negatives 
(n=81) 
Mean age (SD)* 46 (13) 39 (12) 
Gender   
 Male 28 (47%) 31 (53%) 
 Female 61 (55%) 50 (45%) 
Current smoking   
 Yes 22 (51%) 21 (49%) 
 No 67 (53%) 60 (47%) 
Current alcohol consumption   
 Yes 17 (53%) 15 (47%) 
 No 72 (52%) 66 (48%) 
*p<0.05 
 
 
Results 
 
Population 
During the study period 170 patients were studied (mean age 43 years (SD: 13), 59 
(35%) males, 89 (52%) H. pylori infected). Table 1 shows that H. pylori positive and 
negative patients were comparable for all baseline characteristics except age. 
 
MUC5AC allele fragment length 
Figure 1 shows that MUC5AC SacI-restricted allele fragment lengths ranged from 
6.2 to 11.2 kbp (mean 7.9 (SD: 0.7)). However, the vast majority of observations 
(92%) were in a much narrower range: 7.0-9.0 kbp. With these figures the number of 
repeats can be estimated by subtracting the non-VNTR domains between the 
restriction sites (in total 2.1 kbp) from the allele fragment length and dividing by the 
length of a single repeat (24 bp). The (calculated) number of repeats ranged from 
170 to 380 (mean 243 (SD: 30). In a previous study MUC6 allele fragment length 
had been measured for the majority of patients in our study population. Figure 2 
shows that MUC5AC allele fragment length and MUC6 allele fragment length were 
independent. 
 
Figure 1. Distribution of MUC5AC SacI restriction allele fragment lengths. 
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Figure 2. Distributions of SacI restricted MUC5AC allele fragment lengths for H. 
pylori positive and negative patients. 
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MUC5AC allele fragment length and H. pylori infection 
Mean MUC5AC allele fragment length was identical for H. pylori positive and 
negative patients (7.9 vs. 7.9 kbp). Figure 3 shows that the distribution of MUC5AC 
allele fragment lengths was also similar for both groups (p=0.7). Figure 4 shows 
scatter plots of the various combinations (i.e. genotypes) of MUC5AC allele 
fragment lengths for H. pylori positive and negative patients separately. The length 
of the smaller allele fragment (horizontal axis) is plotted against the length of the 
longer allele fragment (vertical axis). Therefore the area under the diagonal is empty. 
The size of the symbol correlates with the number of patients having that particular 
genotype. When comparing both figures no differences in the genotype distribution 
could be detected for H. pylori positive and negative patients. 
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Figure 3. Scatter plots of the SacI restricted MUC5AC genotypes vs. H. pylori  
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*The size of the circles correlates with the number of patients with that combination of allele lengths 
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Discussion 
 
The aim of this study was to investigate the relationship between MUC5AC VNTR 
polymorphism and H. pylori infection. Our data show that the number of MUC5AC 
repeats is highly polymorphic, but that the influence on allele length is limited. We 
did not find any association between MUC5AC VNTR polymorphism and H. pylori 
infection. 
 
Degree of variation 
Few other studies investigated the MUC5AC VNTR polymorphism. Vinall et al.7 
studied the MUC5AC VNTR polymorphism using several restriction enzymes (but 
not the SacI enzyme we used) and showed that there is VNTR variation in the 
MUC5AC gene, but that the variation in allele length is limited (0.5-1.0 kbp). This 
confirms the limited allele length variation we found in our population, although the 
range was a little wider in our population. However, the aforementioned study used 
the Centre d’Étude du Polymorphisme Humain (CEPH) series of families in France 
and these may be much more homogeneous than our study population. Furthermore, 
Escande et al.18 detected a MUC5AC length polymorphism using the SacI enzyme. 
When studying one volunteer they found two bands of 8.2 and 8.4 kbp, which are 
close to the average MUC5AC allele fragment length we found in our study 
population. 
The allele length variation in the MUC5AC gene is much less extensive than the 
allele length variation for MUC6. In a previous publication we showed that MUC6 
PvuII restricted allele fragment length ranged from 7 to 19 kbp in the same 
population.13 This difference in allele length variation may be caused by the huge 
difference in tandem repeat size: 507 bp for MUC6 and 24 bp for MUC5AC.7 
Another explanation for the limited VNTR variation may be that the MUC5AC 
VNTR section is interrupted by so-called “cysteine-rich domains”, whereas most 
other mucins have uninterrupted tandem repeat sections. It seems that these 
“cysteine-rich domains” stabilize the gene structure and limit the VNTR length, 
while long stretches of simple repeats are susceptible to VNTR mutation because of 
homologous recombination.18 
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Lack of association with H. pylori infection 
Our data show no association of MUC5AC VNTR polymorphism with H. pylori 
infection. This is in contrast with our results for MUC6: in the same population short 
alleles were associated with a higher prevalence of H. pylori infection.13 
Furthermore, Vinall et al. suggested that short MUC1 alleles were associated with 
H. pylori infection.12 
The lack of an association of MUC5AC and H. pylori may have several causes. First 
of all it may be explained by the fact that the differences in MUC5AC allele length 
were limited, and the majority of observations were close to the population mean. 
Genotypes with two extremely long or short alleles were not available in the 
population. Therefore, the MUC5AC molecules will not be very different among 
studied patients. 
Secondly, we hypothesized that MUC5AC would be important for H. pylori because 
studies reported the geographical co-localization of MUC5AC and H. pylori,13 
probably because MUC5AC is the primary carrier of Lewis b (Leb),15 which is the 
primary target for the bacterial BabA receptor.16 However, even though Leb may be 
important for bacterial binding it may not be necessary for colonization. For 
example, Guruge et al.19 showed that colonization with H. pylori was not different in 
transgenic mice with and without expression of Leb. 
And finally, even though mucins 1, 5AC, and 6 have similar overall structures, there 
are also many differences.5,20 Therefore, they may be involved in different biological 
mechanisms, which may explain difference in their association with H. pylori. For 
example, Kawakubo et al.21 showed that MUC6, but not MUC5AC, had an 
antibiotic effect on H. pylori, caused by terminal α1,4-linked N-acetylglucosamine 
residues, which have antibiotic activity against H. pylori on MUC6. More research 
is necessary to further elucidate the different functions of the mucins. 
 
In conclusion, although the number of repeats in the MUC5AC gene was highly 
polymorphic, the variation in allele length was limited. There was no association 
between MUC5AC VNTR polymorphism and H. pylori infection. 
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Abstract 
 
Objective: To measure the prevalence of metronidazole and/or clarithromycin 
resistant Helicobacter pylori. 
Methods: All positive H. pylori cultures with known metronidazole and/or 
clarithromycin susceptibility between 1998 and 2003 were selected from the 
database of the Microbiology Laboratory in ‘s-Hertogenbosch. Clarithromycin en 
metronidazole resistance were determined using E-test® with cutoff MIC-values of 
≥2 µg/ml en ≥8 µg/ml, respectively. 
Results: Of the 960 cultures with known metronidazole susceptibility 135 (14%) 
were resistant. Of the 959 cultures with known clarithromycin susceptibility 26 (3%) 
were resistant. Female gender was associated with antibiotic resistance (adjusted 
odds ratios: 2,48 (1,1-5,7) for clarithromycin en 1,63 (1,1-2,4) for metronidazole 
resistance). 
Conclusion: Prevalence of both metronidazole and clarithromycin resistant H. 
pylori strains is low in ‘s-Hertogenbosch, The Netherlands. Therapy with a proton 
pump inhibitor, clarithromycin and amoxicillin can be used as empirical first-line H. 
pylori eradication. 
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Introduction 
 
Since it became clear that not only patients with peptic ulcer disease but also a 
subgroup of patients with functional dyspepsia have symptomatic benefit from H. 
pylori eradication, H. pylori test-and-treat constitutes an important component of 
many guidelines for treatment of patients with dyspeptic symptoms.1,2 Therefore, a 
growing number of dutch patients is treated for H. pylori infection.  
With 7-day triple therapy regimens consisting of a proton pump inhibitor, 
clarithromycin and amoxicillin (or metronidazole) high eradication rates can be 
achieved, but if the bacteria are resistant against one (or both) of the antibiotics used 
success rates are largely decreased.3 Although, H. pylori can be/become resistant 
against clarithromycin and metronidazole (amoxicillin resistance is very rare) most 
patients are treated without prior culture with determination of the antibiotic 
susceptibility pattern.  
Since for culture a biopsy (and therefore endoscopy) is necessary, which is 
troublesome for the patients and associated with considerable while it often is not 
necessary for treatment of the dyspeptic symptoms. 
In the Dutch Dyspepsia Guideline triple therapy with a PPI, clarithromycin, and 
amoxicillin is advised as first-line therapy. This choice is based on the low 
prevalence of clarithromycin resistance in The Netherlands.1,4 However, the use of 
macrolide antibiotics (e.g. clarithromycin) for other indications (such as pneumonia) 
has increased. This may have led to an increase in the prevalence of clarithromycin 
resistance. Such an increase has been observed in several European countries.5,6 
Moreover, rapidly increasing metronidazole resistance rates were reported for the 
north of The Netherlands, as well as for several other European regions.6-8 Thus, it is 
important to reevaluate the the rates of both clarithromycin and metronidazole 
resistance. Unfortunately, there is only one recent Dutch investigation on this matter. 
This report mentioned 26% primary metronidazole resistance and 5% primary 
clarithromycin resistance in the “Zaanstreek”.9 The aim of the present study was to 
investigate the prevalence of clarithromycin and/or metronidazole resistant H. pylori 
in and around ’s-Hertogenbosch, The Netherlands, and whether resistance patterns 
had changed during the study period. 
 
Methods 
 
All H. pylori positive cultures with determination of clarithromycin and/or 
metronidazole susceptibility between January 1st 1998 en December 31st 2003 were 
selected from the database of the Microbiology Laboratory in ’s-Hertogenbosch, 
The Netherlands. Of these cultures data regarding clarithromycin and metronidazole 
susceptibility, age, and gender were extracted. For culture Belo-Horizonte medium 
was used and plates were incubated micro-aerobically during 7 days. Clarithromycin 
and metronidazole resistance were determined with the E-test method® (AB Biodisk, 
Sweden) using cut-off MIC-values ≥2 µg/ml and ≥8 µg/ml respectively. The 
relationships between calendar year, age, gender, and clarithromycin/metronidazole 
resistance was analyzed using adjusted logistic regression analysis. 
 
Figure 1. Prevalence of antibiotic resistant H. pylori in and around ‘s-
Hertogenbosch, The Netherlands, from 1997 to 2003. (The brackets indicate the 
standard error of the proportion.) 
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Results 
 
During the study period 961 H. pylori positive cultures were identified. Mean age of 
these patients was 56 years (SD: 15) and 546 (57%) of these patients were males. Of 
the 960 culture with known metronidazole susceptibility 135 (14%) were resistant 
and of 959 cultures with known clarithromycin susceptibilty 26 (3%) were resistant. 
Both clarithomycin and metronidazole resistance rates were higher in females than 
in males. The prevalence of clarithromycin resistance was 4% in females and 2% in 
males (adjusted odds ratio: 2.48 (1.1-5.7)). The prevalence of metronidazole 
resistance was 17% in females and 12% in males (adjusted odds ratio: 1.63 (1.1-
2.4)). There was no association of resistance with age. 
Figure 1 shows the variation in the prevalence of clarithromycin and metronidazole 
resistance during the study period. The prevalence of metronidazole resistance 
seemed to be slightly decreasing over time (adjusted odds ratio: 0.85 (0.8-1.0), while 
the prevalence of clarithromycin resistance appeared to be slightly increasing over 
time (adjusted odds ratio: 1.21 (1.0-1.5). Remarkable is the continuously decreasing 
number of H. pylori positive cultures from 244 in 1998 to 91 in 2003. 
 
 
Discussion 
 
Our results illustrate that the prevalence of clarithromycin and metronidazole 
resistant H. pylori is low in the ’s-Hertogenbosch area. Especially if one takes into 
account that there is probably some degree of secondary resistance (i.e. resistance 
induced by a failed attempt to eradicate H. pylori) in this study population. For the 
Dutch dyspepsia guideline indicates that endoscopy with biopsies for culture and 
determination of antibiotic susceptibility is only necessary after two failed attempts 
to eradicate H. pylori.1 And after failure of H. pylori eradication the prevalence of 
(secondary) antibiotic resistant H. pylori is considerably higher. Unfortunately, the 
database did not provide data about previous H. pylori eradication therapy. 
Therefore, we could not separate primary and secondary resistance. Nonetheless, we 
think that the data presented in this paper are relevant for clinical practice, as we 
illustrate that metronidazole resistance is low and clarithromycin resistance is very 
low, even with the possible inclusion of patients with secondary antibiotic 
resistance, which implicates that the prevalence of primary antibiotic resistance may 
be even lower. 
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Prevalence of antibiotic resistance in our study population is lower than the figures 
recently reported for another Dutch area (De Zaanstreek) (26% primary 
metronidazole resistance and 5% primary clarithromycin resistance).9 However, two 
other studies, not yet published as papers, report results comparable to our findings. 
In a recent Ph D thesis the prevalence of (both primary and secondary) resistance in 
6,648 positive H. pylori cultures form the northeast of The Netherlands was 
described. This study showed a decreasing metronidazole resistance from 28% in 
1996 to 13% in 2001, while clarithromycin resistance varied between 1 and 3% 
without a clear trend in time.10 Furthermore, an abstract has been published 
investigating the prevalence of primary resistance in 1,127 H. pylori positive 
cultures from the east of The Netherlands between 1997 and 2002. This study 
reported a stable prevalence of primary metronidazole resistance, on average 14%, 
and a decreasing prevalence of primary clarithromycin resistance from 3% in 1997 
to 0% in 2002.11 (chapter 4B) Thus, the results of the present study seem to be 
generalizable to areas with a population comparable to our region and the 
northern/eastern parts of The Netherlands. 
Compared with other European countries both clarithromycin and metronidazole 
resistance rates are low. This is probably caused by the much lower rates of 
antibiotic consumption in The Netherlands.12 
 
In our study population metronidazole resistance seems tob e decreasing, as was also 
described for the northwest of The Netherlands.9 An increasing trend, as was 
previously reported in the northeast of The Netherlands (from 7% in 1993 to 32% in 
1996) could not be confirmed by our data.7 By the way, unpublished data from the 
research group in the northeast of The Netherlands show that in that area too the 
initial increase turnd into a decrease after 1996.10 
There might be an increasing trend for clarithromycin resistance. However, this is 
entirely caused by the year 2003, while between 1998 and 2002 there was a stable 
rate of resistance. It is not clear what caused this increase in 2003. There may be 
increased selection of patients with secondary resistance given the steep decline of 
the total number of H. pylori cultures in 2003. And since as firstline therapy usually 
triple therapy with a proton pump inhibitor, clarithromycin, and amoxicillin is used 
failure of this regimen will often lead to the induction of clarithromycin but not 
metronidazole resistance. However, in the northwest of The Netherlands also a 
slight increase of (primary) clarithromycin resistance was reported.9 Thus, it seems 
advisable to establish whether this trend sustains in the years to come. Systematic 
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surveillance with national sampling of well documented clinical isolates would be 
very suitable for this purpose. 
 
We conclude that the prevalence of metronidazole resistant H. pylori and 
clarithromycin resistant H. pylori is low in and around ‘s-Hertogenbosch, The 
Netherlands. First-line H. pylori eradication with a proton pump inhibitor, 
clarithromycin and amoxicillin, as advised in the Dutch dyspepsia guideline, can be 
used for without prior culture and susceptibility testing. 
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Abstract 
 
Background: Most patients treated for H. pylori infection receive empirical therapy 
based on epidemiological data of antibiotic resistance. However, previous European 
studies indicate that resistance patterns may be changing. Therefore, the aim of this 
study was to investigate the prevalence of primary clarithromycin and/or 
metronidazole resistant H. pylori strains over a six-year period (1997-2002) in a 
regional hospital. 
Methods: All patients visiting Hospital Slingeland, Doetinchem, The Netherlands 
between 1997 and 2002 with a positive H. pylori culture were included in this study. 
Susceptibility to metronidazole and clarithromycin was determined by disk 
diffusion. 
Results: Of the 1355 patients with an H. pylori positive culture, 1127 did not have a 
history of H. pylori eradication, 58 did, and for 170 this information was not 
available. Mean rates of primary resistance to metronidazole and clarithromycin 
were 14.4% (162/1125) and 1.0% (11/1123), respectively. Primary metronidazole 
resistance was stable throughout the study period and primary clarithromycin 
resistance showed a decreasing trend. Patients of foreign descent and from 
secondary care had a higher chance of harboring primary metronidazole resistant H. 
pylori (adjusted OR (95%CI): 1.75 (1.1-2.8), and 1.60 (1.1-2.2), respectively). 
Patients with failed H. pylori eradication had a higher chance of harboring 
metronidazole resistant H. pylori (43% vs. 14%, p<0.0001) and clarithromycin 
resistant H. pylori (5.3% vs. 1.0%, p=0.004) than untreated patients. 
Conclusions: Primary metronidazole resistance is stable at a low level, while 
primary clarithromycin resistance is virtually absent in the eastern part of The 
Netherlands. Therefore, triple therapy with a proton pump inhibitor, clarithromycin 
and amoxicillin can remain the empirical treatment of choice in The Netherlands. 
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Introduction 
 
During the past decade it has been established that not only patients with peptic 
ulcer disease but also a subgroup of patients with functional dyspepsia benefit from 
Helicobacter pylori eradication.1,2 Therefore, H. pylori test-and-eradicate has been 
incorporated in most guidelines for treatment of primary care patients with dyspeptic 
symptoms.3-5 As a result, nowadays many patients receive therapy for H. pylori 
infection. 
Several therapy regimens are effective for treatment of this infection, but the current 
European guidelines as well as the Dutch guidelines recommend triple therapy based 
on a proton pump inhibitor or ranitidine bismuth citrate, combined with two 
antibiotics (clarithromycin and amoxicillin or metronidazole) as first-line 
treatment.3-5 These regimens reach high cure rates in clinical trials.6 However cure 
rates are substantially lower in case of resistance to the antibiotics used.7-9 
H. pylori can be (or become) resistant to clarithromycin and metronidazole and 
ideally therapy should be based on culture results. However, with the new non-
invasive management strategies, fewer patients have upper gastrointestinal 
endoscopy.10 Even if endoscopy is performed taking biopsies for culture is often 
omitted because of the high cost. Therefore culture-based antimicrobial 
susceptibility data are not generally available in routine clinical practice. Thus, the 
choice of therapy is usually based on epidemiological data of the local prevalence of 
antibiotic resistant H. pylori strains. 
However, the prevalence of antibiotic resistant H. pylori strains may be changing. 
Van der Wouden et al.11 reported a rapid increase in metronidazole resistance in the 
northern part of The Netherlands. And several studies in other countries also showed 
increasing rates of both metronidazole and clarithromycin resistance.12-15 Therefore, 
in order to be able to decide which combination of antibiotics should be used for 
treatment of H. pylori infection recent data on the local antibiotic resistance patterns 
are needed. Unfortunately there is only one recent Dutch study. This study by 
Loffeld et al.16 showed fairly stable rates of antibiotic resistance. But more research 
is necessary to confirm this for other parts of The Netherlands. 
Therefore, the aim of this study was to evaluate the prevalence of both primary and 
secondary clarithromycin and/or metronidazole resistant H. pylori strains in the 
eastern part of The Netherlands and to monitor changes over a six-year period 
(1997-2002). 
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Methods 
 
Study population 
All patients who underwent diagnostic upper gastrointestinal endoscopy in Hospital 
Slingeland, Doetinchem, The Netherlands, between January 1st 1997 and December 
31st 2002 who had a culture positive for H. pylori were included in this study. Data 
regarding antibiotic susceptibility, gender, age, country of origin, referring physician 
(primary or secondary care), and previous (failed) H. pylori eradication were entered 
into a database. 
 
H. pylori culture and antibiotic susceptibility testing 
H. pylori was cultured from one gastric biopsy specimen (antrum or corpus) on 
chocolate agar and a Skirrow plate (Regional Laboratory Arnhem, The Netherlands). 
Plates were incubated in a micro-aerobic atmosphere at 37ºC and examined after 3, 
7 and 10 days of incubation. H. pylori was identified by colony appearance, Gram 
staining and positive biochemical tests (catalase, oxidase and urease). 
Susceptibility to metronidazole and clarithromycin was determined by disk 
diffusion: a 16µg metronidazole disk and a 30µg clarithromycin disk were placed on 
separate chocolate agar plates with 3-5 for H. pylori suspected colonies. Plates were 
incubated in a microaerophilic atmosphere at 37ºC for 72h. Antibiotic susceptibility 
was determined by measuring the growth inhibition zone around the disk. Strains 
were considered resistant to clarithromycin when the growth inhibition zone was 
<19 mm and to metronidazole when it was <23 mm.17 
 
Data analysis 
Primary outcome was the prevalence of resistance to metronidazole or 
clarithromycin. Baseline characteristics of patients harboring antibiotic resistant and 
susceptible strains were compared using the χ2 test. Baseline characteristics and 
study year were related to the presence of antibiotic resistance using unadjusted and 
adjusted logistic regression analyses. Data were analyzed using SAS software (SAS 
Institute Inc., USA). Statistical significance was defined as a p-value<0.05. Missing 
values were excluded from analyses. 
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Results 
 
Population 
During the study period 1355 patients had a culture positive for H. pylori. Fifty-
eight of these patients had had a previously failed attempt to eradicate H. pylori, for 
170 there were no data available regarding prior H. pylori eradication. The 
remaining 1127 patients who did not have a history of H. pylori eradication were 
studied for primary metronidazole and clarithromycin resistance. Table 1 shows the 
baseline characteristics of these patients related to the presence of primary 
metronidazole and clarithromycin resistance. 
 
Table 1. Baseline characteristics in relation to primary metronidazole resistance and 
primary clarithromycin resistance. Percentages and (numbers) are presented. 
  Metronidazole Clarithromycin 
  Susceptible 
% (n) 
n=963 
Resistant 
% (n) 
n=162 
Susceptible 
% (n) 
n=1112 
Resistant 
% (n) 
n=11 
Gender     
 Male  54 (520) 49 (79) 53 (594) 36 (4) 
 Female  46 (442) 51 (83) 47 (517) 64 (7) 
Age in years: mean (SD) 55 (16) 56 (17) 55 (16) 60 (20) 
Descent     
 Dutch 86 (822) 80 (130) 85 (939) 91 (10) 
 Foreign 14 (135) 20 (32) 15 (167) 9 (1) 
Referring physician*     
 Primary 64 (602) 52 (82) 62 (676) 50 (5) 
 Secondary 36 (345) 48 (76) 38 (417) 50 (5) 
*p<0.05 for the difference between metronidazole susceptible and resistant strains 
 
Prevalence of antibiotic resistance (Figure 1) 
Metronidazole susceptibility was successfully tested in 1125 patients and resistance 
was found in 162 (14.4%, 95%CI: 12.3%-16.5%) of these patients. Clarithromycin 
susceptibility was successfully tested in 1123 patients and resistance was found in 
11 (1.0%, 95%CI: 0.4%-1.6%) of these patients. 
Figure 1 shows that the prevalence of metronidazole resistance was fairly stable 
during the study period (odds ratio for study year 0.96 (95%CI: 0.9-1.1)). 
Furthermore, figure 1 shows that the prevalence of clarithromycin resistance 
decreased during the study period (odds ratio for study year 0.58 (95%CI: 0.40-
0.9)), although this result is difficult to interpret due to the low number of patients 
with clarithromycin resistant strains. 
 
Figure 1. Proportions of primary metronidazole and clarithromycin resistant H. 
pylori strains. (The brackets indicate the standard error of the proportion.) 
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Factors associated with primary antibiotic resistance 
Table 2 shows that patients of foreign descent and patients referred by a secondary 
care physician were more likely to harbor metronidazole resistant strains. It was not 
feasible to perform these analyses for clarithromycin resistance due to the very low 
number of clarithromycin resistant H. pylori strains. 
 
Secondary antibiotic resistance 
Prevalence of both metronidazole and clarithromycin resistance was higher in the 58 
patients with a previous (failed) attempt to eradicate H. pylori than in previously 
untreated patients (metronidazole: 43% vs. 14% p<0.0001 and clarithromycin: 5.3% 
vs. 1.0% p=0.004, respectively). 
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Table 2. Factors associated with primary metronidazole resistance 
Factor Unadjusted analysis 
Odds ratio (95% CI) 
Adjusted analysis 
Odds ratio (95% CI) 
Age group (old vs. young) 1.11 (0.8-1.6) 1.23 (0.8-1.8) 
Gender (female vs. male) 1.24 (0.9-1.7) 1.22 (0.9-1.7) 
Descent (foreign vs. Dutch) 1.50 (1.0-2.2) 1.75 (1.1-2.8)* 
Referring physician 
(secondary vs. primary care) 
1.62 (1.2-2.3)* 1.60 (1.1-2.2)* 
Year of the study period 0.96 (0.9-1.1) 0.93 (0.8-1.1) 
*p<0.05 
 
 
Discussion 
 
Because most patients are treated for H. pylori without prior susceptibility testing it 
is important to gather epidemiological data on the current prevalence of antibiotic 
resistance to guide empirical therapy, which was the aim of this study. The present 
study shows that primary metronidazole resistance was stable throughout the study 
period (1997-2002) with a mean prevalence of 14%. Furthermore the results show 
that the prevalence of primary clarithromycin resistance was very low (mean 
prevalence 1%) and showed a decreasing trend. 
 
Our figures are somewhat lower than those reported recently by Loffeld et al.16 for 
976 H. pylori positive cultures from another Dutch region (26% primary 
metronidazole resistance and 5% primary clarithromycin resistance). This can partly 
be explained by the higher proportion of patients of Mediterranean descent (who 
have a higher prevalence of antibiotic resistance) in the study by Loffeld et al. 
However, our results are comparable to data from other Dutch regions, published as 
abstracts only. Arents et al.18 studied 6648 H. pylori positive cultures in the north of 
The Netherlands and found that primary metronidazole resistance had decreased 
from 28% in 1996 to 13% in 2001, and that clarithromycin resistance ranged from 1-
3% without evident trends. Moreover, Janssen et al.19 found a 14% metronidazole 
resistance and a 3% clarithromycin resistance when studying 961 H. pylori positive 
cultures in the south of The Netherlands. 
 
Our results do not confirm the rapid increase in metronidazole resistance (from 7% 
in 1993 to 32% in 1996) as reported by Van der Wouden et al.11 for 1037 isolates 
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from the north of The Netherlands. However, more recent data from that area did not 
confirm this increase; in fact they showed that this increase turned into a decrease 
after 1996.18 
 
Compared with other European countries both primary metronidazole resistance and 
primary clarithromycin resistance are low in The Netherlands.12-14, 20-21 These 
differences in primary antibiotic resistance may be related to the use of antibiotics 
for other indications. In The Netherlands sales of antibiotics are lower than in any 
other country of the European Union. In fact, in France, Spain, Italy and Greece 
sales of macrolide antibiotics are about four times higher than in The Netherlands 
and this may explain the higher prevalence of clarithromycin resistance in these 
countries.22-24 
 
Our results showed that patients originating from foreign countries (nearly all from 
Turkey) were more likely to harbor strains resistant to metronidazole than patients of 
Dutch descent. This is confirmed by other research16 and it probably reflects the 
higher frequency of metronidazole use for other indications in these countries. 
Furthermore, both metronidazole and clarithromycin resistance were about four 
times higher in patients with a history of failed H. pylori eradication than in 
untreated patients. This reflects the induction of secondary resistance to 
metronidazole and/or clarithromycin depending on the antibiotics used in the failed 
H. pylori eradication. Therefore, it is important to take a thorough medical history 
regarding previous failed H. pylori treatments in order to determine which 
antibiotics can be used for a subsequent attempt to eradicate H. pylori. 
 
In this study H. pylori susceptibility was tested using disk diffusion. Although agar 
dilution is considered the gold standard this method is too demanding for everyday 
practice it can be replaced by E-test or disk diffusion. Initially E-test was considered 
superior to disk diffusion, but several studies show that both methods produce 
comparable results. In comparison to agar dilution both methods are hampered with 
some discordant results for metronidazole susceptibility, especially in the 
intermediate susceptibility range.25-27 
 
Based on our results it should be advised to use clarithromycin based triple therapy 
rather than metronidazole based triple therapy for empirical first-line treatment of H. 
pylori infections in our region. Triple therapy with clarithromycin and amoxicillin is 
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the treatment of choice because it is not hampered by metronidazole resistance28 and 
because this regimen cannot induce double antibiotic resistance (to both 
clarithromycin and metronidazole).29,30 Therefore, failure of this therapy still leaves 
the option of empirical second-line therapy based on metronidazole, preferably 
quadruple therapy since this therapy may overcome metronidazole resistance.9,30 
Regarding the low prevalence of primary antibiotic resistance culture and 
susceptibility testing are not necessary for this combination of first-line and second-
line therapy. 
 
In conclusion, in the eastern part of The Netherlands, primary metronidazole 
resistance was stable at a low level, while primary clarithromycin resistance was 
virtually absent. Therefore, triple therapy with clarithromycin and amoxicillin can 
remain the empirical treatment of choice in this area. 
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Abstract 
 
Introduction: Triple therapies with proton pump inhibitor (PPI)/ranitidine bismuth 
citrate (RBC), clarithromycin (C) and either amoxycillin (A) or a nitro-imidazole (I) 
are widely accepted as treatment for Helicobacter pylori infection. However, it is 
not clear which of these antibiotic combinations should be preferred. 
Methods: To evaluate whether there is a difference in efficacy between triple 
therapies with PPI/RBC, clarithromycin and either amoxycillin or a nitro-imidazole 
the literature was examined for randomized trials comparing these regimens. Studies 
were grouped according to the type of acid inhibitor used (PPI or RBC) and 
differences between pooled cure rates were calculated. 
Results: Forty-seven studies were identified: seven using RBC, thirty-nine using 
PPI, one using both. RBC-C-I was somewhat superior to RBC-C-A, although this 
difference only reached statistical significance in intention-to-treat analysis. Overall 
PPI-C-I and PPI-C-A were equally effective, but in nitro-imidazole-susceptible 
strains PPI-C-I performed better, in nitroimidazole-resistant strains PPI-C-A 
performed better. No serious side-effects were reported and pooled drop-out rates 
were equal. 
Conclusion: In general PPI-C-I and proton pump inhibitor-C-A are equally effective 
and therefore other factors such as local prevalence of resistant strains, cost of 
therapy and options for second-line treatment should determine which regimen 
should be preferred. When using RBC, the RBC-C-I combination is somewhat 
superior to RBC-C-A. 
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Introduction 
 
Helicobacter pylori infection is the main determinant in the pathogenesis of peptic 
ulcer disease and curing this infection is the treatment goal in patients diagnosed 
with peptic ulcers.1,2 After curing the infection ulcer relapse rates are dramatically 
reduced3-5 and ulcer complications are prevented.6,7 The ideal eradication regimen 
should be simple, safe, cheap and of short duration. It should reach a cure rate ≥80% 
in intention-to-treat and ≥90% in per-protocol analysis. 
Triple therapy with a proton pump inhibitor (PPI), plus clarithromycin (C) and either 
amoxycillin (A) or a nitro-imidazole (I) for at least one week is the currently 
recommended fist-line therapy.8 These regimens have been shown to be sufficiently 
effective and safe in many populations.9 However, it is not clear which of these 
combinations of antibiotics should be preferred. Furthermore, triple therapies 
containing ranitidine bismuth citrate (RBC) have emerged as a valid alternative 
which expanded the number of triple therapies we have to choose from. RBC is a 
co-precipitate of ranitidine hydrochloride and bismuth citrate. It is more soluble than 
a simple admixture of these compounds, which enables adequate penetration of the 
gastric mucous layer.10 A recent review by our group showed that RBC and PPI 
based triple regimens were comparably effective when using the 
clarithromycin/amoxycillin combination, but that RBC was superior to PPI when 
using the clarithromycin/nitro-imidazole combination.11 
Recent meta-analyses of the literature showed comparable cure rates for triple 
regimens containing clarithromycin and either amoxycillin or a nitro-imidazole.9,12,13 
Laheij et al., when analysing data of 53,228 patients, found per-protocol cure rates 
of 86% (PPI-C-A), 87% (PPI-C-I), 88% (RBC-C-A) and 91% (RBC-C-I).12 Pooled 
results of studies using the aforementioned regimens were used. However, this 
might not be the best way to assess differences in efficacy, because many factors are 
known to influence eradication and the prevalence of these factors differs among 
populations. The difference between these pooled data does not necessarily reflect 
the “true” difference since it is also influenced by differences in treatment groups. 
This problem does not arise when one only uses results from randomised 
comparative clinical trials, because such studies compare the efficacy of different 
regimens in the same population. This means that even if different studies use 
different patient groups, the pooled treatment groups are similar. Therefore, in this 
paper we compare clarithromycin/nitro-imidazole and clarithromycin/amoxycillin 
containing triple regimens using randomised comparative studies only. 
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It is well known that nitro-imidazole resistance reduces cure rates of the PPI-C-I 
regimen.14-16 There is some evidence that using RBC instead of a PPI in combination 
with clarithromycin and a nitro-imidazole improves efficacy in nitro-imidazole 
resistant strains.17,18 Because of the influence of nitro-imidazole resistance, cure 
rates will be analysed separately in nitro-imidazole susceptible and resistant 
subgroups in this paper. Clarithromycin resistance reduces the efficacy of the PPI-C-
I and the PPI-C-A regimen to a similar extent, but data are still scarce14,19 
The aim of this paper is to compare systematically the efficacy of triple regimens 
with clarithromycin and either amoxycillin or a nitro-imidazole by using results 
from randomised comparative studies only. The results of this literature review 
should help physicians choose between the different triple therapy regimens 
presently available for the treatment of Helicobacter pylori infection. 
 
 
Methods 
 
An extensive Medline search was performed to identify reports of clinical studies 
available to August 2000. A manual review of all abstracts from the following major 
international meetings was also performed: the Digestive Disease Week of the 
American Gastroenterological Association (1996-2000), the European Helicobacter 
pylori Study Group meeting (1995-1999) and the United European Gastroenterology 
Week (1994-1999). In addition all papers and reviews were evaluated to identify 
citations to other studies not yet included in the computerized literature search. 
Only randomised trials comparing triple regimens containing PPI/RBC, 
clarithromycin and either amoxycillin or a nitroimidazole (metronidazole, tinidazole, 
ornidazole) were included. Extended use of a proton pump inhibitor or H2-receptor 
antagonist was allowed. H. pylori eradication had to be confirmed at least 4 weeks 
after treatment by at least one reliable method (culture, histology or urea breath test). 
Studies had to have at least an abstract in English, Dutch, German or French. 
Duplicate reports or studies obviously reporting results from the same population 
were eliminated and only the most recent abstract or full paper was used. All studies 
we identified are included in this review. 
Data were extracted from each study and entered into a computerized database. 
Pooling was performed by combining the cure rates from intention-to-treat (ITT) 
and per protocol (PP) analyses for the different treatment modalities. Studies were 
grouped according to the type of acid inhibitor used: PPI or RBC. Funnel plots were 
constructed as a crude measure to detect bias in the selection of studies.20 The 
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weighted differences were plotted against study sample size. Differences in the 
pooled cure rates and dropout rates between the different treatment modalities and 
95% confidence intervals (95%CI) were calculated. The methods used to calculate 
the pooled differences weighted for effect size were based on χ square function for 
comparative analysis of two rates.21 
 
 
Results 
 
Identified studies 
A total of seventy studies comparing triple therapy regimens with clarythromycin 
and either amoxycillin or a nitro-imidazole could be identified. In case of missing or 
conflicting data, we tried to contact the authors in order to obtain the necessary data. 
Fourteen were excluded because a prospective randomised design was lacking,22-35 
three because the number of patients in the different treatment groups was not 
mentioned,36-38 and one because it contained conflicting data.39 Finally, five studies 
were excluded because there was no clear statement that randomisation was 
performed.40-44 
The remaining 47 studies contained valid data. Twenty-five of these were published 
as full papers; twenty-two as abstracts only. Some of the abstracts gave only limited 
information. 
Thirty-nine studies compared triple therapy regimens containing a proton pump 
inhibitor, clarithromycin and either amoxycillin or a nitro-imidazole.45-83 Seven 
studies compared regimens containing ranitidine bismuth citrate, clarithromycin and 
either amoxycillin or a nitro-imidazole.84-90 One study compared all aforementioned 
treatments.91 
 
Study design 
All forty-seven studies used a randomised comparative design. Eight of these studies 
used a double-blind design,49,54,56,58,63,77,88,90 nine a single-blind 
design,45,47,52,60,61,73,76,81,83 nine studies used open label treatment,46,67,71,78,79,84,87,89,91 
and the remaining twenty-one studies did not mention whether or not a blinding 
method was used. 
 
Populations studied 
The studied populations varied widely: twelve papers studied patients with peptic 
ulcer disease,45,49,54-57,63,71,74,76,79,80 six studied patients with non-ulcer dyspepsia 
(NUD),65,81,87-90 and twenty-six included both ulcer and NUD patients.47,48,50-53,58-
61,64,67-70,72,73,75,77,78,82-86,91 In one paper ulcer and NUD patients were studied 
separately.46 One study included only patients with insulin dependant diabetes.65 The 
remaining study included healthy individuals with H. pylori infection.62  
There were large differences in the number of patients studied in each trial. The 
median number of patients included in the intention-to-treat analysis was 49 per 
treatment arm (range: 18-192). 
 
RBC-C-A vs. RBC-C-I 
Eight comparative studies could be identified in the literature comprising seventeen 
treatment arms. Length of therapy was five days in one study,84 ten days in 
another,89 and seven days in the remaining six studies. All studies used RBC 400 mg 
twice daily and amoxycillin 1000 mg twice daily. Three studies used clarithromycin 
500 mg twice daily,84,85,89 one used clarithromycin 250 mg three times daily,86 three 
used clarithromycin 500 mg twice daily in the amoxycillin arm and clarithromycin 
250 mg twice daily in the nitro-imidazole arm,87,88,90 and one used clarithromycin 
250 mg twice daily in the nitro-imidazole arm and both clarithromycin 250 mg and 
500 mg twice daily in the amoxycillin arm.91 All studies used a nitro-imidazole 
dosage of 400 or 500 mg twice daily, except for one that used 250 mg twice daily.91  
 
Figure 1. Intention-to-treat analysis: RBC-C-A vs. RBC-C-I. Differences in cure 
rates (%) and 95% confidence intervals. 
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Table 1. Treatment regimens and cure rates of studies comparing triple regimens 
with ranitidine bismuth citrate, clarithromycin and either amoxycillin or a nitro- 
imidazole 
Study Therapy RBC-C-A RBC-C-I 
   ITT (n) PP (n) ITT (n) PP (n) 
RBC400bdC500bdA1000bd, 5d 88% (40) 88% (40)     Cammarota 
et al.84 RBC400bdC500bdT500bd, 5d     93% (40) 93% (40) 
RBC400bdC500bdA1000bd, 7d 86% (99) 94% (89)     Sung et al.85 
RBC400bdC500bdM400bd, 7d     90% (99) 96% (92) 
RBC400bdC250tdA1000bd, 7d 89% (35) 91% (34)     Cammarota 
et al.86 RBC400bdC250tdT500bd, 7d     91% (35) 91% (35) 
RBC400bdC500bdA1000bd, 7d 71% (55) 82% (45)     Ricciardiello 
et al.87 RBC400bdC250bdT500bd, 7d     78% (50) 84% (44) 
RBC400bdC500bdA1000bd, 7d 83% (109) 84% (103)     Wetterhus et 
al.88 RBC400bdC250bdM400bd, 7d     86% (114) 88% (106) 
RBC400bdC500bdA1000bd, 10d 96% (26) 100% (25)     Crawford et 
al.89 RBC400bdC500bdM500bd, 10d     80% (25) 87% (23) 
RBC400bdC250bdA1000bd, 7d 70% (50)*       
RBC400bdC500bdA1000bd, 7d 76% (50)*       
Susi91 
RBC400bdC250bd/M250bd, 7d     94% (100)*   
RBC400bdC500bdA1000bd, 7d 81% (110) 85% (105)     Hetzel et 
al.90 RBC400bdC250bdM400bd, 7d     88% (102) 93% (97) 
*Differences between treatment modalities are statistically significant (p<0.05). 
Results are given as cure rate (number of patients studied) 
RBC=ranitidine bismuth citrate, C=clarithromycin, A=amoxycillin, M=metronidazole, T=tinidazole, 
ITT=intention-to-treat, PP=per-protocol, d=day 
 
Intention-to-treat analysis 
Intention-to-treat cure rates were provided by all eight studies, resulting in a pooled 
cure rate for the amocycillin arm (RBC-C-A) of 81.4% (467 out of 574, range: 71%-
96%). For the nitro-imidazole arm (RBC-C-I) the pooled intention-to-treat cure rate 
was 88.3% (499 out of 565, range: 78%-94%). One study reached a significantly 
better result for the nitro-imidazole containing regimen: Susi found cure rates of 
73% (RBC-C-A) and 94% (RBC-C-I), difference 21% (95%CI: 11%-31%) in favour 
of the nitro-imidazole containing regimen.91  
The weighted difference between the pooled cure rates for the two treatment arms 
was statistically significant in favour of RBC-C-I (weighted difference 6.2% 95%CI: 
2.2%-10.3%). (Table 1, Figure 1) 
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Per-protocol analysis 
Per-protocol cure rates were given for seven out of eight studies. For the amoxycillin 
arm the pooled per-protocol cure rate was 88.0% (388 out of 441, range 82%-
100%). For the nitro-imidazole arm this was 90.8% (397 out of 437, range 84%-
96%). In none of the studies the difference between the cure rates for the different 
treatment arms reached statistical significance. And the weighted difference between 
the pooled cure rates (2.0% in favour of RBC-C-I, 95%CI: –1.8%-5.8%) did not 
reach statistical significance either. 
 
Nitro-imidazole resistance 
Only one study measured antibiotic susceptibility.85 In this study there was no 
statistically significant difference in cure rates for nitro-imidazole susceptible and 
resistant strains. 
 
Side effects 
Seven studies mentioned the number of dropouts due to adverse events, but only five 
formally assessed type and severity of side effects. It was not possible to analyse 
these data because all studies measured side effects differently. None of the studies 
reported significant differences in the incidence and severity of side effects between 
the treatment arms. Side effects were mild and mostly self-limited not leading to 
discontinuation of therapy. Pooled dropout rates were equal for both regimens. 
 
PPI-C-A vs. PPI-C-I 
Forty comparative studies could be identified in the literature comprising 102 
treatment arms. Most studies (34) used a one week regimen. Two studies used a five 
day regimen,52,57 two studies used a ten day regimen,46,70 one study used a fifteen 
day regimen,74 and one study used both seven and fourteen day regimens.73 
Several proton pump inhibitors were used. Twenty-four studies used omeprazole 20 
mg: twenty-one twice daily, two once daily,60,64 and one twice daily in the 
amoxycillin arm and once daily in the nitro-imidazole arm.50 Six studies used 
lansoprazole 30 mg: four twice daily,48,52,61,69 one once daily,77 and one twice daily 
in the amoxycillin arm and once daily in the nitro-imidazole arm.65 Six studies used 
pantoprazole 40 mg: five twice daily,65,67,71,79,82 one once daily.51 One study used 
rabeprazole 20 mg twice daily.58 In three studies more than one comparison between 
PPI-C-A and PPI-C-I using different proton pump inhibitor regimens was made. 
Uygun et al.46 used omeprazole 20 mg twice daily in one comparison and once daily 
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in the other, Paoluzi et al.73 used omeprazole 20 mg twice daily and lansoprazol 30 
mg twice daily in different comparisons whereas Jonas et al.68 used both omeprazole 
20 mg once daily and lansoprazole 30 mg once daily. 
Thirteen studies used clarithromycin 500 mg twice daily,45,46,55,47-59,70-73,75,79,82 and 
one study used it three times daily.67 Nine studies used clarithromycin 250 mg twice 
daily,48,51,52,60,61,64,68,69,77 and one used it three times daily.65 Two studies made 
several comparisons with clarithromycin 250 mg and 500 mg twice daily 
regimens.63,91 Eleven studies used clarithromycin 500 mg twice daily in the 
amoxycillin arm and 250 mg twice daily in the nitro-imidazole 
arm.47,49,50,53,54,56,62,65,76,78,83 Three studies compared several amoxycillin arms using 
both clarithromycin 500 mg and 250 mg twice daily with one nitro-imidazole arm 
using either clarithromycin 500 mg twice daily74 or clarithromycin 250 mg twice 
daily.80,81 
Nearly all studies used amoxycillin 1000 mg twice daily. Exceptions: one study used 
amoxycillin 750 mg twice daily,75 one used 500 mg twice daily,60 one used 500 mg 
four times daily,74 and another used both 500 and 1000 mg twice daily.80  
Most studies used a nitro-imidazole dosage of 400 or 500 mg twice daily. Two 
studies used 250 mg four times daily,48,51 two others used 500 mg three times 
daily,67,74 and one study used 250 mg twice daily.91 
 
Intention-to-treat analysis 
Intention-to-treat cure rates were given for all studies but one.50 The pooled 
intention-to-treat cure rate was 79.0% (2,351 out of 2,976 range 24%-95%) for the 
amoxycillin arm and 79.3% (2,293 out of 2,890, range 42%-100%) for the nitro-
imidazole arm (Figure 2, Table 2). In five individual studies the difference was 
statistically significant in favour of the nitro-imidazole containing 
regimen,52,63,65,68,79 in one study it was in favour of the amoxycillin containing 
regimen.62 The weighted difference between the pooled eradication results for the 
two treatment arms (1.0% in favour of PPI-C-I 95%CI: –0.9%-2.9%) however was 
not statistically significant. 
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Table 2. Treatment regimens and cure rates of studies comparing triple regimens 
with a proton pump inhibitor, clarithromycin and either amoxycillin or a nitro-
imidazole. 
Study Therapy PPI-C-A PPI-C-I
   ITT (n) PP (n) ITT (n) PP (n) 
O20bdC500bdA1000bd, 7d 87% (83) 94% (70)    Fock et al.  45
O20bdC500bdM400bd, 7d 85% (80) 94% (66) 
O20udC500bdA1000bd,10d 58% (48) 65% (43)    
O20udC500bdT500bd,10d 50% (42) 62% (34) 
O20udC500bdOr500bd,10d 58% (48) 62% (45) 
O20bdC500bdA1000bd, 10d 63% (40) 69% (36)    
Uygun et 
al.46 
O20bdC500bdOr500bd, 10d 42% (38) 52% (31) 
O20bdC500bdA1000bd, 7d 87% (61) 91% (57)    Houben et 
al.47 O20bdC250bdM400bd, 7d 82% (61) 84% (55) 
L30bdC250bdA1000bd, 7d 82% (50) 89% (46)    Pilotto et 
al.48 L30bdC250bdM250qd, 7d 86% (50) 91% (47) 
O20bdC500bdA1000bd, 7d 79% (48) 83% (41)    Malfertheine
r et al.49 O20bdC250bdM400bd, 7d 86% (49) 93% (41) 
O20bdC500bdA1000bd, 7d 83% (42)    Cammarota 
et al.50 O20udC250bdT500bd, 7d 72%  (65) 
P40udC250bdA1000bd, 7d 85% (40) 85% (40)    Pilotto et 
al.51 P40udC250bdM250qd, 7d 82% (38) 89% (35) 
L30bdC250bdA1000bd, 5d 59% (56)*60% (55)*    Neville et 
al.52 L30bdC250bdM400bd, 5d 81% (53)* 84% (51)* 
O20bdC500bdA1000bd, 7d 72% (116)78% (106)    Lee et al.53 
O20bdC250bdM400bd, 7d 73% (192) 79% (177) 
O20bdC500bdA1000bd, 7d 78% (50) 87% (39)    Veldh v Z et 
al.54 O20bdC250bdM400bd, 7d 85% (48) 92% (39) 
O20bdC500bdA1000bd, 7d 89% (27) 89% (27)    Gisbert et 
al.55 O20bdC500bdM500bd, 7d 93% (27) 96% (26)  
O20bdC500bdA1000bd, 7d 94% (127)95% (110)    Lind et al.56 
O20bdC250bdM400bd, 7d 87% (127) 91% (116) 
O20bdC500bdA1000bd, 5d 71% (24) 74% (23)*    Gisbert et 
al.57 O20bdC500bdM500bd, 5d 92% (24) 96% (23)* 
R20bdC500bdA1000bd, 7d 95% (19) 100 (18)    Stack et al. 58 
R20bdC500bdM400bd, 7d 100 (18) 100 (17) 
O20bdC500bdA1000bd, 7d 67% (58) 67% (58)    Perri et al. 59 
O20bdC500bdT500bd, 7d 60% (50) 68% (44) 
O20udC250bdA500bd, 7d 88% (41) 90% (40)    Goh et al. 60 
O20udC250bdM400bd, 7d 80% (41) 84% (38) 
L30bdC250bdA1000bd, 7d 86% (121)90% (114)    Misiewicz et 
al.61 L30bdC250bdM400bd, 7d 87% (118) 91% (109) 
O20bdC500bdA1000bd, 7d 82% (68)*85% (60)    Laine et al.62 
O20bdC250bdM500bd, 7d 67% (61)* 75% (53) 
    
    
 87 
Table 2 continued 
Study Therapy PPI-C-A PPI-C-I
   ITT (n) PP (n) ITT (n) PP (n)  
O20bdC250bdA1000bd, 7d 79% (117)85% (107)    
O20bdC250bdM400bd, 7d 90% (117) 94% (105)
O20bdC500bdA1000bd, 7d 91% (117)98% (102)    
Lind et al. 63 
O20bdC500bdM400bd, 7d 85% (124) 92% (106) 
O20udC250bdA1000bd, 7d 80% (50) 82% (49)    Tursi et al. 64 
O20udC250bdT500bd, 7d 70% (50) 73% (48) 
L30bdC500bdA1000bd, 7d 82% (66)*86% (63)    Bazzoli et 
al.66 L30udC250bdM500bd, 7d 94% (66)* 94% (65) 
P40bdC500tdA1000bd, 7d 77% (44) 81% (42)    Dehesa et 
al.67 P40bdC500tdM500td, 7d 63% (46) 67% (43) 
L30udC250bdA1000bd, 7d 24% (21)*33% (15)*    
L30udC250bdT500bd, 7d 62% (26)* 76% (21)* 
O20udC250bdA1000bd, 7d 50% (22) 65% (17)    
Jonas et al. 68 
O20udC250bdT500bd, 7d 55% (40) 67% (33) 
L30bdC250bdA1000bd, 7d 70% (23)    Lamouliatte 
et al.69 L30bdC250bdT500bd, 7d 77% (22)    
O20bdC500bdA1000bd, 10d 83% (48)    Sue et al. 70 
O20bdC500bdM500bd, 10d 86% (51)   
P40bdC500bdA1000bd, 7d 90% (150)93% (145)    Frevel et 
al.71 P40bdC500bdM500bd, 7d 90% (147) 96% (138) 
O20bdC500bdA1000bd, 7d 85% (87) 88% (84)    Pieramico et 
al.72 O20bdC500bdM500bd, 7d 84% (81) 87% (78) 
L30bdC500bdA1000bd, 7d 77% (26) 80% (25)    
L30bdC500bdM500bd, 7d 70% (27) 83% (23) 
L30bdC500bdA1000bd, 14d 92% (26) 92% (26)    
L30bdC500bdM500bd, 14d 76% (25) 79% (24) 
O20bdC500bdA1000bd, 7d 64% (28) 67% (27)    
O20bdC500bdM500bd, 7d 63% (27) 63% (27) 
O20bdC500bdA1000bd, 14d 85% (27) 85% (27)    
Paoluzi et 
al.73 
O20bdC500bdM500bd, 14d 83% (23) 86% (22) 
O20bdC250bdA500qid, 15d 64% (45) 78% (37)    
O20bdC500bdA500qid, 15d 67% (46) 82% (38)    
Michopoulos 
et al.74 
O20bdC500bdM500tid, 15d 71% (34) 80% (30) 
O20bdC500bdA750bd, 7d 93% (100)    Jaup et al. 75 
O20bdC500bdM400bd, 7d 95% (100)  
O20bdC250bdA1000bd, 7d 82% (50)    
O20bdC250bdM250bd, 7d 84% (50)    
O20bdC500bdA1000bd, 7d 84% (50)    
Susi91 
O20bdC500bdM250bd, 7d 88% (50)    
O20bdC500bdA1000bd, 7d 70% (43) 81% (37)    Tzathas et 
al.76 O20bdC250bdM500bd, 7d 49% (43) 72% (29) 
L30udC250bdA1000bd, 7d 49% (49) 52% (46)*    Lamouliatte 
et al.77 L30udC250bdT500bd, 7d 67% (49) 75% (44)* 
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Table 2 continued 
O20bdC500bdA1000bd, 7d 59% (150)64% (139)    Perri et al. 78 
O20bdC250bdT500bd, 7d 68% (150) 74% (138) 
P40bdC500bdA1000bd, 7d 75% (102)78% (99)*    Di Mario et 
al.79 P40bdC500bdT500bd, 7d 87% (110)90% (107)
O20bdC250bdA500bd, 7d 91% (35) 91% (35)    
O20bdC250bdA1000bd, 7d 77% (31) 89% (27)    
O20bdC500bdA500bd, 7d 74% (38) 85% (33)    
Lee et al. 80 
O20bdC250bdM500bd, 7d 81% (37) 91% (33) 
O20bdC200bdA750bd, 7d 90% (29) 93% (28)    
O20bdC400bdA750bd, 7d 79% (28) 96% (23)    
O20bdC200bdM250bd, 7d 89% (28) 100 (25) 
O20bdC250bdA1000bd/ 7d 86% (29) 86% (29)    
O20bdC500bdA1000bd/ 7d 93% (28) 96% (27)    
Unge et al. 81 
O20bdC250bdM400bd/ 7d 96% (26) 96% (26) 
P40bdC500bdA1000bd, 7d 82% (61) 88% (57)    Takats et 
al.82 P40bdC500bdT500bd, 7d 80% (44) 83% (42) 
O20bdC500bdA1000bd, 7d 87% (110)93% (103)    Neville at 
al.83 O20bdC250bdM400bd, 7d 84% (111) 87% (107) 
P40bdC250tdA1000bd, 7d 61% (23)    Gasbarrini et 
al.65 P40bdC250tdT500bd, 7d 62% (21)    
*Differences between treatment modalities are statistically significant (p<0.05). 
Results are given as cure rate (number of patients studied) 
O=omeprazole, L=lansoprazole, P=pantoprazole, R=rabeprazole, C=clarithromycin, A=amoxycillin,
M=metronidazole, T=tinidazole, Or=ornidazole, ITT=intention-to-treat, PP=per-protocol, d=day 
 
Figure 2. Intention-to-treat analysis: PPI-C-A vs. PPI-C-I. Differences in cure rates 
(%) and 95% confidence intervals. 
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Jonas et al. 199668*
Laine et al. 199762
Lamouliatte et al. 199877
Lamouliatte et al. 199669
Michopoulos et al. 199774
Malfertheiner et al. 199949
Lind et al. 199663*
Lind et al. 199663*
Lee J, et al. 199953
Lind et al. 199956
Lee C, et al. 199980
Uygun et al. 199946*
Uygun et al. 199946*
Veldhuyzen van Zanten et al. 199954
Total
Paoluzi et al. 199873*
Paoluzi et al. 199873*
Paoluzi et al. 199873*
Gisbert  et al. 199955
Gisbert  et al. 199857
Neville et al. 199983
Perri et al. 199859
-75 75
*different comparisons within the same study. 
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Per-protocol analysis 
Per-protocol cure rates were given for all but five studies.65,69,70,75,91 The pooled per- 
protocol cure rate was 83.4% (2,096 out of 2,512, range 33%-100%) for the 
amoxycillin arm and 84.1% (2,040 out of 2,426, range 52%-100%) for the nitro-
imidazole arm. In six studies the difference between the cure rates for the different 
treatment arms reached statistical significance, in all studies in favour of the nitro-
imidazole containing regimen.52,57,63,68,77,79 The weighted difference between the 
pooled cure rates (0.9% in favour of PPI-C-I) did not reach statistical significance 
(95%CI: –0.9%-2.7%). 
 
Nitro-imidazole resistance  
Few studies measured antibiotic resistance patterns. Seven studies described cure 
rates for the different regimens in nitro-imidazole resistant and sensitive subgroups: 
five studies contained both ITT and PP rates,45,47,51,52,61 one ITT rates only,56 and one 
PP rates only.58 One study contained PP rates but only for the nitro-imidazole 
containing regimen.60 
In the intention-to-treat analysis the pooled cure rate for the amoxycillin arm was 
85.9% (238 out of 277, range: 40%-97%) for the nitro-imidazole susceptible 
subgroup and 87.9% (138 out of 157, range: 72%-100%) for the nitro-imidazole 
resistant subgroup. For the nitro-imidazole arm these figures were 90.9% (249 out of 
274, range 81%-95%) and 75.5% (111 out of 147, range: 43%-83%), respectively. 
The cure rates of the amoxycillin containing regimen were comparable in both 
groups (weighted difference: 1.1% in favour of the resistant subgroup, 95%CI: –
4.7%-6.8%). The nitro-imidazole containing regimen however performed 
considerably worse in the nitro-imidazole resistant subgroup as compared to the 
nitro-imidazole susceptible subgroup (weighted difference: 15.2% 95%CI: 8.2%-
22.3%). 
In the nitro-imidazole susceptible group eradication rates were slightly higher for the 
nitro-imidazole containing regimen than for the amoxycillin containing regimen but 
this difference did not reach statistical significance (weighted difference: 2.0% 
95%CI: –2.5%-6.4%). 
In the nitro-imidazole resistant subgroup the nitro-imidazole containing regimen 
performed worse than the amoxycillin containing regimen (weighted difference: 
11.1% 95%CI: 2.7%-19.5%).  
The per-protocol analysis showed a similar pattern as the intention-to-treat analysis, 
however in the per-protocol analysis the difference between the amoxycillin and 
nitro-imidazole containing regimens for the nitro-imidazole susceptible subgroup 
reached statistical significance (weighted difference: 7.4% in favour of PPI-C-I, 
95%CI: 1.5%-13.4%). 
 
Figure 3. Per-protocol cure rates of triple therapies with a PPI, clarithromycin (C) 
and either amoxycillin (A) or a nitro-imidazole (I) in nitro-imidazole susceptible and 
nitro-imidazole resistant subgroups. 
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Side effects 
It was not possible to analyse side effect data because all studies measured side 
effects in different ways. Twenty-one studies mentioned the number of dropouts due 
to side effects, fifteen formally assessed type and severity of side effects, but these 
data could not be analysed statistically because all studies used different methods to 
record and analyse side effects. There were no obvious differences in the incidence 
and severity of side effects between different treatment arms.  Side effects were mild 
and self-limited and mostly did not lead to discontinuation of therapy. Pooled 
dropout rates were equal for both regimens. 
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Discussion 
 
The use of systematic reviews and meta-analyses combining the results of related, 
randomised clinical trials is becoming increasingly common and has come to play an 
important role in evidence based medicine. They provide a framework for research 
synthesis, increase power and precision, provide an overall estimate and range of 
effect and identify greater-than-expected variability among study results.92,93 
There are several sources of bias in meta-analysis: publication bias (studies showing 
a significant effect are more likely to be published), location bias (the probability of 
identifying relevant studies is influenced by their results, for example studies with 
significant results are more likely to be published in the English language and in 
journals indexed in one of the major databases), multiple publication bias (different 
papers representing duplicate representations of the same trial) and poor 
methodological quality of small studies.94 Although we performed an extensive 
search of the literature, included studies in other languages than English, checked 
thoroughly for possible multiple publication and checked studies for methodological 
weaknesses, some bias cannot be excluded. The construction of a funnel plot is a 
crude method to detect selection bias.20 In our study the plot for the PPI group was 
symmetrical indicating that the amount of selection bias is limited. In the RBC 
group number and size of the studies were too small to draw any conclusions. 
Differences in dose, dosing frequency and therapy duration had to be ignored, as 
subgroups would otherwise have got too small for a proper analysis. This could have 
influenced our results. Clarithromycin 500 mg twice daily gives significantly higher 
cure rates than clarithromycin 250 mg twice daily for PPI-C-A but not for PPI-C-I.9 
Excluding studies using clarithromycin 250 mg twice daily in both arms did not 
change the results. PPI dosing once daily instead of twice daily might give lower 
eradication results.9,95 Excluding studies using PPI once daily did not change the 
results. Furthermore, extending therapy from one to two weeks increases eradication 
rates by 5-10%,96 however since nearly all studies used a seven day regimen; 
excluding studies with other therapy durations did not influence the results. 
Differences between patients included by different studies may have caused 
variation between the results of different studies but both pooled patient groups had 
the same composition, since only randomised comparative trials were evaluated.  
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RBC-C-A vs. RBC-C-I 
Our results show that the combination of RBC/clarithromycin with a nitro-imidazole 
gives a higher cure rate than the combination with amoxycillin. In the per-protocol 
analysis however this difference did not reach statistical significance. This is mainly 
caused by the fact that the study by Susi,91 which showed the largest difference 
between cure rates of the different regimens in intention-to-treat analysis, was not 
included in per-protocol analysis. Furthermore, the small number of patients in this 
analysis renders it vulnerable for type II statistical error. None of the studies 
reported differences in dropout rates and type and severity of side effects. Side 
effects were mostly mild and self-limiting. These results are somewhat different 
from the results of the meta-analysis by Laheij et al.,12 but this can be explained by 
the fact that we only used randomised comparative studies, as mentioned in the 
introduction. 
There is evidence that the combination of clarithromycin and a nitro-imidazole with 
RBC performs well despite the presence of nitro-imidazole resistance whereas the 
combination with a PPI significantly looses efficacy in case nitro-imidazole 
resistance is encountered.15,17,18,97 Van der Wouden et al. used a one week regimen 
containing RBC, clarithromycin and metronidazole with comparable eradication 
rates in metronidazole resistant and susceptible groups (ITT: 98% (59 out of 60) and 
95% (20 out of 21), respectively).18 
In a recent review by our group Van Oijen et al. systematically compared triple 
regimens with clarithromycin, a nitro-imidazole and either a PPI or RBC, and 
showed that triple therapies with RBC, clarithromycin and a nitro-imidazole give 
better cure rates than triple therapies with a PPI, clarithromycin and a nitro-
imidazole, although the difference reached statistical significance in ITT analysis 
only.11 Unfortunately few studies analysed in this review measured antibiotic 
resistance, making statistical analysis of nitro-imidazole resistant/susceptible 
subgroups impossible.  
Resistance to clarithromycin probably affects both regimens equally, but the 
prevalence of clarithromycin resistance is still low in most countries and impact on 
actual results is therefore limited.98,99 
Because of these facts it would have been better to assess results in this paper for 
nitro-imidazole resistant/susceptible subgroups separately, but only one individual 
study  reported cure rates in these subgroups.85 Sung et al. reported no statistically 
significant difference in eradication rates for nitro-imidazole susceptible and 
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resistant bacteria, which is in concordance with the results by Van der Wouden et 
al.18 
Our results support these findings. We show that when using RBC, the nitro-
imidazole containing regimen gives better cure rates than the amoxycillin containing 
regimen. This picture is much the same as for the proton pump inhibitor triple 
therapies in the nitro-imidazole susceptible subgroup. Therefore we believe that the 
clarithromycin/nitro-imidazole combination should only be used with RBC. 
 
PPI-C-A vs. PPI-C-I 
Our results show that the pooled cure rates are equal for triple therapies with a PPI, 
clarithromycin and either amoxycillin or a nitro-imidazole. None of the studies 
reported differences in dropout rates and incidence and severity of side effects. Side 
effects were mostly mild and self-limiting. Therefore, in general, we cannot 
conclude that either regimen is superior to the other. This means that other factors, 
like local prevalence of antibiotic resistant strains, cost of therapy and options for 
second-line treatment, will determine which regimen should be chosen. 
In ITT analysis five studies showed a statistically significant difference in favour of 
the nitro-imidazole containing regimen, one in favour of the amoxycillin containing 
regimen. In PP analysis six studies showed a statistically significant difference in 
favour of the nitro-imidazole containing regimen. There is however a probable 
explanation for this heterogeneity. These differences could easily have been caused 
by differences in the prevalence of nitro-imidazole resistance in different 
populations. The prevalence of nitro-imidazole resistance varies greatly from 
country to country. In European countries it’s increasing and varies from 7 to 
49%.100 In the United States it ranges from 20 to more than 50% while in Asia and 
Central Africa it may be as high as 84%.99 Recent reviews show that nitro-imidazole 
resistance decreases cure rates of triple therapy regimens based on a nitro-imidazole 
by 25 to 50%.14-16 Therefore it is interesting to compare triple regimens with a 
proton pump inhibitor, clarithromycin and either amoxycillin or a nitro-imidazole in 
nitro-imidazole susceptible and resistant subgroups. 
In seven studies these subgroups could be analysed. As expected nitro-imidazole 
resistance reduced the cure rate of the nitro-imidazole containing regimen but did 
not affect the amoxycillin containing regimen. Therefore in the nitro-imidazole 
resistant group PPI-C-A gave significantly better results than PPI-C-I. In the nitro-
imidazole susceptible group PPI-C-I gave better cure rates than PPI-C-A, but this 
latter difference did not reach statistical significance in ITT analysis. 
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This means that in areas with a high prevalence of nitro-imidazole resistance the 
PPI-C-A regimen performs better, while in areas with a low prevalence of nitro-
imidazole resistance the PPI-C-I regimen gives higher cure rates. 
Data on cure rates in clarithromycin resistant strains are still scarce, but it probably 
affects both regimens equally. Because the prevalence of clarithromycin resistant 
strains is below 10% in most countries, impact on actual cure rates is 
limited.14,45,60,101,102 
Therapies based on a nitro-imidazole might be cheaper because the clarithromycin 
dose can probably be reduced from 500 mg to 250 mg twice daily without reducing 
efficacy.9 This could be an important argument in countries where cost of therapy 
plays an important role. 
Another argument for making a choice between therapies is the number of options 
left for second-line therapy. When the first therapy fails, the options for second-line 
therapy are limited because Helicobacter may have acquired resistance against one 
or both antibiotics used in the first attempt.103 Amoxycillin resistance is virtually 
unknown but Helicobacter can be or become resistant against clarithromycin and 
nitro-imidazoles. This means that there is a problem associated with regimens 
combining both clarithromycin and a nitro-imidazole. Although these regimens are 
very effective, patients who are not cured will develop at least single, and usually 
double resistance, leaving no empirical second-line therapy.16,103-105 Culture and 
susceptibility testing are needed in patients who are not cured by this regimen.106 
This is especially a problem in areas with high prevalence of nitro-imidazole 
resistance, where more treatment failures will occur by using this regimen.15,16,103 
Strains with double resistance cannot easily be eradicated by therapies using either 
clarithromycin or a nitro-imidazole, rendering all standard therapies less suitable. 
Using a first-line therapy based on clarithromycin and amoxycillin cannot induce 
double resistance and therefore it will always leave open the (empirical) option of 
quadruple therapy (PPI-bismuth-tetracycline-I) based on a nitro-imidazole as 
second-line therapy. 
Based on the arguments listed above physicians in different countries will eventually 
make different choices between these anti-H. pylori therapies. 
 
In conclusion, our results show that when using a regimen based on RBC, 
combination with clarithromycin and a nitro-imidazole gives higher cure rates than 
combination with clarithromycin and amoxycillin. When using a PPI based regimen 
no overall difference between cure rates for PPI-C-A and PPI-C-I was found, but in 
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the nitro-imidazole susceptible subgroup PPI-C-I gives higher cure rates and in the 
nitro-imidazole resistant subgroup PPI-C-A gives higher cure rates. This means that 
factors like local prevalence of resistant strains, cost of therapy and options for 
second-line treatment will determine which regimen should be chosen. The 
clarithromycin/nitro-imidazole combination is cheaper but carries the risk of 
inducing double resistance. We recommend that when using clarithromycin and a 
nitro-imidazole, these antibiotics should be combined with RBC instead of a proton 
pump inhibitor. 
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Abstract 
 
Background: Many patients treated for H. pylori infection are using a proton pump 
inhibitor beforehand. There is conflicting evidence whether pre-treatment influences 
the efficacy of H. pylori eradication. Aim of this study was to investigate the 
influence of pre-treatment on cure rates of H. pylori eradication. 
Methods: Patients with H. pylori positive peptic ulcer disease or functional 
dyspepsia were treated with two-day quadruple therapy (lansoprazole 30mg b.d., 
colloidal bismuthsubcitrate 8dd120mg, tetracycline 8dd250mg and metronidazole 
8dd250mg). Patients were randomized to receive either three-day pre-treatment with 
lansoprazole 30mg b.d. or no pre-treatment. H. pylori was diagnosed using CLO, 
histology and culture. 
Results: Twenty-five (66%) of 38 patients with pre-treatment and 32 (84%) of 38 
patients without pre-treatment were cured (p=0.06). After adjustment for diagnosis, 
smoking status, and metronidazole resistance the influence of pre-treatment became 
slightly less pronounced (OR 0.44 95%CI: 0.1-1.7). Non-smokers and patients with 
peptic ulcer disease were more likely to achieve H. pylori eradication than smokers 
and patients with functional dyspepsia, respectively (adjusted odds ratios: 4.79 (1.2-
19) and 4.32 (1.0-18)). 
Conclusions: This two-day quadruple therapy reached an overall cure rate of 75%. 
Non-smokers and patients with peptic ulcer disease were more likely to achieve H. 
pylori eradication. Three-day pre-treatment with a proton pump inhibitor may 
decrease cure rates of this two-day quadruple therapy. 
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Introduction 
 
During the past decade it has been established that not only patients with peptic 
ulcer disease but also a subgroup of patients with functional dyspepsia benefit from 
Helicobacter pylori eradication.1,2 Therefore H. pylori test-and-eradication has been 
incorporated in most guidelines for treatment of patients with dyspeptic symptoms.3 
As a result, nowadays many patients receive therapy for H. pylori infection. 
Usually triple and quadruple therapies are used and reach high cure rates4 but none 
of the current therapies reaches 100% cure in clinical trials5 and several studies 
reported that cure rates in routine clinical practice are even lower.6 Cure rates are 
influenced by antibiotic resistance,7 duration of therapy,8 and compliance.9 
Another factor that has been implicated in therapy failure is pre-treatment with a 
proton pump inhibitor. This may be an important factor as many patients treated for 
H. pylori infection are already using proton pump inhibitors.10 Although pre-
treatment was advocated in the assumption that elevating gastric pH before starting 
the antibiotics would increase cure rates, several studies showed that pre-treatment 
was related to therapy failure for dual therapy with omeprazole and amoxicillin. 
Eradication rates were 30-70% lower in patients with pre-treatment.11-14 
The few studies investigating the influence of pre-treatment on triple and quadruple 
therapies did not find differences in eradication rates for patients with and without 
pre-treatment.15-17 However, the high eradication rates of seven-day triple and 
quadruple therapies make it difficult to study factors associated with therapy failure.  
In this paper we used a very short quadruple therapy to study the influence of pre-
treatment. In our area fairly high cure rates were reached with this quadruple 
regimen, and because of its short duration we assumed it to be more vulnerable to 
the effect of pre-treatment. That renders this regimen suitable for studying the effect 
of pre-treatment in a fairly small population. The aim of this study is to evaluate the 
influence of three-day pre-treatment with lansoprazole on cure rates of a two-day, 
intensified quadruple therapy, combining lansoprazole, bismuth, metronidazole and 
tetracycline. 
 
 
Methods 
 
Study population 
The study was conducted in 1997 at Bernhoven hospital, The Netherlands, with 
approval of the local ethics committee. Patients over 18 years with H. pylori positive 
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peptic ulcer disease or functional dyspepsia who fulfilled the exclusion criteria (use 
of bismuth compounds/antibiotics/proton pump inhibitors during the past 4 weeks, 
prior H. pylori eradication, pregnancy or lactation, known allergic reaction to the 
study medication) were eligible. All participating patients gave written informed-
consent. 
 
Investigations 
All patients had upper gastrointestinal endoscopy both before and 4-6 weeks after 
treatment. At endoscopy seven biopsies were taken: four from the antrum (two for 
histology, one for CLO® (Delta West, Australia), one for culture) and three from the 
corpus (two for histology and one for CLO®). Biopsies for histologic examination 
were fixed in neutral buffered 4% formaldehyde and H. pylori identification was 
performed on Giemsa-stained sections of paraffin embedded tissue. For culture 
Belo-Horizonte medium was used and plates were incubated microaerobically for 
seven days. Resistance to metronidazole and clarithromycin was determined by E-
test® (AB Biodisk, Sweden) with cutoff values of 2 and 8 µg/ml, respectively. 
Patients were considered H. pylori positive when two out of three tests (CLO®, 
histology, culture) were positive. Patients were regarded to be cured when all three 
tests were negative. 
Patient compliance was assessed both by interview and pill count. Side effects were 
registered using the questionnaire developed by De Boer et al.18 
 
Intervention 
Patients received open label therapy with two-day quadruple therapy consisting of 
lansoprazole 30mg b.d., together with colloidal bismuthsubcitrate (De-Nol®) 120mg, 
tetracycline 250mg and metronidazole 250mg (all three taken 8 times a day, at 9, 11, 
13, 15, 17, 19, 21, and 23 hours). Patients were randomly allocated to three-day pre-
treatment with lansoprazole 30mg b.d. or no pre-treatment at all. 
 
Randomization procedure 
After inclusion each patient received a (sequentially) numbered, sealed, opaque, 
envelope containing the recipe (with or without pre-treatment according to 
randomization) and an instruction on how to take the drugs. The envelopes were 
filled before the start of the study using a computer-generated randomization list. 
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Data analysis 
Primary outcome of the study was H. pylori eradication. The study was designed as 
a pilot study with 80% power to detect a 20% decrease in cure rate due to pre-
treatment, for an estimated 85% cure rate of this quadruple therapy without pre-
treatment (α=0.05). 
Baseline characteristics and eradication rates for both groups were compared using 
the χ2 test. Pre-treatment and baseline characteristics were related to H. pylori 
eradication by means of unadjusted and adjusted logistic regression analyses, using 
the SAS® statistical software package (SAS Institute Inc., USA). Statistical 
significance was defined as a p-value<0.05. Missing values were excluded from 
analyses. 
 
 
Results 
 
Study population 
Seventy-six patients were randomized. Table 1 shows the baseline characteristics of 
these patients. Unfortunately, despite adequate randomization, the pre-treatment 
group contained more patients with functional dyspepsia. 
 
Eradication rates, compliance, and adverse events 
Twenty-five (66%) of 38 patients with pre-treatment were cured, whereas 32 (84%) 
of 38 patients without pre-treatment were cured (p=0.06). All patients reported to 
have taken more than 90% of pills. 
Sixty-seven patients returned the side effects questionnaire. Eighty-five percent of 
patients reported “no side effects”, or “slight discomfort, not interfering with daily 
activities”, 10% reported “moderate side effects, sometimes interfering with daily 
activities” and 4% reported “severe side effects”. None of the patients discontinued 
therapy because of side effects. Most frequently reported side effects were metallic 
taste, nausea and diarrhoea. There were no differences in incidence or severity of 
side effects between the treatment arms. 
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Table 1. Baseline characteristics (intention to treat population) 
 With 
pre-treatment 
(n=38) 
Without 
pre-treatment 
(n=38) 
Gender   
 Male 21 (55%) 29 (76%) 
 Female 17 (45%) 9 (24%) 
Age   
 ≤50 years 17 (45%) 14 (37%) 
 >50 years 21 (55%) 24 (63%) 
Diagnosis*   
 Peptic ulcer disease 14 (37%) 23 (61%) 
 Functional dyspepsia 24 (63%) 15 (39%) 
Current smoking 15 (39%) 19 (50%) 
Antibiotic susceptibility   
 Metronidazole resistant 7 (23%) 5 (19%) 
 Metronidazole susceptible 24 (77%) 22 (81%) 
 Clarithromycin resistant 0 (0%) 0 (0%) 
 Clarithromycin susceptible 31 (100%) 27 (100%) 
*p<0.05 
 
Table 2. Factors associated with treatment outcome. 
 
 
Unadjusted analysis Adjusted analysis* 
Factor Odds 
ratio 
(95%CI) Odds 
ratio 
(95%CI) 
Pre-treatment 0.36 (0.1-1.1) 0.44 (0.1-1.7) 
Diagnosis (PUD vs. FD) 2.58 (0.9-7.8) 4.32** (1.0-18) 
Smoking  0.37 (0.1-1.1) 0.21** (0.1-0.8) 
Metronidazole resistance 0.44 (0.1-1.7) 0.51 (0.1-2.3) 
Male gender 1.58 (0.5-4.6)   
Age class >50 years 1.08 (0.4-3.1)   
*adjusted for pre-treatment, diagnosis, smoking, and metronidazole resistance 
**p<0.05 
 113 
Factors associated with treatment outcome 
Table 2 shows that there is a tendency towards treatment failure for patients with 
pre-treatment. For these patients the risk of treatment failure almost triples, although 
this effect becomes somewhat less pronounced after adjustment for diagnosis, 
smoking and metronidazole resistance. 
Furthermore, table 2 shows that diagnosis and smoking status are important 
predictors of treatment outcome. After adjustment, patients with peptic ulcer disease 
have an over 4 times bigger chance of treatment success compared to patients with 
functional dyspepsia, whereas smokers have an almost five times bigger chance of 
treatment failure compared to non-smokers. 
 
 
Discussion 
 
Aim of this study was to investigate the influence of pre-treatment with a proton 
pump inhibitor on H. pylori eradication. Many patients treated for H. pylori 
infection receive pre-treatment, either intentional, in an attempt to enhance cure rates 
of H. pylori eradication as used to be advocated, or unintentional, by using a proton 
pump inhibitor for treatment of gastrointestinal symptoms, peptic ulcer disease or 
reflux oesophagitis before starting H. pylori eradication. This warrants the need to 
further investigate the influence of pre-treatment. 
 
Theoretically pre-treatment with a proton pump inhibitor may influence eradication 
rates in several ways. Firstly, proton pump inhibitor therapy prevents degradation of 
acid labile antibiotics and decreases the minimum inhibitory concentration of the 
antibiotics.19 Consequently, pre-treatment may increase the effectiveness of the first 
doses of antibiotics by elevating gastric pH before starting eradication therapy. 
Secondly, proton pump inhibitor therapy decreases bacterial load, especially in the 
antrum.20 This may seem an advantage because less bacteria have to be killed. 
However, the remaining bacteria are in a less active, dormant, state21 and are 
therefore less vulnerable to the actions of antibiotics. 
 
In the present pilot study we evaluated the effect of three-day pre-treatment with 
lansoprazole on eradication rates of a two-day intensified quadruple therapy. The 
results show a trend for patients with pre-treatment towards lower eradication rates. 
But, although patients with pre-treatment have an 18% lower cure rate, this 
difference does not reach statistical significance (p=0.06). This may be due to type II 
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error, as the power of this pilot study was only sufficient for detection of a 
difference of over 20%. Furthermore, adjustment for diagnosis, smoking status and 
metronidazole resistance slightly decreased the influence of pre-treatment. This may 
be explained by the higher number of patients with functional dyspepsia, that have 
lower cure rates than patients with peptic ulcer disease, in the pre-treatment group. 
However, a 10-20% decrease may well be possible in case of this two-day quadruple 
therapy. An effect of that magnitude would be clinically relevant and might have 
consequences for clinical practice. Possibly, patients using a proton pump inhibitor 
should be advised to either interrupt the proton pump inhibitor therapy before 
starting H. pylori eradication or take an eradication regimen of longer duration. 
We used a two-day quadruple therapy in order to be able to demonstrate the 
influence of pre-treatment without the necessity to study a large number of patients. 
Seven-day quadruple regimens have higher cure rates and may possibly overcome 
any deleterious effect of pre-treatment. However, there are no published data on this. 
For 7-day proton pump inhibitor triple therapy two studies, investigating 89 and 101 
patients, found no difference in cure rates between patients with and without pre-
treatment.16,17 However, the high cure rates of these therapies require large study 
populations to detect a 10-15% difference in eradication rates. Therefore more 
research is necessary to definitely settle the issue of pre-treatment. 
 
The overall eradication rate of this two-day quadruple therapy was 75%, which is 
comparable to other research with two-day quadruple therapy.22,23 Although this is 
inadequate for use in routine clinical practice, these results after just two days of 
therapy emphasize the efficacy of quadruple therapy. 
Being a non-smoker and having peptic ulcer disease were associated with a bigger 
chance of achieving H. pylori eradication. Smoking has been identified by several 
studies to be an important factor associated with treatment failure.24-26 The 
underlying mechanism is still unknown, although decreased gastric blood flow,27 
damage to the gastric mucosa,28 and increased acid secretion29 have been implicated. 
The higher cure rates for patients with peptic ulcer disease (vs. functional dyspepsia) 
are consistent with other studies, typically reporting 5-15% higher eradication rates 
for patients with peptic ulcer disease.30-32 This may be caused by the higher 
prevalence of more virulent H. pylori strains33,34 that cause more inflammation35 in 
patients with peptic ulcer disease, as several studies have shown that patients with 
more virulent strains36 and with more inflammation37 can be cured more easily. 
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In conclusion, this two-day quadruple therapy reached an overall cure rate of 75%. 
Although this is not sufficient for use in routine clinical practice, these results after 
just two days of therapy emphasize the potency of quadruple therapy in general. 
Non-smokers and patients with peptic ulcer disease were more likely to achieve H. 
pylori eradication. Three-day pre-treatment with a proton pump inhibitor may 
decrease cure rates of two-day quadruple therapy, but more research is necessary to 
definitely establish the influence of pre-treatment with a proton pump inhibitor on 
routine therapy for H. pylori eradication. 
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Abstract 
 
Background: There is much debate about the influence of pre-treatment with a 
proton pump inhibitor (PPI) on H. pylori eradication. The few studies investigating 
the influence of pre-treatment on triple and quadruple therapies did not find 
differences in eradication rates. However, the high eradication rates make it difficult 
to study factors associated with therapy failure in small populations. In order to 
overcome this problem we performed a meta-analysis. 
Methods: The literature was searched in order to identify randomized clinical trials 
comparing modern triple/quadruple therapies for H. pylori eradication without pre-
treatment with a PPI with exactly the same regimen with pre-treatment. The overall 
risk difference (with - without pre-treatment) was calculated by pooling the risk 
differences of the individual studies weighted by the inverse of their variances. 
Results: Nine studies, investigating a total of 773 patients, were identified. There 
was considerable variation regarding therapy regimen and duration. Pooled 
eradication rates were 81.3% (312/384) for patients with pre-treatment and 81.2% 
(316/389) for patients without pre-treatment. The (weighted) overall risk difference 
was 0.1% (95%CI: -5%; 5%). 
Conclusion: Pre-treatment with a PPI does not influence H. pylori eradication. 
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Introduction 
 
Nowadays many patients receive therapy for H. pylori infection. The modern triple 
and quadruple therapies reach high cure rates1 in clinical trials, although they never 
cure all patients. Moreover, cure rates are reported to be lower in routine clinical 
practice.2 Several factors such as antibiotic resistance,3 short duration of therapy,4 
and poor compliance5 are associated with treatment failure. 
Another factor that has been implicated in therapy failure is pre-treatment with a 
proton pump inhibitor. This may be an important factor as many patients treated for 
H. pylori infection are already using proton pump inhibitors.6 Although pre-
treatment used to be advocated in the assumption that elevating gastric pH before 
starting the antibiotics would increase cure rates, several studies showed that pre-
treatment was related to therapy failure for dual therapy with omeprazole and 
amoxicillin: eradication rates were 30-70% lower in patients with pre-treatment.7-10 
This may be explained by the proton pump inhibitor induced transition of H. pylori 
into a dormant state which renders the bacteria less vulnerable to the actions of 
antibiotics.11,12 
Unfortunately, few studies investigated the influence of pre-treatment on triple and 
quadruple therapies. Most of these studies did not find differences in eradication 
rates and concluded therefore that pre-treatment did not influence cure rates of these 
therapies.13-15 However, the high eradication rates of seven-day triple and quadruple 
therapies make it difficult to study factors associated with therapy failure, unless 
large numbers of patients are investigated. Otherwise these trials are vulnerable for 
type II error. This problem may be overcome by pooling results from individual 
studies. Therefore the aim of this study was to evaluate the influence of pre-
treatment with a proton pump inhibitor on H. pylori eradication by pooling the 
results from individual studies identified by systematically reviewing the literature. 
By only including randomized comparative trials the influence of other factors 
related to treatment outcome was minimized, because the pooled populations should 
be comparable, differing only with regard to pre-treatment. 
 
 
Methods 
 
Search strategy 
Bibliographical searches were performed in the Cochrane Controlled Trials register 
(the Cochrane Library issue, 2004), Medline, Current Contents, and Cinahl, (to 
 122
August 2004) in order to identify studies investigating pre-treatment. The following 
search terms were used: (Helicobacter OR pylori) AND (pre-treatment OR 
pretreatment). Reference lists of all identified trials and reviews were searched to 
identify other relevant studies. Furthermore abstracts from the following major 
Gastroenterological meetings (1994-until August 2004) were manually searched: the 
Digestive Disease Week of the American Gastroenterological Association, the 
United European Gastroenterology Week, the World Congress of Gastroenterology, 
and meetings of the European Helicobacter pylori Study Group. All papers were 
examined for eligibility by two independent reviewers. Disagreements were resolved 
by consulting a third reviewer. In case of several publications of the same trial, only 
the most recent publication was included. 
 
Inclusion criteria 
• Randomized comparative trials, comparing a triple/quadruple therapy for 
treatment of H. pylori infection without pre-treatment with a proton pump 
inhibitor with exactly the same regimen with pre-treatment with a proton pump 
inhibitor; 
• Diagnosis of H. pylori infection before treatment with: urea breath test, faecal 
antigen test, biopsy-based urease test, histology, or culture; 
• Cure of H. pylori infection confirmed with: urea breath test, or two biopsy-
based tests (CLO/histology/culture), at least four weeks after finishing therapy; 
• Clear description of the numbers of patients treated and cured in each treatment 
group; 
 
Data extraction 
From each study the following data were extracted independently by two reviewers: 
citation, therapy regimen, pre-treatment regimen, numbers of patients treated and 
cured for each treatment arm, a description of the study population, study quality, 
and whether the study was published as a full paper. Quality was assessed using the 
Jadad score system (assessing randomisation, blinding and patient attrition, maximal 
score: 5).16 Both databases were compared and checked for inconsistencies. 
 
Data analysis 
For each individual study the risk difference was calculated by subtracting the 
eradication rate without pre-treatment from the eradication rate with pre-treatment. 
An overall estimate was calculated by pooling the individual risk differences 
weighted by their inverse variances. 
Furthermore a heterogeneity coefficient was calculated by summation of the squared 
differences between the individual risk differences and the pooled risk difference. 
Possible sources of heterogeneity were explored by examining subgroups of therapy 
regimens. In addition to this a funnel plot was constructed by plotting standard error 
against the difference in eradication rates in order to graphically detect any 
asymmetries, which may be caused by publication bias or by an exaggeration of the 
effect in small low-quality studies. 
 
 
Results 
 
The bibliographical search resulted in 649 hits in Medline, Current Contents, and 
Cinahl and 78 hits in the Cochrane Controlled Trials Register. Of these studies only 
7 investigated cure rates of triple/quadruple therapies with or without pre-
treatment.13-15,17-20 In addition to this, 3 abstracts were identified.21-23 Of the 10 
studies identified 1 was excluded because the antibiotics were given for a shorter 
period of time in the pre-treatment group.19 The remaining nine studies fulfilled the 
predefined inclusion criteria and were included in this review. Table 1 shows the 
characteristics of these papers. It shows that most studies are small (mean 86 
patients) and that there is considerable variation in the (pre-)treatment regimens 
used. The funnel plot (figure 1) was fairly symmetrical and showed more variation 
among the smaller studies.  
 
Figure 1. Funnel plot (inverted) 
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Pooled eradication rates were 81.3% (312/384) for patients with pre-treatment and 
81.2% (316/389) for patients without pre-treatment. The (weighted) overall risk 
difference (eradication rate with pre-treatment - eradication rate without pre-
treatment) was 0.1% (95%CI: -5%;5%). However, the Forest plot (figure 2) shows 
that there was heterogeneity among the studies, and this was statistically significant. 
A large part of this heterogeneity was caused by two studies reporting the biggest 
risk differences: -18%18 and +33%,22 whereas the remaining studies reported risk 
differences ranging from -8% to +10%. 
 
Figure 2. Forest plot 
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In order to examine this heterogeneity subgroups were analysed. When looking at 
the different patient populations the pooled risk difference was 2.4% (82.3% vs. 
78.6%; 95%CI: -7%; 11%) for studies investigating patients with peptic ulcer 
disease (n=230) and it was -0.7% (80.8% vs. 82.4%; 95%CI: -6%; 5%) for studies 
investigating patients with both peptic ulcer disease and functional dyspepsia 
(n=543). When looking at “quadruple therapies” only (n=192) the pooled risk 
difference was -6.3% (70.5% vs. 76.3%, 95%CI: -19%; 6%). For all “modern triple 
therapies” (n=491) it was 2.7% (83.2% vs. 80.6%, 95%CI: -3%; 9%). When these 
were further subdivided in triple therapies combining a proton pump inhibitor, 
clarithromycin and amoxicillin (n=172) and triple therapies combining a proton 
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pump inhibitor, a macrolide and a nitro-imidazole (n=241) the pooled risk 
differences were 2.8% (70.9% vs. 69.8%, 95%CI: -10%; 16%) and 7.3% (90.8% vs. 
83.5%, 95%CI: -1%; 16%), respectively. The number of studies was too small to 
perform meta-regression analyses. 
 
 
Discussion 
 
The literature search confirmed that few studies investigated the influence of pre-
treatment. Furthermore, these studies included relatively few patients and therefore 
did not have adequate power to detect possibly relevant differences in cure rates. In 
order to overcome this problem we pooled the results of nearly eight hundred 
patients and we did not find a difference in cure rates between patients with and 
without proton pump inhibitor pre-treatment. 
 
Of course meta-analysis is vulnerable to several biases, such as publication and 
selection bias. In order to minimize these biases abstracts were included and papers 
were not selected on the basis of language. Furthermore study selection and data 
extraction were done by two independent reviewers using pre-defined criteria and all 
data were thoroughly checked in order to identify duplicate reports. In addition to 
this, the constructed funnel plot showed no evident asymmetries, which usually are 
suggestive of publication bias or exaggeration of the treatment effect by small 
studies of low quality. 
 
Unfortunately there was considerable heterogeneity among the studies included. 
Much of this heterogeneity was caused by two studies reporting the biggest risk 
differences.18,22 One of these studies reported an 18% lower cure rate (not 
statistically significant) in the pre-treatment group when investigating the influence 
of 3-day pre-treatment with lansoprazole on a 2-day quadruple therapy.18 However 
the authors state that the pre-treatment effect may have been exaggerated by the 
inclusion of more patients with functional dyspepsia, who are more difficult to cure, 
in the pre-treatment group.24 Moreover the duration of this quadruple therapy was 
very short, which may render it more vulnerable to therapy failure than quadruple 
therapies of longer duration. This may explain why Perng et al.23 did not find a pre-
treatment effect when using 7-day quadruple therapy. 
The other study claimed a 33% higher cure rate in the pre-treatment group when 
investigating the influence of 49-day pre-treatment with omeprazole on 7-day triple 
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therapy with clarithromycin and metronidazole, including only 36 patients.22 A 
similar study including 105 patients and using 7-day pre-treatment showed a much 
smaller pre-treatment effect.15 
 
Furthermore, when looking at the evidence it is remarkable that none of the studies 
clearly found a pre-treatment effect. If there were a pre-treatment effect one would 
expect that even in a group of underpowered studies, at least some of these studies 
would find a statistically significant difference in cure rates. 
 
In conclusion, there is no evidence from the literature that pre-treatment with a 
proton pump inhibitor influences cure rates of triple and quadruple therapies for H. 
pylori eradication. 
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Abstract 
 
Background: It has been established that a H. pylori test-and-treat strategy is as 
effective as prompt endoscopy followed by targeted treatment, but cheaper, for the 
primary management of dyspeptic patients. Therefore, an open access urea breath 
test (UBT) facility was established in a community hospital in The Netherlands. 
General practitioners (GPs) were informed about the H. pylori test-and-treat strategy 
for patients with dyspeptic symptoms, less than 55 years old, and without alarm 
symptoms. Our aim was to evaluate the open-access UBT facility and the associated 
H. pylori test-and-treat protocol in everyday practice. 
Methods: Data from all patients having a 13C UBT were registered. Furthermore, 
data from the endoscopy registration were retrieved. Absolute numbers and 
proportions of patients <55 years having upper gastrointestinal endoscopy in 2003 
(after introduction of the UBT) and in 2001 (before introduction) were compared, 
using a similar hospital nearby, without an open-access UBT facility, as a reference. 
Finally, general practitioners were sent questionnaires about the UBT service. 
Results: Between May 2002 and December 2003, 1201 UBTs were performed in 
primary care patients (841 for primary screening, 355 for confirmation of 
eradication). Of 841 patients referred for primary screening (mean age 45 years, 
24% ≥55 years, 46% male, 18% of Turkish/Moroccan descent) 35% tested positive. 
Older age and Turkish/Moroccan descent were associated with a higher probability 
of having a positive UBT. Although the absolute number of endoscopies in both 
hospitals increased, the proportion of patients <55 years having endoscopy 
decreased significantly in the hospital with UBT facility (from 60% in 2001 to 45% 
in 2003 (p<0.0001)), but not in the hospital without the UBT facility (from 57% to 
52%, p=0.10). More than 80% of GPs reported in the questionnaire that the UBT 
was very useful and decreased the numbers of patients referred for endoscopy. 
Conclusions: The UBT facility was appreciated and frequently used by GPs. One 
out of three dyspeptics in primary care in The Netherlands is still infected with H. 
pylori. Although the proportion of young patients referred for endoscopy decreased, 
still many patients under the age of 55 were endoscoped. These data was well as the 
questionnaire results demonstrate that the proposed guideline was not yet properly 
implemented. 
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Introduction 
 
Dyspepsia is common: an estimated 20-40% of the general population experiences 
dyspeptic symptoms each year. Although only 25% of these patients consult their 
general practitioners, dyspeptic symptoms still account for 2-5% of all primary care 
consultations. About 25% of dyspeptics are referred to secondary care or for 
endoscopic examination within one year after the first dyspepsia-related physician 
visit.1,2 Moreover, many of these patients use acid suppressive drugs, which are 
among the most frequently used drugs worldwide.3 Thus, dyspepsia constitutes a 
major health problem. 
Dyspeptic symptoms can have several causes such as gastro-oesophageal reflux 
disease, peptic ulcer disease, and malignancy. If no organic pathology can be 
detected during endoscopy patients are diagnosed as having “functional dyspepsia”. 
In most Western populations the majority of patients referred for endoscopy are 
diagnosed with functional dyspepsia (50-70%), followed by gastro-oesophageal 
reflux disease (20-35%) and peptic ulcer disease (5-15%), while gastric/oesophageal 
cancer is rare (0-2%).4-7  
Ideally, therapy would focus on correcting the underlying pathophysiological 
mechanism, but unfortunately, symptoms alone are notoriously unreliable for that 
matter.5-8 Upper gastrointestinal endoscopy provides most information and allows 
for targeted therapy, but it is invasive, troublesome to the patients, and associated 
with considerable costs, while in 50-70% of patients no organic cause for their 
symptoms can be found.4,5,9  
Therefore, treatment strategies for dyspepsia have been devised in which patients are 
managed without prior endoscopy. The aim of such a strategy is not to establish a 
firm diagnosis, but to (safely) achieve adequate symptom reduction. The H. pylori 
test-and-treat strategy has been most elaborately investigated.4,10,11 In this strategy 
all patients have a non-invasive test for H. pylori infection. H. pylori positive 
patients receive anti-Helicobacter therapy, while H. pylori negative patients receive 
acid suppressants. As a result, all patients with peptic ulcer disease are adequately 
treated,12 while also some 15% of patients with H. pylori positive functional 
dyspepsia will have symptomatic benefit.13,14 Furthermore, patients with reflux 
disease receive adequate treatment with a proton pump inhibitor after being 
documented to be H. pylori negative.15 Additionally, H. pylori induced gastritis is 
associated with the development of gastric cancer, and (timely) H. pylori eradication 
may prevent development of gastric cancer.16 
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Several studies showed that the H. pylori test-and-treat strategy is safe, cheap, and as 
effective as prompt endoscopy followed by targeted treatment, while the number of 
endoscopies is largely reduced.4,10,11,17,18 Therefore nowadays, most international 
dyspepsia guidelines advise a test-and-treat strategy, although usually this strategy is 
limited to young patients without alarm symptoms in order not to delay diagnosis in 
patients with upper gastrointestinal malignancy.19,20-22  
In view of these developments a H. pylori test-and-treat protocol, comparable to the 
European consensus guideline, was proposed to all general practitioners in our 
region. Because a test-and-treat strategy can not function without a reliable non-
invasive H. pylori test, an open access 13C urea breath test (UBT) facility was 
introduced. The aim of this study was to evaluate the UBT facility and the 
associated H. pylori test-and-treat strategy in everyday practice in The Netherlands. 
 
 
Methods 
 
The proposed test-and-treat protocol 
In May 2002 all general practitioners in the city of Oss, The Netherlands, and the 
surrounding area received a new dyspepsia management protocol by mail. More 
information about this protocol was provided on two training sessions. The general 
practitioners were advised to perform a H. pylori urea breath test in every patient 
under the age of 55 with dyspeptic symptoms and without alarm symptoms 
(unexplained weight loss, anaemia, jaundice, dysphagia, upper gastrointestinal 
bleeding, or persistent vomiting). In case of H. pylori infection triple therapy with a 
proton pump inhibitor, clarithromycin 500mg, and amoxicillin 1000mg, all twice 
daily, followed by a second UBT to test for cure (at least 4 weeks after finishing 
therapy) was advised. In case of a negative (primary screening/confirmatory) UBT 
reassurance and symptomatic acid suppressive therapy were advised. For patients 
over 55 years of age or with alarm symptoms endoscopy was recommended. Of 
course, adherence of the general practitioners to the proposed protocol was 
voluntary and no further actions were taken to change the behaviour of the general 
practitioners. 
 
Data collection/analysis 
Data were collected from three sources: the UBT facility, the endoscopy 
registration, and the questionnaires sent to the general practitioners in our area. All 
data were analysed using the SAS® statistical software package (SAS Institute Inc., 
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USA). Missing values were excluded from analysis. Statistical significance was 
defined as a p-value<0.05. 
 
UBT facility 
Data regarding age, gender, ethnic background, prior therapy for H. pylori 
eradication, current H. pylori status were collected from all patients visiting the open 
access urea breath test facility of Bernhoven Hospital, Oss, The Netherlands, 
between May 2002 and December 2003. Patients were tested after an overnight fast 
using the BreathIDTM system (a validated near patient 13C urea breath test 
manufactured by Oridion Systems, Israel).23 They were not allowed to use acid 
suppressants during one week preceding the test, or antibiotics during four weeks 
before the test. Before the test all patients were questioned about the use of acid 
suppressive medication and antibiotics. 
 
Endoscopy registration 
Data from the hospital’s endoscopy registration were retrieved. The proportion of 
endoscoped patients <55 years in 2003 (after introduction of the UBT) was 
compared with 2001 (before introduction), using Bernhoven Hospital, Veghel (a 
nearby, equally sized hospital, serving a similar population), which does not have an 
open access UBT facility, as a reference. 
 
Questionnaire 
All general practitioners in and around the city of Oss were sent questionnaires (and 
in case of non-response two reminders). This questionnaire was adapted from Shaw 
et al.24 It included 5 statements related to the general physician’s perception of the 
UBT facility, and 5 statements regarding the consequences of a UBT result for 
further treatment of the patient, to be scored on a 5-point Likert scale. Furthermore, 
the monthly number of referrals for UBT or serological H. pylori screening was 
asked. Additionally, questions were asked about the necessity to stop acid 
suppressive therapy before testing and about the timing of a confirmatory UBT, to 
assess GP knowledge about the optimal use of the UBT facility. 
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Results 
 
UBT facility 
Between May 2002 and December 2003 1201 UBTs were performed in 940 adult 
primary care patients visiting the open access UBT facility. Of these tests, 841 were 
primary screening tests because of dyspeptic symptoms, 317 were confirmatory tests 
after a first therapy for H. pylori eradication, 36 after a second, 1 after a third, and 1 
after a fourth attempt to eradicate H. pylori infection. The remaining 5 tests were 
duplicate tests. The mean time the nurse needed to perform the entire test procedure 
was 17 minutes (SD: 3 minutes). Baseline characteristics of the patients are 
summarized in table 1. 
 
Table 1. Baseline-characteristics of primary care patients refer to the open access 
UBT facility 
  Screening test for 
dyspeptic symptoms 
(n=841) 
Confirmatory test after 
1stline therapy 
(n=317) 
Age   
 Mean (SD) 45 (15) 50 (13) 
 <55 years 640 (76%) 201 (63%) 
 ≥55 years 201 (24%) 116 (37%) 
Gender   
 Male 390 (46%) 146 (46%) 
 Female 451 (54%) 171 (54%) 
Ancestry   
 Dutch 691 (82%) 219 (69%) 
 Turkish/Moroccan 150 (18%) 98 (31%) 
Urea breath test   
 Positive 297 (35%) 39 (12%) 
 Negative 544 (65%) 278 (88%) 
 
Overall, of the 841 patients referred for primary screening 297 (35%) were infected 
with H. pylori. The majority of patients (76%) were under 55 years of age, as 
recommended in the protocol. The prevalence of H. pylori infection was lower in 
patients under 55 years (212/640 (33%)) than in patients over 55 years of age 
(85/201 (42%), p-value for difference<0.0001). Furthermore, the prevalence of H. 
pylori infection was higher in patients of Mediterranean (usually Turkish) ancestry 
(108/150 (72%)) than in patients of Dutch ancestry (189/691 (27%), p-value for 
difference<0.0001). In our study population some 18% of patients were of 
Turkish/Moroccan descent which is slightly higher than in the Dutch population as a 
whole (10%). Figure 1 further illustrates the prevalence of H. pylori infection 
according to age group and ancestry. Interestingly, this figure shows that in patients 
of Dutch ancestry less than 30 years of age H. pylori prevalence is only 2%. 
 
Figure 1. Prevalence of H. pylori infection related to age group and ancestry (the 
brackets indicate the standard errors of the estimates). This figure includes data from 
28 patients less than 18 years of age not included in the other analyses. 
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Of the 317 patients tested for cure of the infection after a first attempt to eradicate H. 
pylori, 278 (88%) had a negative urea breath test, irrespective of ancestry. Of the 
297 patients with a positive screening UBT, 224 (75%) were also referred for a 
confirmatory test (of which 196 (88%) were negative) after a median of 43 days. 
Forty-six (21%) of these confirmatory tests were performed within 5 weeks after the 
first test, which demonstrated that these tests were performed within 4 weeks after 
finishing the H. pylori eradication, which is considered to be inadequate. These 
numbers also imply that 25% of patients either were not tested for cure, or did not 
receive therapy for H. pylori eradication. 
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Table 2. Numbers of upper gastrointestinal endoscopies in primary care patients. 
  2001 
(before 
introduction) 
2002 2003 
(after 
introduction) 
Mean age* 52 (16) 54 (16) 57 (16) 
<55 years* 219 (60%) 230 (53%) 216 (45%) 
≥55 jaar* 149 (49%) 204 (47%) 266 (55%) 
Intervention 
group Hospital 
Bernhoven, 
Oss Total 368 434 482 
Mean age** 52 (15) 53 (16) 54 (16) 
<55 years 328 (57%) 312 (55%) 329 (52%) 
≥55 years 248 (43%) 253 (45%) 301 (48%) 
Control group 
Hospital 
Bernhoven, 
Veghel Total 576 565 630 
*p<0.0001, **p=0.02 (for 2003 compared with 2001) 
 
Endoscopy registration 
Table 2 summarizes the results extracted from the endoscopy registration. It shows 
that the absolute number of endoscopies gradually increased between 2001 (before 
the introduction of the UBT facility) and 2003 (after introduction), in our hospital as 
well as in the nearby hospital without open-access UBT facility. However, the 
proportion of patients under 55 years of age having endoscopy decreased 
significantly in our hospital (from 60% in 2001 to 45% in 2003 (p<0.0001)), but not 
in the control hospital (from 57% to 52%, p=0.10). Nonetheless, still 216 patients 
under 55 years were endoscoped in our hospital in 2003. 
 
Questionnaire 
Questionnaires were returned by 53 of 100 general practitioners. On average these 
general practitioners reported to refer 2 (SD: 3) patients a month for UBT, and 0.2 
(SD: 0.4) patients a month for H. pylori serology. Forty-seven (89%) of the 
responding general practitioners stated that that they trusted the UBT result. Forty-
three (81%) reported that the UBT enabled them to improve their treatment of 
patients with dyspeptic symptoms, and forty-one (77%) reported that the open 
access UBT facility had decreased the number of their endoscopy referrals. 
Regarding the consequences of a UBT, 33 (62%) general practitioners stated that a 
negative UBT usually or always enabled them to reassure the patient without 
endoscopy. However, 12 (23%) of GPs stated that they usually referred a patient 
with a negative UBT for endoscopy, and 5 (9%) stated to usually refer for 
 139 
endoscopy if the UBT was positive. Forty-seven (89%) GPs reported to usually or 
always prescribe therapy for H. pylori eradication after a positive UBT, and 31 
(58%) GPs answered to usually or always refer the patient for a confirmatory test 
after eradication. 
The majority of GPs answered that acid suppressive medication had to be stopped 
two weeks before the UBT, as mentioned in the protocol, but 11 (21%) thought this 
period should be as long as 4 weeks, while 6 (11%) answered that acid suppressive 
medication did not have to be stopped at all. Regarding the number of weeks after 
H. pylori eradication after which a confirmatory UBT can be performed, 2 GPs (4%) 
answered that this could be done within two weeks, 34 (64%) answered 4 weeks, 12 
(23%) answered 12-26 weeks, and 5 (9%) did not know. 
 
 
Discussion 
 
The aim of this study was to evaluate the newly introduced, open access UBT 
facility and the proposed H. pylori test-and-treat strategy for primary care patients 
with dyspeptic symptoms in our region. Our results show that the open access UBT 
facility was appreciated and frequently used by general practitioners. However, a 
clear reduction in the number of endoscopic examinations could not be 
demonstrated, although the proportion of young patients having endoscopy 
decreased over time. 
 
Regarding the prevalence of H. pylori infection it should be noted that more than a 
third of all dyspeptic patients were infected, even although the majority of patients 
was under 55 years of age. This is comparable to another recent Dutch study in 
which 38% of primary care patients with dyspeptic symptoms in the north of The 
Netherlands were infected with H. pylori.  Thus, H. pylori infection is still quite 
common among dyspeptic patients in The Netherlands. Therefore, an H. pylori test-
and-treat strategy remains attractive for Dutch physicians. 
4
The risk of being infected with H. pylori increased with age, which, assuming that 
H. pylori infection is acquired during childhood, is usually explained as a cohort 
effect reflecting the H. pylori prevalence as well as sanitary customs during 
childhood. Furthermore, our results show that there is a huge difference in H. pylori 
prevalence between dyspeptic patients of Dutch ancestry and dyspeptic patients of 
Turkish/Moroccan ancestry. Of the patients of Turkish/Moroccan ancestry more 
than 70% were infected. But even in these patients prevalence seemed to be much 
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lower in the subgroup below 20 years of age, possibly because many of these young 
patients were born and raised in The Netherlands. Interestingly, in dyspeptic patients 
of Dutch ancestry below the age of thirty years H. pylori infection was almost 
absent. 
 
H. pylori eradication was successful in seven out of every eight patients treated in 
routine daily practice. Because patients who are not cured have persistent health 
risks, our protocol, as well as the European dyspepsia guideline, advises that all 
patients treated for H. pylori infection should have routine confirmatory testing in 
order to prevent future disease and to reassure the patient. However, our results 
show that a quarter of the patients treated for H. pylori infection did not have a 
second UBT. 
 
In this real-life, observational study we could not demonstrate an effect on the total 
number of endoscopies, which is somewhat surprising since trial data show that the 
test-and-treat strategy decreases the number of endoscopies needed to manage 
dyspepsia. For example, a randomized trial in The Netherlands reported a 67% 
reduction in the number of endoscopies when comparing test-and-treat with prompt 
endoscopy, while the degree of symptom reduction was similar in both groups.4 
Other comparative studies have shown similar results.11, 24  
However, there are several factors that make it difficult to find a decrease in the 
number of endoscopies in this population. Firstly, participation of the general 
practitioners was voluntarily and all endoscopy referrals were honoured, regardless 
of the protocol. Therefore, some GPs probably did not follow the suggested protocol 
at all, while others may have implemented the protocol only partially, which is 
understandable since the Dutch primary care dyspepsia guideline leaves it up to the 
general practitioner to choose between endoscopy, acid suppressive therapy, and H. 
pylori test-and-treat. This non-adherence to the proposed test-and-treat protocol is 
illustrated by the questionnaires in which a considerable proportion of GPs indicated 
to usually refer patients with a negative UBT for endoscopy. 
Secondly, most general practitioners in The Netherlands refer only a minority of 
patients for prompt endoscopy (even if over 55 years of age). Therefore, the 
reduction of the number of endoscopies may not be as evident when comparing test-
and-treat with “usual care”, as opposed to comparing test-and-treat with direct 
endoscopy. In fact, the proposed test-and-treat protocol may even have increased the 
numbers of endoscopies in patients over 55 years compared to usual care, yielding 
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little overall benefit. This is supported by Ladabaum et al. who compared a test-and-
treat strategy with usual care in patients with ulcer-like dyspepsia and found no 
differences in endoscopy rates after 1 year.25 
And finally, patients were free in the choice of the hospital where the endoscopy 
will be performed. Since waiting lists for endoscopy were very short in our hospital, 
there was inflow of patients from surrounding areas, which may have masked any 
decrease caused by the introduction of the test-and-treat protocol. 
However, the decreased proportion of patients less than 50 years of age in our 
hospital (compared to a nearby hospital serving a similar population but without 
open-access UBT facility) suggests that fewer young patients were referred for 
endoscopy in our hospital. This is supported to some extent by the fact that about 
75% of responding GPs stated that the UBT had decreased their endoscopy referrals. 
But overall, it seems that the UBT was mainly used for a group of dyspeptic patients 
of whom previously only a minority was referred for endoscopy. 
 
This trial and the questionnaire results have demonstrated to us that we have to 
educate our GPs more about the test-and-treat protocol and the proper use of 
diagnostic resources in order to obtain the full benefit for this management strategy. 
More education regarding the UBT should be provided since more than a third of the 
general practitioners did not know when confirmatory breath testing should be done, 
more than 10% did not know that acid suppression should be stopped in order to 
avoid false-negative test results, and more than 10% reported often not to eradicate 
H. pylori in case of a positive test result. 
 
In conclusion, the UBT facility was appreciated and frequently used by general 
practitioners for management of patients with dyspeptic symptoms. One out of three 
dyspeptics in primary care was infected with H. pylori, especially elderly patients 
and patients of Turkish/Moroccan ancestry. In patients of Dutch ancestry under the 
age of 30 H. pylori infection was rare. The real-life cure rate for proton pump 
inhibitor based triple therapy in The Netherlands was 88%. Although the proportion 
of young patients referred for endoscopy decreased after the introduction of the 
open-access UBT facility, still many patients under the age of 55 were endoscoped, 
suggesting that the proposed guideline was not yet properly implemented and 
continuing education is needed in order to realize the benefits of the test-and-treat 
strategy in everyday care. 
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Abstract 
 
Background: With the advent of empirical treatment strategies many primary care 
patients with upper gastrointestinal symptoms are treated with proton pump 
inhibitors without prior investigation. However, the effectiveness of this approach in 
this population is still unclear. 
Methods: In this observational study general practitioners across The Netherlands 
prospectively registered data from patients with uninvestigated upper 
gastrointestinal symptoms for whom they decided to start treatment with 
esomeprazole 20/40mg once daily for two or four weeks. The severity of upper 
gastrointestinal symptoms was measured by means of a questionnaire before and 
after treatment. The proportions of patients with complete symptom relief (no 
dyspeptic symptoms during the last week of treatment) was calculated and related to 
patient characteristics. 
Results: Out of 2,892 patients 1,330 (46%) reported complete symptom relief. 
Being male, and being treated for 4 weeks (vs. 2) were associated with a higher 
probability of experiencing complete symptom relief (OR (95%CI): 1.19 (1.0-1.4), 
1.23 (1.0-1.5), respectively). Patients using antacids/H2-receptor-
antagonists/prokinetics at baseline, patients with epigastric pain-predominant 
symptoms, patients with moderate/severe symptoms, and patients with more than 4 
symptoms, all had a lower probability of achieving complete symptom relief (0.69 
(0.6-0.8), 0.65 (0.5-0.9), 0.70 (0.5-0.9), 0.57 (0.5-0.7), respectively). 
Conclusion: Almost half of primary care patients with uninvestigated upper 
gastrointestinal symptoms selected by their general practitioners for empiric proton 
pump inhibitor treatment reported complete symptom relief during treatment with 
esomeprazole. 
 147 
Introduction 
 
Upper gastrointestinal symptoms are very common in the general population: about 
25%-40% of people suffer from such symptoms at least once a year.1 Although only 
a quarter of these patients actually seek medical attention, upper gastrointestinal 
symptoms still account for up to 5% of all primary care consultations and some 15-
25% of these patients are referred to secondary care or for upper gastrointestinal 
endoscopy within in the same year.2,3 
Of the patients with upper gastrointestinal symptoms some (20-30%) have gastro-
oesophageal reflux disease, and some 5-10% have peptic ulcer disease. In the 
majority of patients no organic cause can be found and their condition is labelled 
“functional dyspepsia” (60-70%).4 Unfortunately, the presenting symptoms are 
notoriously unreliable for predicting findings at endoscopy and additional 
investigations such as upper gastrointestinal endoscopy and/or pH registration are 
necessary for establishing a firm diagnosis.5,6 
Many patients with upper gastrointestinal symptoms are treated with proton pump 
inhibitors. These drugs are very effective for treatment of gastro-oesophageal reflux 
disease7,8 and peptic ulcer disease,9 but much less for functional dyspepsia.10 
However, with the advent of empirical treatment strategies many patients with upper 
gastrointestinal symptoms are treated with proton pump inhibitors without prior 
investigation.11 
Although much research has been done with proton pomp inhibitors, only a few 
studies have investigated the effectiveness of proton pump inhibitors in primary care 
patients with uninvestigated upper gastrointestinal symptoms. Therefore, the aim of 
this study was to examine the effectiveness of esomeprazole for treatment of 
primary care patients with uninvestigated upper gastrointestinal symptoms. 
 
 
Methods 
 
Study design and population 
This study was solely observational. Between September 2001 and February 2003 
participating general practitioners (GPs) across The Netherlands prospectively 
registered data about empiric esomeprazole treatment of adult patients with 
uninvestigated upper gastrointestinal symptoms, who had not used a proton pump 
inhibitor during one month before starting treatment with esomeprazole. GPs were 
free in deciding which treatment strategy they chose to manage the symptoms of 
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each individual patient. Therefore, only patients for (with) whom the GP decided to 
start treatment with esomeprazole were registered. Furthermore, GPs were free in 
their choice of dose and duration of esomeprazole therapy. Patients were excluded 
from analysis if they had not returned for a second visit within one week after the 
end of treatment. 
 
Data collection 
All data were gathered by questionnaires filled out by the GPs. Before treatment 
data regarding age, gender, and current medication were registered. Furthermore, 
patients were asked about the number of days with upper gastrointestinal symptoms 
during the last week before entering the observational period, as well as about the 
severity of seven upper gastrointestinal symptoms (heartburn, retrosternal pain, 
regurgitation, bloating, epigastric pain, nausea and vomiting) using a 4-point Likert 
scale (none, mild, moderate, severe). 
At the second visit, within one week after finishing treatment, patients were asked 
the same questions about the number of days with upper gastrointestinal symptoms 
during the last week of esomeprazole treatment. Furthermore, the severity of the 7 
symptoms mentioned above was registered again. 
 
Data analysis 
The primary outcome was “complete symptom relief” defined as 0 days with upper 
gastrointestinal symptoms during the last week of esomeprazole therapy. The 
relationships between baseline characteristics, severity/kind of symptoms, 
dose/duration of therapy and the primary outcome (complete symptom relief) were 
investigated by means of unadjusted and adjusted logistic regression analyses using 
the SAS® statistical software package (SAS Institute Inc., USA). Symptom severity 
was defined as the highest score (mild, moderate or severe) reported for any of the 
individual symptoms. Furthermore, patients were sub grouped based on their 
symptoms. Patients with heartburn, acid regurgitation or retrosternal pain as most 
severe symptom were classified as “reflux-predominant”. Patients with epigastric 
pain as most severe symptom were classified as “epigastric pain-predominant”. 
Patients with nausea, bloating or vomiting as most severe symptom were classified 
as “dysmotility-predominant”. Statistical significance was defined as a p-value 
<0.05. Missing values were excluded from analyses. 
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Results 
 
Study population 
During the study period 3,405 patients were included by 449 general practitioners. 
Of these patients, 513 did not return for a second visit (within one week after 
finishing esomeprazole therapy) and were excluded from the study. The remaining 
2,892 patients were included in the analyses. Table 1 shows the baseline 
characteristics of these patients. 
 
Table 1. Patient characteristics 
  Number (%) 
(n=2,892) 
Mean age (SD) 52 (16) 
Gender  
 Male 1,328 (47%) 
 Female 1,527 (53%) 
Predominant symptom  
 Reflux-like* 1,286 (44%) 
 Epigastric pain 262 (9%) 
 Dysmotility-like** 106 (4%) 
 Mixed 1,238 (43%) 
Most severe symptom  
 Mild 313 (11%) 
 Moderate 1,655 (57%) 
 Severe 924 (32%) 
Baseline medication  
 None 1,879 (66%) 
 Antacid 364 (13%) 
 H2-receptor antagonist 499 (18%) 
 Prokinetic 110 (4%) 
*most severe symptom: heartburn, regurgitation, or retrosternal pain 
**most severe symptom: bloating, nausea, or vomiting 
 
Baseline symptoms 
Only 109 patients (4%) reported just one symptom and the remaining patients 
reported a combination of symptoms: 329 (11%) reported to have two symptoms, 
600 (21%) three symptoms, 750 (26%) four, 559 (19%) five, 383 (13%) six, and 162 
(6%) all seven symptoms. Table 1 shows that after symptom sub grouping “reflux-
predominant” symptoms were most common (1,286 patients (44%)), followed by 
“mixed symptoms without predominant pattern” (1,238 patients (43%)), while there 
were only small subgroups with “epigastric pain-predominant” symptoms (262 
patients (9%)) and “dysmotility-predominant” symptoms (106 patients (4%)). 
Three-hundred-and-thirteen patients (11%) had only mild symptoms, 1,655 patients 
(57%) had at least one moderate symptom but no severe symptoms, and 924 (32%) 
reported at least one severe symptom. 
Figure 1 illustrates that most patients had experienced upper gastrointestinal 
symptoms on three or more days of the week prior to treatment, a large group of 
patients (1,026, 39%) even on every day of that week. 
 
Figure 1. Number of days with upper gastrointestinal symptoms during the last week 
before treatment and during the last week of treatment. 
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Intervention 
All patients were treated with esomeprazole once daily, but GPs were free in their 
choice of dose and duration. Eighteen-hundred-and-ninety patients (66%) used 
40mg of esomeprazole while the remaining patients used 20mg of esomeprazole. 
Two-thousand-one-hundred-and-forty-seven patients (76%) were treated for 2 
weeks, 666 (24%) for four weeks. Nearly all patients (95%) reported to have taken 
all pills as prescribed. 
 
 150
 151 
Treatment success 
Of the 2,892 patients included 1,330 (46%) reported complete symptom relief, 
defined as zero days with upper gastrointestinal symptoms during the last week of 
esomeprazole therapy. Figure 1 shows that another 1,047 patients (37%) had 
experienced symptoms on only one or two days during the last week of treatment. 
The incidence of side effects was low (4%). 
 
Table 2. Factors associated with complete symptom relief 
 
Unadjusted 
analysis 
Adjusted analysis** 
 
Odds 
ratio 
(95% 
CI) 
Odds 
ratio 
(95% 
CI) 
Age group (≥50 years vs. <50 years) 0.99 (0.9-1.1) 0.95 (0.8-1.1) 
Male gender 1.19* (1.0-1.4) 1.19* (1.0-1.4) 
Epigastric pain-predominant (vs. other) 0.72* (0.6-0.9) 0.65* (0.5-0.9) 
Moderate/severe symptoms (vs. mild) 0.62* (0.5-0.8) 0.70* (0.5-0.9) 
Number of symptoms (>4 vs. ≤4) 0.54* (0.5-0.6) 0.57* (0.5-0.7) 
Baseline antacid/H2RA/prokinetic use  0.69
* (0.6-0.8) 0.69* (0.6-0.8) 
Esomeprazole dose (40mg vs. 20mg) 0.78* (0.7-0.9) 0.99 (1.0-1.0) 
Esomeprazole duration (4 vs. 2 weeks) 1.18 (1.0-1.4) 1.23* (1.0-1.5) 
*p<0.05 
**Odds ratios adjusted for age group, gender, predominant symptom, symptom severity, number of 
symptoms, baseline use of antacids/ H2-receptor antagonists/ prokinetics, and dose/ duration of 
esomeprazole treatment. 
 
Factors associated with treatment success 
Table 2 shows that being male, and using esomeprazole for four weeks (vs. two) 
were associated with a higher probability of achieving complete symptom relief. 
Furthermore, this table shows that using antacids/ H2-receptor-antagonists/ 
prokinetics at baseline, having predominant epigastric pain, having severe 
symptoms, and having more than 4 symptoms at inclusion were associated with a 
lower probability of achieving complete symptom relief. Surprisingly, in unadjusted 
analysis, patients treated with 20 mg of esomeprazole more often had complete 
symptom relief than patients treated with 40mg of esomeprazole. However, this 
effect disappeared after adjustment for age, gender, predominant symptom, 
symptom severity, number of symptoms, baseline medication use, and treatment 
duration. Therefore, this effect was probably caused by confounding by indication: 
patients with mild symptoms were more often treated with 20mg of esomeprazole, 
whereas patients with more severe symptoms were more often treated with 40mg of 
esomeprazole. 
Figure 2 further illustrates the relationship between the number of symptoms 
reported at baseline and the proportion of patients with complete symptom relief. It 
shows that the more symptoms a patient reported at baseline the lower the chance of 
becoming asymptomatic after treatment. 
 
Figure 2. Complete symptom relief related to the number of symptoms reported at 
baseline. 
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Symptom subgroups 
Treatment effect 
Figure 3 shows that although the proportion of symptom-free patients was somewhat 
lower in the patients with predominant epigastric pain, overall the response patterns 
were fairly similar for the various symptom subgroups, suggesting that symptom sub 
grouping is of little use for predicting response to proton pump inhibitor therapy. 
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Figure 3. Number of days with upper gastrointestinal symptoms during the last week 
of treatment, according to symptom sub group. 
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Changes in symptom pattern 
Figure 4 illustrates the relationships between the symptom patterns before and after 
esomeprazole therapy. Again, this figure shows that the proportion of asymptomatic 
patients after treatment is lower in the “epigastric pain-predominant” group. 
Furthermore, it shows that the majority of patients with reflux-predominant 
symptoms still had reflux-predominant symptoms after therapy, while some 
switched to the “mixed” group. Of the patients with “mixed symptoms” at baseline 
who did not become symptom-free, the majority still had mixed symptoms, while 
some were classified as “reflux-predominant”. For patients with initially “epigastric 
pain-predominant” symptoms the majority of (still symptomatic) patients switched 
to other sub groups, especially the “mixed” group, and the “dysmotility-
predominant” group, while hardly any of these patients were still in the “epigastric 
pain-predominant” group. Of the patients with initially “dysmotility-predominant” 
symptoms a substantial proportion patients still had “dysmotility-predominant 
symptoms” after therapy, but the majority of these patients switched to the “mixed” 
group. 
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Figure 4. Symptom patterns after therapy for the various sub groups defined at 
baseline. 
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Discussion 
 
With the increasing popularity of empirical treatment strategies, an increasing 
number of primary care patients with upper gastrointestinal symptoms are treated 
with proton pump inhibitors without prior investigation. However, most research 
with proton pump inhibitors focused on investigated patients with an endoscopic 
diagnosis, mainly patients with gastro-oesophageal reflux disease or peptic ulcer 
disease. This warranted the need to further investigate the effectiveness of proton 
pump inhibitors in uninvestigated primary care patients which was the objective of 
this study. Our results show that GPs mainly selected patients with reflux-
predominant or mixed symptoms and only few patients with epigastric pain-
predominant or dysmotility-predominant symptoms for proton pump inhibitor 
therapy. Of these patients almost half were completely symptom free after treatment 
with esomeprazole. 
 
Unfortunately, this study was solely observational. Therefore, there was no control 
group: no placebo-treatment and no active comparative treatment. As a result the 
effect of esomeprazole treatment over placebo treatment cannot be established, nor 
can we establish whether empiric proton pump inhibitor therapy is more effective 
than other management strategies for patients with dyspeptic symptoms. Since for 
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treatment of dyspeptic symptoms the placebo effect can be very large (10-30% 
depending on the population studied and the outcome used),13-15 we can only state 
that 46% of patients became symptom-free during esomeprazole treatment but not 
necessarily because of this therapy. 
Furthermore, there is a selection bias because we did not include consecutive 
patients. In our study a subgroup of patients with uninvestigated upper 
gastrointestinal symptoms was included because the intervention itself 
(esomeprazole therapy) was the main inclusion criterion. Probably, each GP decided 
for (or preferably: with) each individual patient with upper gastrointestinal 
symptoms whether to proceed with empiric symptomatic treatment with an antacid, 
with an H2-receptor antagonist, or with a proton pump inhibitor therapy, or 
alternatively proceed with endoscopy, or with an H. pylori test (followed by triple 
therapy if positive). This implicates that only a subgroup of patients with upper 
gastrointestinal symptoms was included in this study, which is reflected by the 
relatively large proportion of patients with reflux-predominant symptoms, and the 
relatively small proportions of patients with epigastric pain-predominant, and 
dysmotility-predominant symptoms.  
However, many GPs participated which implicates that the population described in 
this paper may well reflect the population selected for proton pump inhibitor therapy 
by Dutch primary care physicians in everyday practice. Furthermore, we obtained 
data from a very large sample of primary care patients, and despite the lack of a 
control treatment, questions about the symptomatic effect of empiric proton pump 
inhibitor treatment in real life were answered. 
 
It is difficult to compare our results with other studies. Firstly, because few studies 
investigated the effectiveness of proton pump inhibitors in uninvestigated primary 
care patients. Secondly, because there are large differences in both patient selection 
and outcome measures. Nonetheless, we will discuss some interesting results from 
other studies, with a special emphasis on the effectiveness of proton pump 
inhibitors. 
Meineche-Schmidt13 studied 829 patients with uninvestigated dyspeptic symptoms 
who would normally have been treated by their GPs with a proton pump inhibitor or 
with an H2-receptor antagonist and found that 66% and 63% of patients treated with 
omeprazole 40 mg and 20 mg for two weeks experienced complete relief of the 
predominant dyspeptic symptom (in the majority of patients this was epigastric pain) 
vs. 35% in the placebo group. These figures are higher than those reported in our 
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study, but the definition of complete symptom relief was less strict. In the study by 
Meineche-Schmidt symptom relief at the time of the second visit was sufficient: 
there was no period of time specified during which the symptoms had to be absent. 
Veldhuyzen van Zanten et al.14 studied 1,250 H. pylori negative, but further 
uninvestigated primary care patients with dyspeptic symptoms, excluding heartburn. 
In this study all patients received a 1-week acid suppression trial with esomeprazole 
40mg o.d. or b.i.d. followed by a further 7 weeks of esomeprazole 40mg o.d. or 
placebo. After the 1-week acid suppression trial 39% of the patients treated with 
esomeprazole 40mg o.d. and 43% of the patients treated with esomeprazole b.i.d. 
had “no more than mild symptoms on no more than one of the last three days of 
treatment”. This is comparable to our results, even though patients with predominant 
heartburn were excluded and patients were treated for only one week. On the other 
hand the outcome is less strict than ours. The outcome at four weeks may be more 
suitable for comparison with our results, because of the similarity of treatment 
duration and because of the similarity in the definition of the outcome. After 4 
weeks of treatment 38% of patients treated with 40mg of esomeprazole and 25% of 
patients in the placebo-group had “no more than mild symptoms on no more than 
one day in the preceding week”. This is slightly lower than in our study, which may 
well be because Veldhuyzen van Zanten et al. excluded  patients with predominant 
heartburn and those who were H. pylori positive, as it is well established that proton 
pump inhibitors are more effective in H. pylori positive patients than in H. pylori 
negative patients. 
Another study, by Armstrong et al.15 used a (secondary) outcome measure which 
was comparable to our primary outcome in a quite similar population. They studied 
390 uninvestigated patients with heartburn-predominant dyspepsia and found that 
after four weeks of therapy with omeprazole 20mg once daily, 36% had no 
heartburn during the last 7 days (while this was 13% for patients treated with 
ranitidine 150mg b.i.d.). These results are comparable to our findings. 
Furthermore, in a randomized clinical trial by our own group we compared 
empirical proton pump inhibitor therapy with esomeprazole 40 mg o.d. for four 
weeks, with H. pylori test-and-treat (i.e.: triple therapy for H. pylori positives, 
esomeprazole 40 mg o.d. for H. pylori negatives) in 181 primary care patients with 
uninvestigated dyspeptic symptoms including heartburn.16 We found that 
immediately after the first treatment step 46% of patients in the empirical 
esomeprazole group were symptom free (vs. 54% in the test-and-treat group). Again 
these data are comparable to our figures. 
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One can also compare our results with studies investigating specific groups of 
patients. When keeping in mind the expected distribution of underlying diseases in 
our study population (mainly functional dyspepsia and gastro-oesophageal reflux 
disease) each with a different expected efficacy of proton pump inhibitor therapy, 
our results seem plausible: they are slightly higher than those obtained for patients 
with functional dyspepsia and lower than those obtained for patients with proven 
gastro-oesophageal reflux disease. For example Talley et al.10 compared treatment 
with omeprazole 20mg/10mg for 4 weeks with placebo in 1,262 patients with 
functional dyspepsia and showed that 38%/36% vs. 28% had complete symptom 
relief defined as no symptoms during the last 3 days of treatment. And Johnsson et 
al.8 compared two weeks of esomeprazole 40mg once daily and 20mg b.i.d. versus 
placebo for treatment of 440 patients with endoscopically proven gastroesophageal 
reflux disease and showed that respectively 71%, 65% and 16% had “no heartburn 
symptoms during the last three days” of treatment, which is of course higher than in 
our population.  
 
In summary, 46% of primary care patients with uninvestigated upper gastrointestinal 
symptoms selected by their GPs for empiric proton pump inhibitor therapy were 
completely symptom free during the last week of esomeprazole therapy. 
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Abstract 
 
Background: Despite the fact that acetylsalicylic acid (ASA) and non-steroidal anti-
inflammatory drugs (NSAIDs) are notorious for their upper gastrointestinal side-
effects it is not clear whether these drugs influence the effectiveness of PPI 
treatment. 
Methods: In this observational study general practitioners across The Netherlands 
prospectively collected data from patients with uninvestigated upper gastrointestinal 
symptoms for whom they had decided to start treatment with esomeprazole 40mg. 
Age, gender, co-medication, severity of upper gastrointestinal symptoms, 
compliance and side-effects were registered, both before and after therapy. The 
proportions of patients with complete symptom relief (i.e. zero days of upper 
gastrointestinal symptoms during the last week of esomeprazole therapy) were 
compared for patients with and without ASA/NSAID co-medication.  
Results: Between September 2003 and December 2005 data from 2,897 patients 
were registered. Of these patients, 672 used ASA/NSAID co-medication, while 
2,225 did not. Cure rates were similar for patients with or without ASA/NSAID co-
medication (37% vs. 41%, p=0.08). The ASA/NSAID users were older (mean age: 
59 years vs. 51 years, p<0.0001), more often used H2-receptor antagonists at 
inclusion (15% vs. 10%, p=0.0002), and less often experienced reflux-predominant 
symptoms (6% vs. 10%, p=0.002), but after adjustment for these factors use of 
ASA/NSAID co-medication still did not influence treatment outcome (odds ratios 
(95%CI): 0.85 (0.6-1.2), 0.89 (0.7-1.1), resp.). 
Conclusion: Overall, 40% of primary care patients with upper gastrointestinal 
symptoms were completely symptom-free after treatment with esomeprazole and 
use of ASA/NSAID co-medication did not decrease the effectiveness of 
esomeprazole therapy. 
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Introduction 
 
Upper gastrointestinal symptoms are common in the general population. An 
important factor in the aetiology of upper gastrointestinal disease is the use of 
acetylsalicylic acid (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs).1 
These drugs are widely used for prevention of ischemic events and for treatment of 
pain and inflammation in a variety of conditions, and their use may in future include 
chemoprevention of various malignancies and Alzheimer’s disease. However, they 
are notorious for their gastrointestinal side-effects: of patients using ASA/NSAIDs 
some 25-40% develop dyspeptic symptoms, and up to 20% develop peptic ulcer 
disease which may be complicated by bleeding or perforation.2-5 
The mechanisms by which ASA and NSAIDs cause gastrointestinal disease have not 
been fully elucidated. Mucosal damage may be the result of direct and systemic 
actions of ASA/NSAIDs leading to inhibition of prostaglandin synthesis, decrease of 
mucosal blood flow, altered secretion of mucus and bicarbonate, impaired cell 
restitution, increase influx of neutrophilic cells and impairment of nitric oxide-
mediated capillary blood flow. Additionally, ASA/NSAIDs can cause upper 
gastrointestinal symptoms in the absence of macroscopic mucosal injury. In that 
case there is even more uncertainty about the underlying mechanisms.2 
In the general population many patients with upper gastrointestinal symptoms are 
treated with proton pump inhibitors often with a good response. However, it is not 
clear whether the concomitant use of ASA/NSAIDs is associated with a decreased 
response to proton pump inhibitor therapy. Most research regarding ASA/NSAIDs 
and upper gastrointestinal disease focused on the reduction of the risk of peptic ulcer 
disease or on relief of upper gastrointestinal symptoms. And although several studies 
showed that proton pump inhibitor therapy reduces the risk of peptic ulcer disease 
and also provides some symptom relief, there are no published data investigating 
whether use of ASA/NSAIDs is associated with a lower response rate to proton 
pump inhibitor therapy in everyday practice.6-10 Therefore, the aim of this study was 
to investigate the influence of ASA/NSAID co-medication on the effectiveness of 
esomeprazole for treatment of primary care patients with upper gastrointestinal 
symptoms. 
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Methods 
 
Population 
In this observational study, participating general practitioners (GPs) across The 
Netherlands prospectively registered data from adult patients with reflux-like upper 
gastrointestinal symptoms for whom they were going to prescribe empiric proton 
pump inhibitor therapy with esomeprazole. GPs were free in deciding what 
treatment strategy to use for each individual patient. Therefore, only patients for (or 
rather: with) whom the GP decided to start treatment with 40mg of esomeprazole 
were included. Exclusion criteria were the presence of alarm symptoms (weight loss, 
dysphagia, anaemia/upper gastrointestinal bleeding), or the use of a proton pump 
inhibitor during one month prior to inclusion. 
 
Intervention 
All patients were treated with 40mg of esomeprazole once daily. The duration of 
therapy was decided by the general practitioner. 
 
Data collection 
Patients visited their general practitioners twice: before starting esomeprazole 
therapy and immediately after finishing esomeprazole treatment. At the first visit, 
data regarding age, gender, and medication use (acetylsalicylic acid, NSAIDs, H2-
receptor antagonists, antacids, pro-kinetics) were registered. 
During the second visit, patients were asked on how many days they had 
experienced upper gastrointestinal symptoms during the last week of esomeprazole 
therapy and whether the symptoms had improved, had become worse or had 
remained the same during therapy. Furthermore, compliance with therapy, and the 
occurrence of (serious) adverse events were registered. Both before and after 
therapy, questionnaires were used to assess the severity of 8 upper gastrointestinal 
symptoms (heartburn, regurgitation, belching, epigastric pain, lower abdominal pain, 
nausea, vomiting and early satiety) on a 7-point Likert scale (0=no symptoms, 
6=very severe symptoms). 
 
Data analysis 
The primary outcome was complete symptom relief defined as 0 days with upper 
gastrointestinal symptoms during the last week of esomeprazole therapy. 
Proportions of patients with complete symptom relief were compared for patients 
with and without ASA/NSAID co-medication. Furthermore, the relationships 
between ASA/NSAID co-medication, other baseline characteristics and complete 
symptom relief were investigated by means of unadjusted and adjusted logistic 
regression analysis using the SAS® statistical software package (SAS Institute Inc., 
USA). Patients were sub grouped according to the predominant symptom. If the 
severity of heartburn or regurgitation was 2 points higher than any of the other 
symptoms patients were classified as reflux-predominant. If the severity of upper 
abdominal pain was 2 points higher than any of the other symptoms patients were 
classified as epigastric-pain predominant. If the severity of nausea, vomiting or 
bloating was 2 points higher than any of the other symptoms patients were classified 
as dysmotility-predominant. Statistical significance was defined as a p-value<0.05. 
Missing values were excluded from analyses. 
 
Figure 1. Details of ASA/NSAID co-medication. 
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Results 
 
ASA/NSAID co-medication 
Between September 2003 and December 2004 data from 2,897 patients were 
registered by 346 GPs. Of these patients, 672 (23%) used ASA/NSAID co-
medication (223 used only ASA, 423 only an NSAID, and 26 patients used both 
ASA and an NSAID). Figure 1 provides details about ASA/NSAID co-medication. 
It shows that only a small subgroup of the NSAID users (27%) used COXII selective 
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inhibitors. Furthermore, the majority of patients using ASA (96%) were long-term 
users, while of the patients using NSAIDs, 178 (43%) were long-term users. Of the 
patients with ASA co-medication, 46% indicated that (in retrospect) the 
gastrointestinal symptoms arose around the time they started the ASA. For the 
patients with NSAID co-medication this was the case for 53%. 
 
Figure 2. Mean symptom severities (at baseline) for patients with/without 
ASA/NSAID co-medication. 
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Figure 3. Highest symptom severity (at baseline) for patients with/without 
ASA/NSAID co-medication. 
0%
10%
20%
30%
40%
1 2 3 4 5 6
Highest symptom rating
Pr
op
or
tio
n 
of
 re
sp
. p
op
ul
at
io
n
No ASA/NSAID
ASA/NSAID
 
 166
Baseline symptoms 
Figure 2 shows that heartburn and upper abdominal pain had the highest mean 
severity scores (2.6 and 2.4, resp). This does not seem to be very severe, but figure 3 
shows that the majority of patients reported to have at least one symptom with a 
severity of three or more. Figures 2 and 3 show that there were no differences 
regarding the mean symptom severities and the highest symptom severity between 
patients with or without ASA/NSAID co-medication. 
Additionally, figure 4 illustrates that few patients reported only one or two 
symptoms while the majority of patients described a symptom complex of on 
average 5 (SD: 2) symptoms, which was similar for patients with and without 
ASA/NSAID co-medication. However, it proved to be very hard to create symptom 
subgroups: nearly all patients 87% had no predominant symptom pattern: only 9% 
had reflux-predominant symptoms, 3% epigastric pain-predominant, and 2% 
dysmotility-predominant. The proportion of patients with reflux-predominant 
symptoms was slightly lower in the population with ASA/NSAID co-medication 
(table 1). 
 
Figure 4. Number of reported symptoms (at baseline) for patients with/without 
ASA/NSAID co-medication. 
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Intervention 
All patients were treated with esomeprazole 40mg once daily, but general 
practitioners were free in their choice of therapy duration. Eighty-four percent 
(2,435) of patients were treated for two weeks, 11% (328) for four weeks. Nearly all 
patients (93%) reported to have taken all pills as prescribed. These figures were 
similar for patients with and without ASA/NSAID co-medication (table 1). 
 
Table 1. Baseline characteristics in relation to ASA/NSAID co-medication 
* p-value for difference<0.05 
  No ASA/NSAID 
n (column %) 
(n=2,225) 
ASA/NSAID 
n (column %) 
(n=672) 
Mean age (SD)* 51 (15) 59 (15) 
Male gender 1018 (46%) 307 (46%) 
Baseline medication use   
 Antacids 223 (10%) 81 (12%) 
 H2-receptor antagonists* 217 (10%) 100 (15%) 
 Prokinetics 47 (2%) 18 (3%) 
Mean number of symptoms (SD) 5.0 (1.8) 5.0 (1.8) 
Mean symptom severity (SD) 1.6 (0.7) 1.5 (0.7) 
Symptom pattern   
 Mixed* 1,899 (85%) 608 (90%) 
 Reflux-predominant* 212 (10%) 38 (6%) 
 Epigastric pain-predominant 74 (3%) 19 (3%) 
 Dysmotility-predominant 40 (2%) 7 (1%) 
Esomeprazole duration   
 2 weeks 1,878 (85%) 557 (84%) 
 4 weeks  252 (11%) 76 (11%) 
 Other 88 (4%) 34 (5%) 
 
Comparison of patients with/without ASA/NSAID co-medication 
Table 1 summarizes the baseline characteristics and the characteristics of the 
intervention for patients with and without ASA/NSAID co-medication separately. It 
shows that patients with ASA/NSAID co-medication were older, more often used 
H2-receptor antagonists at baseline, more often had mixed symptoms, and less often 
had reflux-predominant symptoms. 
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Influence of ASA/NSAID co-medication on cure rates 
Overall, regardless of co-medication, 40% (1,149/2,897) of patients experienced 
complete symptom relief. Of the 672 patients with ASA/NSAID co-medication, 247 
(37%) experienced complete symptom relief, while of the 2,225 patients not using 
ASA/NSAID co-medication 902 (41%) experienced complete symptom relief. The 
4% difference in cure rates was not statistically significant (p-value=0.08). 
There seemed to be a trend towards lower cure rates in ASA users (35% vs. 40% (in 
patients not using ASA), p=0.08), but not in NSAID users (37% vs. 40% (in patients 
not using NSAIDs), p=0.24). Therefore, ASA and NSAID co-medication were 
entered separately in a logistic regression model. Of the 26 patients using both ASA 
and an NSAID only 6 (23%) had complete symptom relief, but due to the low 
number of patients this 17% difference was not statistically significant. 
There were no important differences in cure rates between patients who indicated 
that the gastrointestinal symptoms had started after starting the co-medication 
compared to patients indicating that they already had the symptoms before starting 
the co-medication, neither for ASA (38% vs. 34%), nor for NSAIDs (37% vs. 37%). 
Furthermore, there was no difference in cure rates between patients using the 
NSAIDs chronically or incidentally (37% vs. 37%). Additionally, there was no 
difference in cure rates between patients using COXII selective NSAIDs vs. non-
selective NSAIDs (39% vs. 37%). 
 
Factors associated with treatment success 
Table 2 shows the results of the adjusted analysis. It shows that use of ASA and 
NSAID co-medication was not associated with treatment success, but that several 
other factors were associated with treatment success: longer duration of 
esomeprazole treatment, having reflux-predominant symptoms, and having low 
symptom severity, were associated with a higher chance of achieving complete 
symptoms relied, while using prokinetics at baseline, and having 6 or more 
symptoms were associated with treatment failure. 
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Table 2. Factors associated with complete symptom-relief 
 
Unadjusted 
analysis 
Adjusted 
analysis* 
 
Odds 
ratio 
(95% CI) Odds 
ratio 
(95% CI) 
ASA co-medication 0.79 (0.6-1.0) 0.85 (0.6-1.2) 
NSAID co-medication 0.88 (0.7-1.1) 0.89 (0.7-1.1) 
Male gender 1.11 (1.0-1.3)   
Age***  0.90 (0.8-1.0) 0.99 (1.0-1.0) 
Baseline antacid use 0.92 (0.7-1.2)   
Baseline H2-RA use 0.80 (0.6-1.0) 0.83 (0.6-1.1) 
Baseline prokinetic use** 0.49 (0.3-0.9) 0.56 (0.3-1.0) 
Esomeprazole duration (4 wks vs. 2)** 1.33 (1.1-1.7) 1.36 (1.1-1.7) 
Reflux-predominant (vs. other)** 1.79 (1.4-2.3) 1.45 (1.1-1.9) 
Epigastric pain-pred. (vs. other) 1.26 (0.8-1.9)   
Dysmotility-pred. (vs. other)  0.78 (0.4-1.4)   
Mean symptom severity (≥1.6 vs. <1.6)** 0.60 (0.5-0.7) 0.82 (0.7-1.0) 
Number of symptoms (≥6 vs. <6)** 0.54 (0.5-0.6) 0.63 (0.5-0.8) 
*adjusted for ASA co-medication, NSAID co-medication, age, gender, baseline medication, duration of 
esomeprazole therapy, predominant symptom pattern, symptom severity and number of symptoms. 
**p<0.05 
***age unadjusted: ≥55 vs. <55 yrs, adjusted: as continuous variable 
 
 
Discussion 
 
Use of ASA/NSAIDs is an important factor in the aetiology of upper gastrointestinal 
symptoms, but it is not clear whether ASA/NSAID co-medication influences the 
effectiveness of proton pump inhibitor therapy for treatment of upper 
gastrointestinal symptoms. Investigating that topic was the aim of this study. 
 
We studied a large population of almost three thousand patients with upper 
gastrointestinal symptoms selected by their GPs for proton pump inhibitor therapy. 
Almost one in four patients used ASA/NSAIDs, of which about a third used ASA 
continuously, a third used NSAIDs intermittently, and a third used NSAIDs 
continuously. We found similar cure rates for patients with and without 
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ASA/NSAID co-medication. Initially, the data seemed to suggest a trend towards 
lower cure rates in the ASA/NSAID group. However, there were differences 
between the patient groups: the ASA/NSAID users were older, and less often had 
reflux-predominant symptoms. After adjustment for these factors the possible trend 
towards lower cure rates disappeared. 
Furthermore, we did not find any relationship between the frequency of 
ASA/NSAID use (continuous or intermittent), the association of the start of 
ASA/NSAID use with the beginning of the upper gastrointestinal symptoms, and the 
type of NSAID used (COXII selective or non-selective). Therefore, we conclude 
that ASA/NSAID co-medication does not decrease the effectiveness of 
esomeprazole therapy for treatment of upper gastrointestinal symptoms. 
 
Few other studies investigated the influence of ASA/NSAID co-medication on the 
outcome of proton pump inhibitor treatment. Meineche-Schmidt reported that 
NSAID use was not associated with treatment success of proton pump inhibitor 
therapy. But in that study only 67 patients used NSAIDs, of which 33 patients 
during proton pump inhibitor therapy.[11] 
Most other studies did not compare patients with or without ASA/NSAIDs, but 
primarily focused on ASA/NSAID users. Most of these studies focused on 
prevention of peptic ulcer disease, and these studies show that proton pump inhibitor 
therapy decreases the risk of development of peptic ulcer disease in NSAID 
users.[6,7,8] 
Few studies focused on symptomatic response in patients with upper gastrointestinal 
symptoms using ASA/NSAIDs. For example, Hawkey et al.[9] conducted two 
studies in which 608 and 556 continuous NSAID users (without ulcers or erosive 
oesophagitis and without H. pylori infection) were randomized to 4 weeks 
esomeprazole 40 mg, esomeprazole 20mg, or placebo, all once daily. They found 
that both esomeprazole 40 and 20 mg were significantly more effective in reducing 
upper gastrointestinal symptoms than placebo. As secondary outcome, the 
proportion of patients with upper gastrointestinal symptom relief was reported, 
defined as scores of 0 or 1 on a 7-point Likert scale for 7 consecutive days, allowing 
≤2 days with a score of 2, which is less strict than our outcome: 0 days with upper 
GI symptoms during the last week of treatment. They reported upper gastrointestinal 
symptom relief for 72% of patients treated with esomeprazole 40mg, 70% of 
patients treated with esomeprazole 20mg, and 58% of patients with placebo in one 
population and 72%, 68% and 51% in another population. These figures are much 
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higher than in our population which may partly be caused by the less strict definition 
of symptom relief, but it is also remarkable that the placebo response was very high. 
 
Additionally, our data show that other factors such as treatment duration, baseline 
prokinetic use, symptom pattern were more important predictors of treatment 
success. Patients treated for 4 weeks had a higher chance of treatment success than 
patients treated for two weeks, which seems plausible. It may take some time before 
symptoms have resolved, and our primary outcome (completely symptom-free 
during the last week of therapy) may have been more difficult to achieve for patients 
who were only treated for 2 weeks than four patients treated for 4 weeks. Other 
research also showed that longer treatment leads to better healing of oesophagitis or 
peptic ulcer disease.[12] 
Furthermore, patients with many symptoms or with severe symptoms less often 
experienced complete symptom relief, which is comparable to the results of a 
previous study.[12] Moreover, patients using prokinetics at baseline had lower cure 
rates. Prokinetics are usually not the drugs of first choice for patients with upper 
gastrointestinal symptoms. Therefore, prokinetic use may be associated with a 
longer history of symptoms or symptoms less responsive to acid suppression, which 
may explain the association with treatment failure. 
Additionally, patients with reflux-predominant symptoms had a higher chance of 
achieving complete symptom relief, probably because the presence of heartburn 
only is associated with a higher degree of reflux disease which usually responds well 
to proton pump inhibitor therapy. 
 
Overall, 40% of patients experienced complete symptom-relief during the last week 
of esomeprazole treatment. Due to differences in the definition of treatment success 
it is difficult to compare this result with other studies. This result is in line with 
findings in a previous study with a similar population in which we found a 46% cure 
rate.[12] Furthermore, in a randomized clinical trial by our own group, empirical 
proton pump inhibitor therapy with esomeprazole 40 mg o.d. for four weeks was 
compared with H. pylori test-and-treat (i.e.: triple therapy for H. pylori positives, 
esomeprazole 40 mg o.d. for H. pylori negatives) in 181 primary care patients with 
uninvestigated dyspeptic symptoms including heartburn.[13] In that study, 
immediately after the first treatment step, 46% of patients in the empirical 
esomeprazole group were symptom free (vs. 54% in the test-and-treat group), a 
result comparable to the present study. 
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Because this study was solely observational there was no placebo-group. Because it 
is known that the placebo effect may be quite large in patients with dyspeptic 
symptoms, it is not possible to describe the treatment effect solely to the 
esomeprazole therapy. However, the placebo effect is expected to be similar for 
patients with and without ASA/NSAID co-medication, and this comparison was the 
primary aim of this study. Furthermore, this study investigated a large primary care 
population, with patients included across the country, which implicates that the 
results can easily be extrapolated to the population treated with proton pump 
inhibitors in primary care. 
 
In conclusion, 40% of selected primary care patients with upper gastrointestinal 
symptoms experienced complete symptom relief during treatment with 
esomeprazole and use of ASA/NSAID co-medication did not decrease the 
effectiveness of esomeprazole therapy. Other factors such as treatment duration, 
baseline prokinetic use, symptom severity, number of symptoms and reflux-
predominant symptoms were more important predictors of treatment success. 
 
 
References 
 
1. Straus WL, Ofman JJ, MacLean C, Morton S, Berger ML, Roth EA, Shekelle P. 
Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia 
definitions. Am J Gastroenterol 2002; 97: 1951-8. 
2. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated 
gastrointestinal symptoms and ulcer complications. Am J Med 2004; 117: 63S-
71S. 
3. Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a 
predisposing factor for gastroesophageal reflux disease in a Medicaid 
population. Pharm Res 2001; 18: 1367-72. 
4. Hirschowitz BI. Non-steroidal anti-inflammatory drugs and the gastrointestinal 
tract. Gastroentreologist 1994; 2: 207-23.  
5. Huang JQ, Shridhar S, Hunt RH. Role of Helicobacter pylori infection and non-
steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. 
Lancet 2002; 359: 14-22. 
6. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. 
Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In: 
The Cochrane Library, Issue 4, 2002. Oxford: Update Software. 
 174
7. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et 
al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: 
results of a double-blind, randomized, multicenter, active- and placebo 
controlled study of misoprostol vs. lansoprazole. Arch Intern Med 2002; 162: 
169-75. 
8. Bianchi-Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T. Efficacy of 
pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-
inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-
group study. Dig Liver Dis 2000; 32: 201-8. 
9. Hawkey CJ, Talley NJ, Yeomans ND, Jones R, Sung JJY, Langstrom G, Naesal 
J, Scheiman JM. Improvements with esomeprazole in patients with upper 
gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, 
including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100: 1028-36. 
10. Laheij RJF, Van Rossum LGM, Jansen JBMJ, Verheugt FWA. Proton-pump 
inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal 
symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 
2003; 18: 109-15. 
11. Meineche-Schmidt V. Empiric treatment with high and standard dose for 
omeprazole in general practice: two-week randomized placebo-controlled trial 
and 12-month follow-up of health-care consumption. Am J Gastroenterol 2004; 
99: 1050-8. 
12. Janssen MJR, Ligthart SA, Laheij RJF, Jansen JBMJ. Esomeprazole for 
selected primary care patients with uninvestigated upper gastrointestinal 
symptoms. Data on file. 
13. Janssen MJR, Laheij RJF, De Boer WA, Jansen JBMJ. Test-and-treat or treat-
and-test? A randomized comparison of treatment strategies for dyspepsia. Gut 
2005; 54 (Suppl. VII): A8 (Chapter 9 of this thesis). 
Chapter 9 
 175 
 
 
 
Test first or treat first? 
A randomized comparison of treatment strategies 
for dyspepsia 
 
 
 
Marcel J.R. Janssen, Robert J.F. Laheij, Wink A. de Boer & Jan B.M.J. Jansen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 176
Abstract 
 
Background: Treatment strategies for dyspepsia without endoscopy (such as H. 
pylori test-and-treat and empirical acid suppression) are as effective as prompt 
endoscopy followed by targeted treatment, but cost less, especially if patients with 
persisting/relapsing symptoms after the first treatment step do not proceed towards 
endoscopy, but  have another (empirical) treatment step. However, there is much 
debate whether should be started with testing for H. pylori or with proton pump 
inhibitor therapy. 
Methods: Patients referred by their general practitioners for evaluation of dyspeptic 
symptoms without recent endoscopy or H. pylori test were randomized to either the 
“test-first” strategy (first treatment depending on H. pylori status, in case of 
persisting/relapsing symptoms followed by esomeprazole 40mg once daily for 4 
weeks), or to the “treat-first” strategy ( first treatment step with esomeprazole 
irrespective of H. pylori infection, in case of persisting/relapsing symptoms to be 
followed by treatment according to H. pylori status. 
Results: Ninety-two patients were included in the “test first” strategy (mean age 43 
years, 39% males, 57% H. pylori positive), 90 in the “treat first” strategy (mean age 
45 years, 41% males, 51% H. pylori positive). After the first treatment step, 50 
(54%) “test first” patients and 42 (47%) “treat first” patients were symptom-free 
(p=0.18). In these patients symptom relapse was more common in the “treat first” 
strategy (79% vs. 43%, p<0.0001) and these patients had a second course of 
empirical treatment. At 6 months, 49 (53%) “test first” patients were symptom-free, 
compared to 43 (48%) “treat first” patients (p=0.46), while 72 (78%) of the “test 
first” patients and 74 (82%) of the “treat first” patients reported that they felt 
adequately treated (p=0.50), and 28 (30%) vs. 29 (32%) used proton pump inhibitors 
(p=0.95). Overall, only 17 (9%) of patients had endoscopy. 
Conclusions: Both treatment strategies were effective for treatment of patients with 
dyspeptic symptoms. Two thirds of the patients who were symptom-free after the 
first treatment step had relapsing symptoms, and relapse was more common in H. 
pylori positive patients. Because of this, and the other benefits of being H. pylori 
negative, starting with an H. pylori test and eradication if infected seems preferable 
in populations with a high H. pylori infection rate. Although, only half of the 
population was symptom-free after 6 months, the majority of patients felt 
sufficiently treated, and only few patients had had endoscopy. 
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Introduction 
 
Dyspepsia is common in the general population. It is estimated that annually some 
20-40% of the general population experience at least one episode of dyspeptic 
symptoms.1 Although only a minority of these people seek medical attention, 
dyspepsia still accounts for some 3% of primary care consultations and a quarter of 
these patients are referred for endoscopy within a year.2,3 Furthermore, drugs for 
treatment of dyspeptic symptoms are among the most widely used drugs. Thus, 
dyspepsia constitutes an important health issue. 
The aetiology of dyspeptic symptoms is very complex, but usually the underlying 
pathology is divided into gastro-oesophageal reflux disease, peptic ulcer disease, 
gastro-oesophageal malignancy, and functional dyspepsia, each with its own 
treatment options. Ideally, therapy would focus on correcting the underlying 
pathophysiological mechanism, but unfortunately, history is unreliable for that 
matter. Upper gastrointestinal endoscopy provides more information, but is costly, 
troublesome to the patient, and in the majority of patients (some 60-70%) no 
pathology is detected.4,5 
Therefore, other strategies were designed in which patients are treated without 
endoscopic diagnosis. The aim of such a strategy is not to establish a diagnosis, but 
to safely achieve adequate symptom reduction. Several studies showed that such 
strategies are as effective as prompt endoscopy followed by targeted treatment, but 
cost less, mainly due to the lower number of endoscopies.6-9 
The most widely used strategies are “empirical acid suppression” and “H. pylori 
test-and-treat”. In the former strategy, patients with uninvestigated dyspepsia receive 
a course of acid suppressive medication before proceeding to endoscopy. This 
strategy was advised in one of the earliest dyspepsia guidelines, by the American 
College of Physicians,10 and it is still very popular today because it is simple and 
provides immediate symptom relief in patients with gastro-oesophageal reflux 
disease11 and peptic ulcer disease,12 as well as in a subgroup of patients with 
functional dyspepsia.13 This strategy relies heavily on the assumption that a 
sufficiently large number of patients have long-term symptom relief after a course of 
acid suppression; otherwise endoscopy would only be postponed. However, relapse 
rates are usually over 50% within one year. Bytzer et al. showed that applying such 
a strategy with H2-receptor antagonists (which nowadays have largely been replaced 
by the more powerful proton pump inhibitors) led to a 30% reduction in the number 
of endoscopies. Even although in this study patients with persisting or relapsing 
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symptoms all proceeded towards endoscopy, instead of having another course of 
empirical treatment.8 
In the H. pylori test-and-treat strategy all patients have a non-invasive test for H. 
pylori infection. H. pylori positive patients receive anti-Helicobacter therapy, while 
H. pylori negative patients receive acid suppressive medication, as do patients with 
persisting/relapsing complaints after successful H. pylori eradication. As a result, 
patients with H. pylori positive peptic ulcer disease are adequately treated,14 while 
also some 10-15% of patients with H. pylori positive functional dyspepsia will have 
long-lasting symptomatic benefit.15 Patients with H. pylori positive reflux disease 
probably have no change in symptoms.16 H. pylori negative patients (which run a 
very low risk of having peptic ulcer disease) receive a course of acid suppression, 
which adequately treats patients with gastro-oesophageal reflux disease, while it 
may also be of benefit to a subgroup of patients with functional dyspepsia. Much 
research has been dedicated to this strategy and several studies showed that the H. 
pylori test-and-treat strategy is as effective and safe as prompt endoscopy followed 
by targeted treatment, but cheaper. 
However, most studies evaluate only the initial treatment step: either a course of 
empirical acid suppression or a H. pylori test followed by triple therapy in H. pylori 
infected patients and acid suppression in H. pylori negative patients. Therefore, 
these studies do not fully represent the above mentioned treatment strategies. 
Patients with persisting symptoms after the first treatment step could proceed with 
another treatment step (instead of proceeding with endoscopy as is the case in many 
study protocols. In the test-and-treat strategy H. pylori positive patients who did not 
have symptom improvement after (confirmed) H. pylori eradication could be treated 
with a course of acid suppression. And in the empirical treatment strategy patients 
who did not have symptom improvement after a course of acid suppression could 
proceed with a H. pylori test and eradication if infected. 
The same goes for patients with relapsing symptoms: patients with relapsing 
symptoms after empirical proton pump inhibitor therapy could either receive more 
empirical proton pump inhibitor therapy or could be tested for H. pylori and receive 
triple therapy if infected or another course of acid suppression if not infected. 
Similarly, in the test-an-treat strategy, patients with relapsing symptoms after 
(confirmed) H. pylori eradication could be treated with a course of acid suppression, 
and H. pylori patients with relapsing symptoms after a course of proton pump 
inhibitor could receive another course of proton pump inhibitor therapy. By doing 
this, endoscopy could be further postponed or even abolished and cost-effectiveness 
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models showed that such combined multi-step strategies would probably be cost-
effective.17 
However, it is not clear whether it would be better to start with testing for H. pylori 
or with a course of empirical acid suppression. Therefore, the aim of this study was 
to compare two multi-step treatment strategies, one starting with H. pylori test-and-
treat, followed by proton pump inhibitor therapy in case of persisting/relapsing 
symptoms, the other starting with empirical proton pump inhibitor therapy followed 
by H. pylori test and treat in case of persisting or relapsing symptoms. 
 
 
Methods 
 
Population 
Primary care patients with dyspeptic symptoms (including heartburn) were eligible 
for inclusion in this study. Exclusion criteria were: prior H. pylori eradication, upper 
gastrointestinal endoscopy during one year before inclusion, use of H2-receptor 
antagonists/proton pump inhibitors during one week before inclusion, use of 
antibiotics during one month before inclusion, and a history of celiac 
disease/inflammatory bowel disease. There were no age limits. 
Because the Radboud University Nijmegen Medical Centre normally acts as a 
secondary/tertiary referral centre, a special outpatient clinic for primary care patients 
was introduced for this study. General practitioners in and around the city of 
Nijmegen were offered the opportunity to refer patients for evaluation of dyspeptic 
symptoms. They were informed that these patients would be eligible to participate in 
a trial combining H. pylori eradication and proton pump inhibitor therapy in random 
order and they were encouraged to refer patients with uninvestigated dyspeptic 
symptoms; before starting treatment. 
All patients visiting this outpatient clinic who met the in- and exclusion criteria 
mentioned above were invited to participate in this study. Only patients who gave 
written informed consent were included in the study. All patients were treated by a 
single physician. The study protocol was approved by the local Ethics Committee. 
 
Randomization 
After inclusion all patients were given consecutive numbers. Before the start of the 
study, treatment had been allocated to these numbers according to a computer-
generated randomization list. In order to adequately conceal treatment allocation, 
case record forms summarizing the allocated treatment strategy were placed in 
sealed, opaque envelopes labelled with the corresponding patient numbers. Because 
two treatment strategies rather than treatments were compared, patients were treated 
with open label medication. 
 
Figure1. Study flow chart. 
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Treatment strategies 
Patients were treated according to either the “treat first” or the “test first” strategy 
(Figure 1). After inclusion all patients had a urea breath test. In the “treat first” 
strategy patients were blinded to the test result and treated with esomeprazole 40mg 
once daily for 4 weeks, irrespective of their H. pylori status. In case of inadequate 
symptomatic response, patients were told the result of the UBT and subsequently H. 
pylori positive patients received therapy for H. pylori eradication (triple therapy with 
esomeprazole 20mg, clarithromycin 500mg, amoxicillin 1000mg, all b.i.d. for 7 
days, followed by a second urea breath test 5 weeks later, and in case of persistent 
infection second-line quadruple therapy with esomeprazole 20mg b.i.d, colloidal 
bismuth subcitrate 400mg, metronidazole, and tetracycline for 7 days, again 
followed by confirmatory UBT). Patients who were symptom-free after the first 
treatment step were asked to make a new appointment in case of symptom relapse. 
In case of symptom relapse they were informed about their H. pylori status and H. 
pylori positive patients received H. pylori eradication as mentioned above, while H. 
pylori negative patients received a second course of esomeprazole therapy. 
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In the “test first” strategy the result of the UBT was discussed with the patient and 
the first treatment step was determined by the patient’s H. pylori status: H. pylori 
positive patients received H. pylori eradication, H. pylori negative patients were 
treated with esomeprazole for 4 weeks. In case of persisting/relapsing symptoms 
patients were treated with esomeprazole. 
In both treatment strategies patients were referred back to their general practitioners 
after completing two treatment steps or, in case of H. pylori negative patients who 
did not benefit from esomeprazole therapy, after completing the first treatment step. 
The general practitioners received information about H. pylori status, the effect of 
H. pylori eradication (if initially infected) and the effect of esomeprazole therapy. 
Decisions about further treatment were left to general practitioner and patient. 
 
Patient information 
All patients received ample information (both in writing and verbally) about the 
study procedures as well as about dyspepsia in general. Regarding the underlying 
pathology, it was explained that in The Netherlands the majority of patients have 
functional dyspepsia (60-70%), followed by gastro-oesophageal reflux disease (15-
30%) and peptic ulcer disease (5-10%), while upper gastrointestinal malignancy is 
rare (<1%). Furthermore, it was explained that H. pylori negative patients who do 
not use acetylsalicylic acid or non-steroidal anti-inflammatory drugs rarely have 
peptic ulcer disease detected at endoscopy. 
Regarding therapy, it was explained that proton pump inhibitor therapy and H. 
pylori eradication are the mainstays of dyspepsia treatment: proton pump inhibitors, 
largely reducing acid production in the stomach, often providing good symptomatic 
response, although not causing permanent changes/cure, and H. pylori eradication 
being especially beneficial in case of peptic ulcer disease, while in case of functional 
dyspepsia only a subgroup of some 10% of patients have long-lasting symptomatic 
benefit. 
Regarding the prescribed medication, patients were advised to take proton pump 
inhibitors on a daily basis to achieve adequate acid reduction. In case of H. pylori 
eradication patients were carefully instructed to take the pills as prescribed. Patients 
were warned about the side-effects of the antibiotics, and were told that in case of 
non-compliance the risk of persistent infection was high. 
In case of persisting symptoms after two treatment steps it was explained that failure 
of therapy was not associated with a higher risk of organic pathology. Patients not 
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responding to proton pump inhibitor therapy at all were advised not to continue 
taking proton pump inhibitors. 
 
Outcomes 
Primary outcome was the proportion of symptom-free patients 6 months after 
randomization. Secondary outcomes were the proportions of symptom-free patients 
after the first treatment step, the proportions of patients feeling sufficiently treated 
after the first treatment step and at 6 months, and the proportions of patients with 
symptom-relapse after an initially successful first treatment step. 
 
Measurements and follow up 
At the first visit, data regarding age, gender, country of origin, consumption of 
tobacco/alcohol, medication use, and previous endoscopies were registered. 
Furthermore, 13 gastrointestinal symptoms (epigastric pain, abdominal pain, 
heartburn, regurgitations, rumbling, bloating, empty feeling, nausea, vomiting, 
decreased appetite, early satiety, belching, and flatulence) were rated on a 7-point 
Likert scale, ranging from (0=none to 6=very severe). Overall severity of 
gastrointestinal symptoms was measured using a visual analogue scale.  
Additionally, all patients had a 14C urea breath test (HeliprobeTM, Noster system AB, 
Stockholm, Sweden). Patients were not allowed to use proton pump inhibitors or H2-
receptor antagonists during 7 days before the test, and antibiotics during 4 weeks 
before the test. After an overnight fast patients took a HeliCapTM capsule (containing 
1 µCi of 14C urea) with 50ml of water. Ten minutes later a breath sample was 
collected (with the BreathCardTM) and analyzed during 4 minutes. Measuring more 
than 50 counts was regarded as prove of H. pylori infection, measuring fewer than 
25 counts was regarded as prove of absence of H. pylori infection.18 Patients in the 
“treat first” strategy were blinded to the test result. H. pylori eradication was always 
confirmed by a second urea breath test (at least four weeks after finishing therapy). 
All patients were scheduled for a control visit 5 weeks after the first visit. Other 
visits depended on symptomatic response. If patients were symptom-free after the 
first treatment step, they were encouraged to call for a new appointment as soon as 
the symptoms would relapse. At each visit, as well as 6 months after inclusion, study 
outcomes, gastrointestinal symptoms, medication use, and recent endoscopies were 
measured using questionnaires. 
Analysis 
Proportions of “symptom-free”/“sufficiently treated” patients (at six months and 
after the first treatment step), and proportions of patients with relapsing symptoms 
were compared for both treatment strategies using chi-square tests. Baseline 
characteristics were compared for both treatment strategies using chi-square and t-
tests where appropriate. For analyses the SAS® statistical software package (SAS 
Institute Inc., USA) was used. Statistical significance was defined as a p-value<0.05. 
Missing values were excluded from analyses. 
 
Figure 2. Consort diagram. 
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Results 
 
Population 
Between February 2003 and October 2004, 188 patients were included in this study, 
of whom six patients were lost to follow-up (Figure 2). The remaining 182 patients: 
92 in the “test first” group, 90 in the “treat first” group were included in analyses. 
Table 1 shows that both groups had similar baseline characteristics. Additionally, 
this table shows that there was a large subgroup of patients of Mediterranean descent 
(some 34%). In this subgroup the H. pylori infection rate was 85% (whereas in 
patients of Dutch ancestry it was 38%). As a result the H. pylori infection rate was 
high in our study population compared with the Dutch population in general.19 
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Table 1. Baseline characteristics 
  “treat first” 
n (column%) 
(N=90) 
“test first” 
n (column%) 
(N=92) 
Mean age (SD) 45 (14) 43 (12) 
Male gender 37 (41%) 36 (39%) 
H. pylori infected 46 (51%) 52 (57%) 
Mediterranean ancestry 28 (31%) 33 (36%) 
Intoxications   
 Smoking 31 (35%) 36 (40%) 
 Alcohol 29 (33%) 29 (33%) 
Baseline medication   
 Antacids/H2RA 19 (21%) 20 (22%) 
 Proton pump inhibitor  36 (40%) 35 (38%) 
 ASA/NSAIDs 8 (9%) 13 (14%) 
Prior endoscopy 22 (24%) 31 (34%) 
Symptom pattern   
 Mixed 58 (73%) 55 (80%) 
 Reflux-predominant 9 (11%) 6 (9%) 
 Epigastric pain-predominant 3 (4%) 3 (4%) 
 Dysmotility-predominant 9 (11%) 4 (6%) 
 Lower GI-predominant 1 (1%) 1 (1%) 
Overall symptom severity 
(% of VAS (SD)) 
60% (24%) 59 (23%) 
 
Baseline symptoms 
Baseline symptom questionnaires were returned by 155 patients. Figure 3 shows that 
the mean symptom severities were similar for both treatment strategies. 
Furthermore, it shows that there were several symptoms with a mean severity score 
over 2. Overall, mean symptom severity was 1.9 (SD: 1.0), but as many as 72% of 
patients reported one or more symptoms with a severity greater than or equal to 4. 
On the visual analogue scale mean baseline symptom severity was 59 (SD: 23) on a 
scale of 0-100. 
Nearly all patients (99%) reported more than one symptom. These patients had a 
complex of, on average 9 (SD: 3), symptoms. Even when ignoring symptoms with a 
severity of 1 or 2, 88% of patients reported more than one symptom (on average 5 
(SD: 3) symptoms with a severity over 2). Table 1 illustrates that in three quarters of 
these patients there was no predominant symptom subgroup. In case of a 
predominant symptom pattern reflux-predominance was most common with a 
prevalence of 10%. 
 
Figure 3. Baseline symptoms 
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Outcomes after the first treatment step 
After the first treatment step, results were fairly similar for the different strategies: 
of the 92 patients in the “test first” group 50 (54%) reported to be symptom-free and 
63 (68%) reported to feel sufficiently treated, while of the 90 patients in the “treat 
first” group 42 (47%) reported to be symptom-free (p-value for difference: 0.18), 
and 53 (59%) patients felt sufficiently treated (p=0.30, p=0.18, resp.). 
However, in the subgroup of patients of Mediterranean descent cure rates seemed to 
be higher in the “test first” strategy: of the 33 patients of Mediterranean descent in 
the “test first” strategy 18 (69%) were symptom-free and 22 (65%) felt sufficiently 
treated, while of the 28 patients of Mediterranean descent in the “treat first” strategy 
8 (31%) were symptom-free (p-value for difference 0.04) and 12 (35%) felt 
sufficiently treated (p=0.06). On the contrary, of the 59 patients of Dutch descent in 
the “test first” group 32 (54%) were symptom-free and 41 (69%) felt sufficiently 
treated, while of the 62 patients of Dutch descent in the “treat-first” group 34 (55%) 
 185 
 186
were symptom-free (p-value for difference: 0.95) and 41 (66%) felt sufficiently 
treated (p-value for difference: 0.69). 
 
Outcomes after the 2nd treatment step 
After inadequate response to the first treatment step 
Of the 66 patients who were not satisfied with the treatment result of the first 
treatment step, 23 were referred back to their general practitioners (all H. pylori 
negatives without response to proton pump inhibitor therapy). The remaining 43 (H. 
pylori positive) patients proceeded immediately with the second treatment step: 10 
(48%) out of 21 patients in the “test first group” and 13 (62%) of 21 patients in the 
“treat first” group felt sufficiently treated after this second treatment step. Therefore, 
after two consecutive treatment steps, 73 (79%) out of 92 patients in the “test first” 
group and 66 (74%) out of 89 patients in the “treat first” group felt sufficiently 
treated (p=0.41). 
 
In case of symptom relapse after a successful first treatment step 
Of the 116 patients who felt sufficiently treated after the first treatment step, the 
majority (69 (59%)) experienced symptom relapse within the 6 month follow-up 
period. Relapse was more common in patients in the “treat first” group: of the 53 
patients who felt sufficiently treated after the first treatment step in the “treat first 
strategy” 42 (79%) experienced symptom relapse, while of the 63 patients who felt 
sufficiently treated after the first treatment step in the “test first” strategy 27 (43%) 
experienced symptom relapse (p-value for difference<0.0001). 
For the initially H. pylori negative patients there was no difference in relapse rates 
between the strategies (66% vs. 66%), but for the initially H. pylori infected patients 
the relapse rate was higher after proton pump inhibitor therapy (96%) than after H. 
pylori eradication (31%) (p-value for difference<0.001). 
Of the 27 patients in the “test first” group with relapsing symptoms, 22 (all H. 
pylori-, of whom 5 patients initially H. pylori infected) had a second treatment with 
esomeprazole, of whom 18 (82%) became symptom-free after treatment with 
esomeprazole, and all 22 felt sufficiently treated. 
Of the 42 patients in the “treat first” group with relapsing symptoms, 40 had a 
second treatment step: Of the 22 H. pylori positives, who received triple therapy as 
second treatment, 9 (41%) became symptom-free and 11 (50%) felt sufficiently 
treated, while of the 18 H. pylori negatives (at baseline) 14 (78%) became symptom-
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free and 16 (89%) felt sufficiently treated after a second course of esomeprazole 
therapy. 
 
Outcomes at 6 months 
Six months after randomization outcomes were similar for both strategies: in the 
“test first” group 49 patients (53%), in the “treat first” group 43 patients (48%) 
reported to have no upper gastrointestinal symptoms (p-value for difference: 0.46). 
Proportions of patients who felt sufficiently treated were higher, but again similar 
for both strategies: 72 patients (78%) in the “test first” group and 74 patients (82%) 
in the “treat first” group (p-value for difference: 0.50). 
At 6 months, the difference in cure rates between the strategies in the subgroup of 
patients of Mediterranean descent had disappeared: of the 33 patients of 
Mediterranean descent in the “test first” group, 17 (52%) were symptom-free and 23 
(70%) felt sufficiently treated, while of the 28 patients of Mediterranean descent in 
the “treat first” group, 14 (50%) were symptom-free (p-value for difference: 0.91) 
and 21 (75%) felt sufficiently treated (p-value for difference: 0.65). 
However, it is remarkable that there was a strong trend towards a lower proportion 
of patients reporting to feel sufficiently treated in patients of Mediterranean descent 
compared with patients of Dutch ancestry (72% vs. 84%, p=0.05), whereas the 
proportions of symptom-free patients were similar (51% vs. 50%, p=0.95). 
At 6 months, 28 patients (30%) in the “test first” group and 29 patients (32%) in the 
“treat first” group were using proton pump inhibitors. Only 17 (9%) patients had 
upper gastrointestinal endoscopy during the study period: 4 (4%) in the “test first” 
group, 13 (14%) in the “treat first” group (p=0.02). There was a trend towards a 
higher endoscopy rate in patients who had not had triple therapy (14% vs. 5%, 
p=0.05). 
 
H. pylori eradication rate 
Of the 96 H. pylori positive who received triple therapy 94 (98%) had a negative 
UBT after therapy. The remaining two patients were both cured after second-line 
quadruple therapy with esomeprazole, bismuth, metronidazole, and tetracycline.
Figure 4. Main results 
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Side effects 
Of the 96 patients who had had triple therapy, 84 returned the side-effects 
questionnaire, of whom 28 (33%) reported to have had no side-effects at all, 32 
(38%) some side-effects but not bothering, 14 (17%) moderate side-effects, 10 
(12%) severe side effects. Diarrhoea was the most common side-effect (24%), 
followed by nausea (12%), sour tongue/mouth (7%), altered taste (5%), and anal 
itching (5%).  
Of the 157 patients who had had esomeprazole treatment 141 returned the side-
effects questionnaire, 118 (84%) reported not to have had any side effects, 14 (10%) 
reported some not troublesome side-effects, 2 (1%) reported moderate side effects, 6 
(4%) reported severe side-effects. The most commonly reported side effects were: 
headache (3%), abdominal/epigastric pain (3%), and fatigue (2%). 
None of the patients in this study needed medical treatment for side-effects, and all 
side-effects were self-limited. 
 
 
Discussion 
 
Many patients with upper gastrointestinal symptoms are managed without 
endoscopy to guide treatment. These patients are usually treated either with a course 
of acid suppression or with testing for H. pylori followed by H. pylori eradication if 
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infected and acid suppression if not infected. These strategies are not mutually 
exclusive; rather they can be used together. However, it is not clear whether it would 
be better to start with testing for H. pylori or with a course of empirical acid 
suppression. Therefore, the aim of this study was to compare two empirical 
treatment strategies, one starting with H. pylori test and treat, followed by proton 
pump inhibitor therapy in case of persisting/relapsing symptoms, the other starting 
with empirical proton pump inhibitor therapy followed by H. pylori test-and-treat in 
case of persisting or relapsing symptoms. 
 
In this population with an almost 54% H. pylori infection rate we found no 
differences in proportions of “symptom-free”/”sufficiently treated” patients, both 
after the first treatment step and at the end of the 6 month follow-up period. In both 
strategies some 50% of patients were symptom-free and some 60% felt sufficiently 
treated after the first treatment step. However, the relapse rate was much lower in 
the “test first” strategy, and this difference was caused by the (initially) H. pylori 
positive patients. The patients with persisting/relapsing symptoms proceeded with 
the second treatment step and at the end of the 6 month follow-up period, again there 
were no differences between the strategies: some 50% of patients were symptom-
free, and some 80% felt sufficiently treated, while only few patients had had 
endoscopy. 
 
When interpreting these results we should keep in mind several possible biases. First 
of all, the H. pylori infection rate was high compared to data from other Dutch 
patients with upper gastrointestinal symptoms, which may benefit the “test first” 
strategy.19 This was caused by the inclusion of a large subgroup of patients of 
Mediterranean ancestry, with a very high infection rate, reflecting the H. pylori 
prevalence in their countries of origin. The inclusion of this subgroup was caused by 
selection by the GPs, who probably more often referred patients with a high risk of 
being infected with H. pylori because they knew that H. pylori testing was part of 
the study protocol and because there was no open-access UBT available for GPs in 
our area. Because of this selection bias, one should be careful when extrapolating 
the results to the general population. 
Furthermore, we encouraged the GPs to refer patients before starting therapy, but 
almost 40% of patients were using proton pump inhibitors at the time of referral, and 
even more patients had used proton pump inhibitors in the past. This may have 
caused selection of patients not responding to proton pump inhibitor therapy or with 
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relapsing symptoms for referral. However, the response rate to esomeprazole 
therapy is comparable to the response rates we found in two very large studies in 
primary care20,21 which suggests that we did not include a higher proportion of 
patients not responding to proton pump inhibitor therapy. 
Additionally, we may have biased the patients in the “treat first” group, because all 
patients had a H. pylori UBT before starting treatment, but the patients in the “treat 
first” group were blinded to the test result. This may have made these patients very 
aware of the possibility of being infected with H. pylori, and may have made them 
more prone to contact us in case of symptom relapse or even to report treatment 
failure, because they knew that proton pump inhibitor therapy alone would not have 
cured the infection. Nonetheless, the data seem plausible since the higher relapse 
rate in the “treat first” strategy was only found in H. pylori positive patients. 
 
Despite the fact that there are several studies comparing empirical treatment 
strategies with prompt endoscopy, there are hardly any studies directly comparing 
empirical acid suppression and the H. pylori test-and-treat strategy.9 There is only 
one published paper comparing acid suppression with H. pylori test-and-treat. 
Manes et al.22 studied 219 secondary care patients with dyspepsia (excluding 
heartburn), under 45 years, and without alarm symptoms. In this population (60% H. 
pylori infected) after 4 weeks of omeprazole treatment 83% of patients had symptom 
improvement while after H. pylori test-and-treat 71% of patients experienced 
improvement. As in our study, the relapse rate was much lower in the H. pylori test-
and-treat group (26% vs. 71%).  
Furthermore, endoscopy rates in that study were high (88% in the omeprazole group 
vs. 55% in the test-and-treat group) because all patients without symptom 
improvement after the first treatments step, as well as all patients with symptom 
relapse had endoscopy (without the option of a second empirical treatment step. In 
our study patients had a second empirical treatment and in case of eventual 
treatment failure we decided not to perform routine endoscopy in patients with 
treatment failure, because recent data show that failure of proton pump inhibitor 
therapy is not associated with a higher degree of organic pathology, certainly not in 
H. pylori negative patients.22,23 Instead, we decided to provide the patients with 
understandable information about the aetiology and treatment of dyspeptic 
symptoms, and left the decision to perform endoscopy up to the patients and their 
GPs, which resulted in a very low endoscopy rate (9%) and high proportions of 
patients satisfied with the treatment. 
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Furthermore, we found a very high H. pylori eradication rate compared to other 
studies.24,24 This may on one hand be caused by the low prevalence of 
clarithromycin resistance in our area, but we believe that the elaborate explaining of 
the effectiveness of the therapy, the possible side-effects and the importance of 
compliance also was an important factor. 
 
Despite the fact that dyspeptic symptoms often run a relapsing course, studies 
usually investigate only the initial treatment step. Few studies investigated 
protocolized multi-step treatment strategies. Laheij et al.26,27 experimented with an 
empirical treatment strategy with one or two courses of proton pump inhibitor and 
H. pylori test-and-treat in patients with symptom relapse. They showed that such a 
strategy was equally effective as (or even more effective than) but cheaper than 
prompt endoscopy followed by targeted treatment. However, in these studies the 
order of the treatment steps was not studied. All patients in the empirical treatment 
group started with a course of proton pump inhibitor followed by H. pylori test-and-
treat only in case of a first or even second relapse after initial symptom 
improvement. 
 
So which strategy should be preferred? Based on our data it is difficult to decide, 
especially since we did not register costs. Both strategies yielded similar proportions 
of patients “symptom-free” and “sufficiently treated”. Overall, the majority of 
patients experienced symptom relapse within one year, and as a consequence the 
majority of patients had had both proton pump inhibitor therapy and a H. pylori test 
(followed by triple therapy if infected). This may explain why there was no 
difference in cure rates at 6 months even although the relapse rate was much higher 
in patients starting with a course of proton pump inhibitor. Therefore, it seems that 
as long as the different treatment options are used together the majority of patients 
are adequately treated within a short period of time, regardless of the order of 
treatment steps. 
This higher relapse rate (and of course the associated higher proportion of patients 
having a second treatment step) in (H. pylori infected patients in) the “treat first” 
strategy suggests that the “test first” strategy should be preferred in our population, 
especially in the subgroup of patients of Mediterranean origin. Starting with an H. 
pylori test followed by triple therapy in H. pylori positive patients and a course of 
proton pump inhibitor therapy in H. pylori negatives followed by proton pump 
inhibitor therapy in case of persisting/relapsing symptoms (after confirmation of H. 
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pylori eradication) is a simple and straightforward strategy. Patients like the fact that 
there is an investigation before starting therapy, and appreciate H. pylori as an 
understandable and treatable cause of their symptoms.28 Furthermore, there are 
many advantages of being H. pylori negative. It decreases the risk of developing 
future peptic ulcer disease and complications,14 it decreases the risk of developing 
distal gastric cancer,29,30 it prevents the development of an unfavourable gastritis 
pattern during maintenance proton pump inhibitor therapy,31 and it reduces the risk 
of ASA/NSAID gastropathy.32,32 Moreover, since re-infection is rare,34 it needs to be 
given only once in a lifetime. Thus, starting with an H. pylori test is simple, 
effective, and safe. 
 
In conclusion, both treatment strategies were effective for treatment of patients with 
dyspeptic symptoms. Two thirds of the patients who were symptom-free after the 
first treatment step had relapsing symptoms, and relapse was more common in H. 
pylori positive patients. Because of this, and the other benefits of being H. pylori 
negative, starting with an H. pylori test and eradication if infected seems preferable 
in populations with a high H. pylori infection rate. Although, only half of the 
population was symptom-free after 6 months, the majority of patients felt 
sufficiently treated, and only few patients had had endoscopy. 
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Introduction 
 
This chapter continues, where the first chapter of this thesis stopped. Therefore, first 
a short resume of what was established in the “General Introduction”: 
• Dyspepsia is a complex of symptoms; 
• Dyspepsia is associated with considerable health care consumption; 
• Upper gastrointestinal pathology is usually divided into: functional dyspepsia 
(50-70% of patients with dyspeptic symptoms), gastro-oesophageal reflux 
disease (10-30%), peptic ulcer disease (5-15%), gastric/oesophageal malignancy 
(0-2%); 
• Symptoms correlate poorly with diagnosis established at endoscopy; 
• Effectiveness of therapy varies according to the underlying pathology 
Now the story will continue with my personal view on the management of patients 
with dyspeptic symptoms, based on data from the literature as well as on data from 
this thesis. 
 
 
Management of patients with dyspeptic symptoms 
 
Patients with mild symptoms or with a first episode of dyspeptic symptoms have a 
good prognosis and often can be treated with conservative measures or with simple 
antacids. However, patients with severe or longstanding symptoms often need more 
aggressive treatment. Adequately treating these patients remains a challenge for 
every physician. In general there are several strategies a physician can follow when 
confronted with a patient with dyspeptic symptoms. The most widely used strategies 
are (in random order): 
1. prompt endoscopy followed by targeted treatment 
2. H. pylori test-and-treat 
3. empirical acid suppression 
4. treat-and-test 
5. individualized treatment based on the GP’s judgment 
These strategies will be described in the next paragraphs. 
 
1. Prompt endoscopy followed by targeted treatment 
In this strategy endoscopy is performed promptly in all patients, i.e. before starting 
any treatment. Treatment is then determined by the endoscopic diagnosis. 
Endoscopy provides information about the presence and severity of mucosal and 
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establish or rule out the presence of c
structural pathology of the upper gastrointestional tract. It can accurately diagnose 
erosive oesophagitis, peptic ulcer disease, malignancy, and Barrett’s metaplasia, as 
well as other structural abnormalities, such as Schatzki’s rings, oesophageal webs, 
deformations, oesophageal varices, etc. In fact, it is the only way to definitely 
ancer. 
Endoscopy may also have a reassuring effect,2 
especially in patients who worry about having 
gastric or oesophageal cancer. For example, 
one study showed a significant decrease in 
health related anxiety following a normal 
endoscopy, and another study found improved 
patient satisfaction regardless of the outcome, but this may (partly) be explained by 
regression to the mean, and both studies were not controlled.2,3 Other studies yielded 
conflicting results. For example, in a randomized study comparing prompt 
endoscopy with empirical treatment it appeared that patients in the prompt 
endoscopy group were more likely to have another endoscopy during long-term 
follow-up, which is in striking contrast with the supposed reassuring effect.4 
Additionally, endoscopy can be used for interventional purposes, e.g. for 
haemostasis in case of upper gastrointestinal bleeding, for balloon dilatation/stent 
placement in case of obstruction, for rubber band ligation in case of oesophageal 
varices with a high risk of bleeding, for mucosal resection/ablation in case of early 
cancer, or high risk Barrett’s oesophagus, for placement of an intra-gastric balloon 
in case of massive overweight, etc. 
However, there are also several drawbacks. Firstly, there may be misclassification 
because non-erosive reflux disease is missed, and erosive oesophagitis and peptic 
ulcer disease may already be cured by use of (over-the-counter) acid suppressants 
(especially if the patient can not be endoscoped immediately and starts treatment 
before having endoscopy because of the severity of the symptoms) or because of the 
timing of the endoscopy during a period of natural remission. The prompt 
endoscopy strategy therefore works best when there are no waiting lists for the 
procedure. Secondly, endoscopy is associated with considerable costs (although 
these vary widely from country to country), and is therefore a major factor in the 
outcome of many cost-effectiveness analyses.5 Thirdly, the majority of patients think 
that it is a troublesome experience they rather would not undergo (In The 
Netherlands sedation is not often used because of the increased risk of perforation, 
aspiration, and respiratory insuffiency). Fourthly, in the majority of patients (some 
60-70%) no pathology explaining the symptoms is detected and the results are 
therefore not helpful in selecting the optimal therapy.6 And finally, findings at 
endoscopy often do not alter the management of the patient. Thus, although prompt 
endoscopy provides information about then underlying pathology as well as 
opportunities for biopsy and intervention, it is costly, often not feasible because of 
waiting lists, troublesome to the patient, and often does not change treatment.7 
 
2. H. pylori test-and-treat 
In an attempt to reduce the number of (normal) 
endoscopies the H. pylori test-and-scope strategy was 
developed.8 In this strategy all patients have a non-
invasive H. pylori test, which is used as an indirect 
peptic ulcer test, and only H. pylori positive patients 
have endoscopy, while H. pylori negative patients are 
treated symptomatically with acid-suppressants. Several 
studies showed that endoscopy can safely be omitted in 
H. pylori negative patients (less than 55 years of age, 
not using ASA/NSAIDs).9,10 Peptic ulcer disease is 
adequately identified. But although it does reduce the 
number of endoscopies compared to direct endoscopy, 
questions were raised about the value of performing endoscopy in H. pylori positive 
patients. Delaney et al. randomized 478 primary care patients with dyspeptic 
symptoms (under 50 years, H. pylori prevalence approximately 33%) to test-and-
scope or usual care. They showed that the test-and-scope strategy increased 
endoscopy rates over usual practice in primary care (40% vs. 25%) without 
producing significant differences in symptoms or quality of life compared with usual 
management after one year. Therefore, the test-and-scope strategy is not cost-
effective.11 Based on these data the test-and-scope strategy has largely been replaced 
by the H. pylori test-and-treat strategy.  
In the H. pylori test-and-treat strategy all patients have a non-invasive test for H. 
pylori infection. H. pylori positive patients receive (one or more courses of) therapy 
for H. pylori eradication until cured of the infection. H. pylori negative patients are 
symptomatically treated with acid suppressive medication. The same goes for 
initially H. pylori positive patients with persisting/relapsing symptoms after 
successful (and documented) H. pylori eradication. 
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This is a simple and safe strategy. Evidence shows that endoscopy can safely be 
omitted in H. pylori negative patients less than 55 years old not using 
ASA/NSAIDs.12-15 After one or two treatment steps all patients are adequately 
treated: patients with H. pylori positive ulcer disease have had H. pylori eradication, 
patients with H. pylori negative ulcer disease are treated with acid suppression, and 
patients with GERD are treated with acid suppression once H. pylori negative. 
Furthermore, H. pylori infection, which is associated with several risks, is cured in 
all patients and since reinfection rates are very low this means that a major factor in 
the aetiology of upper gastrointestinal disease has been permanently eliminated.16 
Furthermore, H. pylori eradication reduces the risk of future upper gastrointestinal 
disease as will be discussed later in this chapter. 
  
3. Empirical acid suppression 
In this strategy all patients are treated with a 
course of acid suppression, without prior 
endoscopy or H. pylori test.17 This strategy, 
which was recommended in one of the earliest 
dyspepsia guidelines,18 is still very popular in 
primary care since it provides prompt 
symptom relief in a large group of patients. 
The majority of patients with gastro-
oesophageal reflux disease19 and peptic ulcer disease20 will have symptomatic 
benefit as well as a subgroup of patients with functional dyspepsia, although in the 
latter there is a large placebo effect21. This is illustrated by the data in chapters 8A 
and 8B of this thesis, showing that some 40%-50% of patients with uninvestigated 
dyspeptic symptoms became completely symptom-free during treatment with the 
proton pump inhibitor esomeprazole. 
However, since acid suppression does not produce permanent changes, relapse rates 
are high, especially in patients with longstanding or severe symptoms.22 Therefore, 
cost-effectiveness depends on the handling of patients with relapsing symptoms. 
Furthermore, patients with H. pylori positive peptic ulcer disease are not 
appropriately treated since it is known that H. pylori eradication would prevent ulcer 
recurrence, and may thereby reduce the need for further acid suppression.20 In fact, 
patients with peptic ulcer disease may present with ulcer complications (such as 
bleeding or perforation) in case of recurrence after initial healing with a course of 
acid suppression. Since H. pylori is not eradicated, the risk of developing future 
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peptic ulcer disease (and complications), ASA/NSAID gastropathy, or cancer is not 
decreased. 
 
4. Treat-and-test 
In the treat-and-test strategy all patients with dyspeptic symptoms first receive a 
course of acid suppression, and only those with a good symptomatic response are 
tested for H. pylori and treated with triple therapy if H. pylori infected.7 
This strategy relies on the assumption that the symptomatic response to a course of 
acid suppression can be used for diagnostic purposes. It is assumed that patients with 
GERD and peptic ulcer disease respond much better than patients with functional 
dyspepsia. However, this does not seem to be a useful tool because of the high 
placebo response rate in patients with functional dyspepsia. Evidence shows that 
even in patients with reflux-like symptoms the response to acid suppression is not a 
very good test for diagnosing GERD (diagnosed with endoscopy and pH 
registration).23 Therefore, the response to a course of acid suppression is not useful 
for diagnostic purposes. 
 
5. Individualized treatment based on the GP’s judgment 
This relies on the assumption that the GP, based on patient characteristics, can 
provide more optimal, individualized care in comparison to a uniform algorithm for 
all patients. The new Dutch Dyspepsia Guideline relies heavily on the GPs 
evaluation of the individual patient.24 However, this puts the GP in an unfortunate 
position because symptoms poorly predict the underlying pathology. Even the 
presence or absence of alarm symptoms is of little benefit: evidence shows that there 
is no difference between pathology detected at upper endoscopy in selected and 
unselected patients. Therefore, besides the decision whether or not to start treatment 
at all, there are no rational choices to be made by the GP. This is supported by the 
literature, since there are no data showing that GPs can outperform a strategy in 
which all dyspeptics are treated the same regardless of their individual 
characteristics. 
 
 
Factors to keep in mind when examining the literature on 
treatment strategies 
 
After describing the various treatment strategies for patients with upper 
gastrointestinal disease, the question which strategy should be used still remains 
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unanswered. But then again: although the question is simple, it can not be answered 
that easily… 
This is caused by: 
1. Difficulty translating treatment strategies into a study protocol; 
2. Heterogeneity between study populations (making it difficult to compare 
studies); 
3. Differences in study outcomes used (making it difficult to compare the results); 
4. Variability of costs caused by differences in definitions and local circumstances. 
These factors will be discussed in the next paragraphs, and should be kept in mind 
for the remainder of this chapter when various study results are discussed. 
 
1. Translating treatment strategies into a study protocol 
It is difficult to translate treatment strategies into a study design since most 
treatment strategies comprise several treatment steps to be used at variable times 
during follow-up. Therefore, most study designs are no more than simplified 
versions of treatment strategies, often limited to one treatment step, and/or to a short 
follow-up period. But even in case of a short follow-up period there is usually quite 
some time between the end of the first treatment step, and the evaluation of the 
primary outcome. Therefore, what happens after the first treatment step is of vital 
importance. However, if treatment after the first treatment step is not specified in the 
protocol but left up to the GP, there may be much heterogeneity between individual 
patients on one hand, and little difference between the treatment arms on the other 
had. 
 
2. Heterogeneity of study populations 
Usually there are many differences between various study populations. These 
differences may make it difficult to interpret/compare the results. First of all the 
prevalence of underlying disease varies regionally as well as with age. This is partly 
related to H. pylori prevalence. In populations with a high H. pylori prevalence 
(elderly patients; patients from Southern/Eastern Europe, Asia, Africa, South 
America) peptic ulcer disease is much more common. In Northern/Western Europe 
and the United States the prevalence of gastro-oesophageal reflux disease is high. 
And in developing countries, Japan, and elderly patients the prevalence of gastric 
cancer is relatively high. 
Furthermore, it matters whether patients with a first presentation of dyspeptic 
symptoms or patients with chronic/recurrent symptoms are studied. The former can 
 204
be cured more easily. The same goes for populations selected from primary vs. 
secondary care. The latter tend to have more longstanding/more severe symptoms. 
This may lead to higher failure/relapse rates in the latter, even though there seems to 
be little difference in findings at endoscopy between these patient groups. 
 
3. Definition of study outcomes 
Since there is no objective test to determine whether or not a patient has dyspepsia, 
effectiveness can be defined in several ways. Often subjective outcome measures are 
used such as the proportion of symptom-free patients at a certain point in time. 
However, since dyspeptic symptoms tend to run a relapsing course, absence of 
symptoms at a certain moment may not necessarily imply that a patient is 
permanently cured. In an attempt to tackle this problem others used the proportion of 
symptom free days during follow-up. But then, patients have to measure symptoms 
every day by using diaries which is susceptible to several biases, such as recollection 
bias and repetitive testing bias. And what about the relationship between medication 
use and presence of symptoms: is a patient who is symptom-free during treatment 
equal to a patient who is symptom-free without medication? 
In an attempt to use more objective measures others used endoscopy rates as 
primary outcome, or combined outcomes comprising endoscopy referrals, secondary 
care referrals, medication use, etc. However, these outcomes are highly dependent 
on the study protocol. E.g. in many studies all patients with therapy failure by 
definition proceed with endoscopy, while in other studies this decision is left up to 
the GP. This can create large differences in the proportions of patients reaching the 
outcome. Others used quality-of-life as outcome measure but this is not very 
sensitive to (changes in) the severity of dyspeptic symptoms. 
Thus, it is difficult to define an objective outcome when studying dyspepsia. 
Therefore, studies may use different outcomes making it difficult to compare them. 
In general, subjective outcomes measuring the presence of dyspeptic symptoms 
seem to be most valid, although they may vary over time and may be influenced by 
the use of medication. 
 
4. Costs depend on local circumstances and follow-up period 
Firstly, costs are highly variable, depending on local circumstances. For example the 
costs of endoscopy and sick leave are highly variable from country to country. 
Therefore, cost-effectiveness results should be adjusted for these differences when 
comparing study results. 
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Moreover, details of the strategy/study protocol may have profound impact on costs. 
For example the way treatment failure is dealt with is an important cost-modulator. 
E.g. if in a H. pylori test-and-treat strategy all patients with relapsing symptoms 
proceed with endoscopy instead of having a course of proton pump inhibitor therapy 
this has a profound influence on costs. However, both strategies are called H. pylori 
test-and-treat… 
Last but not least the length of the follow-up period may be associated with cost-
effectiveness outcomes. For example, there are costs that are usually made just once 
(incidental costs, e.g. a negative UBT, therapy for H. pylori eradication), while other 
costs tend to continue (recurrent costs, e.g. proton pump inhibitor use in patients 
with chronically relapsing symptoms). The shorter the follow-up period, the bigger 
the impact of incidental costs and the smaller the impact of recurrent costs. 
 
 
Studies comparing treatment strategies 
 
Despite the above mentioned problems (or maybe: because of these problems) there 
are few comparative studies, rendering it difficult to make an evidence based choice. 
Usually the few available studies tend to be small, and therefore have low power. In 
the next pages the outcomes of several important studies will be discussed. These 
are comparative studies regarding: 
1. H. pylori test-and-treat vs. prompt endoscopy; 
2. Empirical acid suppression vs. prompt endoscopy; 
3. H. pylori test-and-treat vs. empirical acid suppression; 
4. Treat-and-test vs. prompt endoscopy; 
5. Hybrid strategies. 
 
1. H. pylori test-and-treat vs. endoscopy 
Most research focused on the H. pylori test-and-treat strategy. Several studies 
compared H. pylori test-and-treat with prompt endoscopy12-14,25,26 A recent meta-
analysis comprising 5 of these studies showed that in the combined population of 
1,924 patients (in primary care or first referral to secondary care, with symptoms 
attributable to the upper gastrointestinal tract including heartburn, overall 43% H. 
pylori infected), there was no difference in the proportion of patients without 
dyspeptic symptoms one year after randomization (RR 0.98; 95%CI: 0.8-1.2), but in 
the test-and-treat group fewer patients had endoscopy (RR 0.25; 95%CI: 0.1-0.4). 
This was confirmed in an individual patient data meta-analysis showing that slightly 
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more patients in the prompt endoscopy group were symptom-free at one year (RR 
0.96; 95%CI: 0.9-1.0), but at much higher costs.26 
Long term results are very scarce. One research group has now completed a 6-year 
follow-up study on the original cohort of included patients, and findings show that 
the difference in resource use at 12 months appears to continue thereafter, with no 
difference in the symptom status between the 2 strategies and a continued increase 
in resource use in the prompt endoscopy patients.27 Overall, these data suggest that 
H. pylori test-and-treat is to be preferred over prompt endoscopy followed by 
targeted treatment. 
 
2. Empirical acid suppression vs. prompt endoscopy 
As early as 1994 the results of a study comparing prompt endoscopy with empirical 
treatment with H2RA for 4 weeks were published. A group of 414 patients with 
dyspeptic symptoms without a prior diagnosis of peptic ulcer disease or reflux 
oesophagitis was studied.17 It was concluded that prompt endoscopy (indeed in this 
study promptly performed) was more cost-effective because there were no 
differences in symptoms or quality of life after 1 year, and in the H2-receptor 
antagonists group the number of endoscopies was only 20% lower, while these 
patients used more H2-receptor antagonists, reported more sick-leave days, and more 
GP visits, and 40% of peptic ulcer patients remained undiagnosed in the empirical 
therapy group. However, in this study H2-receptor antagonists were used instead of 
the more powerful proton pump inhibitors. Furthermore, due to the study design, all 
patients with treatment failure or relapsing symptoms proceeded to endoscopy, 
which by definition led to an unnecessarily high endoscopy rate in the empirical 
treatment group. Finally, H. pylori infection was not taken into account. 
Lewin et al.28 found no differences after one year between usual care, prompt 
endoscopy with targeted treatment, eight weeks therapy acid suppressive therapy, 
and eight weeks prokinetic therapy. They studied 326 primary care patients with 
dyspeptic symptoms (without alarm symptoms, 46% H. pylori infected). 
Unfortunately, the treatment groups were very small, thereby largely reducing 
power. Furthermore, a complex outcome measure was used: “strategy failure” which 
was defined as a combination of either use of medication for more than 8 weeks, 
necessity of additional investigations, GP consultation because of 
persisting/relapsing symptoms, or referral to a specialist. 
Another study, only published in abstract form25, compared proton pump inhibitor 
therapy, prompt endoscopy, H. pylori test-and-scope, and H. pylori test-and-treat. 
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Some 800 dyspeptic patients (age, 30% H. pylori infected) were randomized and no 
differences were found regarding symptoms or cost at 1 year. Again, numbers of 
patients were fairly small in the different subgroups, which reduced power, and only 
the first treatment step was protocolized, while the outcome was registered after one 
year. Unfortunately, because the study is only published in abstract form there is no 
definite and detailed information about the results of this study. 
In a further study published as abstract only, early endoscopy was compared with 
proton pump inhibitor therapy. Kjeldsen et al.29 randomized 368 dyspeptic patients 
(including reflux symptoms, without alarm symptoms) and found similar 
proportions of patients without symptoms (24% vs. 20%) or with symptom 
improvement (84% vs. 76%) after one year, while 43% vs. 32% of patients used 
proton pump inhibitors after one year. Again the groups were fairly small, and only 
the first treatment step was specified, while the outcome was measured after one 
year. 
Two other small studies compared empirical treatment with prompt endoscopy.30,31 
Only, these used some sort of treat-and-test in the empirical treatment arm: patients 
with symptom relapse after the second course of proton pump inhibitor treatment 
were tested for H. pylori and treated with triple therapy if positive. However, 
because only a very small subgroup of patients had H. pylori eradication these 
studies will be included in this paragraph. Both studies were performed by the same 
researchers and used the same design in comparable populations. The first study 
randomized 135 primary care patients with dyspeptic symptoms without alarm 
symptoms (37% H. pylori infected, median age 44 years) to proton pump inhibitor 
therapy (followed by H. pylori test-and-eradication after the second relapse) or 
prompt endoscopy.30 After 6 months 40% in the proton pump inhibitor group were 
symptom free vs. 24% in the endoscopy group. The authors concluded that empirical 
treatment followed by a test-and-eradicate strategy resulted in fewer diagnostic tests, 
more symptom relief and lower medical costs compared with prompt upper 
gastrointestinal radiography or endoscopy in the management of uninvestigated 
patients with persistent dyspeptic symptoms. The second study randomized 80 
patients to prompt endoscopy or proton pump inhibitor therapy (followed by H. 
pylori test-and-eradicate). The proportion of symptom-free days after 1 year was 
similar in both groups, while the empirically treated patients had had fewer 
endoscopies (31% vs. 100%) and lower cost.31 
Therefore, overall, there seems to be little evidence that prompt endoscopy is more 
effective than empirical therapy with a proton pump inhibitor, although cost of 
 208
prompt endoscopy is usually higher. This is confirmed by an individual patient data 
meta-analysis including five of the above mentioned studies and showing that 
despite additional cost, endoscopy is not more effective after one year.32 A study by 
Laheij et al. showed that this pattern continued after the first year of follow-up: after 
almost 7 years of follow-up, there was no difference in dyspeptic symptoms or 
quality of life, while patients in the endoscopy group had more diagnostic 
procedures during the additional follow-up and seemed to use more acid suppressive 
medication than patients in the empirical treatment group.4 
 
3. H. pylori test-and-treat vs. empirical acid suppression 
Few studies compared H. pylori test-and-treat with empirical acid suppression. An 
Italian study randomized 219 secondary care patients with dyspeptic symptoms 
(patients under 45 years, without alarm symptoms, 61% H. pylori infected) to these 
strategies.33 It was shown that in the test-and-treat group fewer patients had 
symptom relapse and fewer patients underwent endoscopy, while achieving similar 
symptom reduction after one year. However, in this study patients had only one 
treatment step, which means that patients with symptom persistence/relapse after 
successful H. pylori eradication did not continue with proton pump inhibitor therapy 
(which means that this strategy is not truly H. pylori test-an-treat), nor did patients 
with relapsing symptoms after a good response to a course of proton pump inhibitor. 
Instead, all patients with persisting/relapsing symptoms had an endoscopy. 
Furthermore, H. pylori prevalence was high in this population. 
Jarbol et al.34 (already mentioned above) cluster-randomized 722 primary care 
patients to initial treatment with either one week of esomeprazole, H. pylori testing 
and eradication treatment if infected (and no treatment if not infected), or one week 
of proton pump inhibitor therapy followed by H. pylori testing and eradication if 
positive only in patients with symptom improvement after proton pump inhibitor 
therapy (treat-and-test). Symptom scores and quality-of-life scores had improved 
similarly in all groups after one year. More endoscopies were performed in the 
proton pump inhibitor group vs. H. pylori test-and-eradicate and treat-and-test (0.36 
vs. 0.28-0.22). H. pylori positive patients given eradication treatment reported a 
higher number of days without dyspeptic symptoms, used less anti-secretory 
medication, and were more satisfied with treatment than H. pylori negative patients. 
However, in this study only a very short initial treatment was defined (e.g. only one 
week of proton pump inhibitor therapy), after which GPs were free in their choice of 
therapy. However, outcomes were measured after one year. This probably led to 
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regression to the mean, because for most of the time treatment is left up to the GP. 
Furthermore, there was no true H. pylori test-and-treat strategy, because in the so-
called test-and-treat arm initial treatment was only specified for H. pylori infected 
patients; proton pump inhibitor treatment for H. pylori negative patients or patients 
with persisting/relapsing symptoms after successful H. pylori eradication was not 
protocolized. 
Another study already mentioned previously randomized some 800 dyspeptic 
patients (30% H. pylori infected) to proton pump inhibitor therapy, endoscopy, H. 
pylori test-and-scope, or H. pylori test-and-treat and found no differences between 
symptoms or cost at 1 year, although there were less endoscopies in the proton pump 
inhibitor group.12 Again, numbers of patients were fairly small in the different sub 
groups, thereby largely reducing power, and again only the first treatment step was 
protocolized, while the outcome was registered after one year. 
Unfortunately, the above mentioned studies were too heterogeneous for meta-
analysis. Although there is no large trial comparing true H. pylori test-an-treat with a 
strategy using empirical acid suppression the evidence suggests that, overall, there 
are no large differences in symptom reduction after one year between these 
strategies. 
 
4. Treat-and-test vs. other strategies 
Studies utilizing the so-called treat-and-test strategy are extremely rare. Two of 
these studies were already described in the comparison of empirical acid suppression 
with prompt endoscopy since only after the second symptom relapse after proton 
pump inhibitor therapy patients proceeded to H. pylori test-and-eradicate. This 
meant that only a very small number of patients were tested (and treated) for H. 
pylori infection.30,31 
 
5. Hybrid strategies 
In chapter 9 of this thesis two multi-step treatment strategies were compared for 
treatment of primary/secondary care patients with dyspeptic symptoms. The “test 
first” strategy started with testing for H. pylori followed by H. pylori eradication if 
infected or a course of proton pump inhibitor if not infected. In case of 
persisting/relapsing symptoms after successful H. pylori eradication patients 
proceeded with a course of proton pump inhibitor therapy. H. pylori negative 
patients with a good response to proton pump inhibitor therapy were treated again 
with a proton pump inhibitor in case of symptom relapse. In fact, this is the “H. 
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pylori test-and-treat” strategy as it is often used in clinical practice. But in study 
protocols usually only the first treatment step of the H. pylori test-an-treat strategy is 
incorporated, although such a limited test-and-treat strategy is still called “test-and-
treat”. 
In the other treatment arm (“treat first”) all patients received a course of proton 
pump inhibitor irrespective of H. pylori status. H. pylori infected patients with 
persisting/relapsing symptoms proceeded with H. pylori eradication. H. pylori 
negative patients with a good response to proton pump inhibitor therapy were treated 
again with a proton pump inhibitor in case of symptom relapse. 
In both treatment arms patients without symptom improvement after two treatment 
steps did not automatically proceed with endoscopy, but were reassured and referred 
back to their GPs for further treatment. This study showed that these treatment 
strategies were equally effective both after the first treatment step and after 6 
months. Only in the sub group of patients of Turkish/Moroccan ancestry with a very 
high rate of H. pylori infection the H. pylori test-and-treat strategy was more 
effective after the first treatment step, but not after 6 months. Furthermore, it showed 
that symptom relapse was more common in H. pylori positive patients not treated 
with antibiotics. Moreover, even although only half of the population was symptom-
free after 6 months, the majority of patients felt adequately treated, and only few 
patients underwent endoscopy. 
 
 
Other factors influencing the choice for a treatment strategy 
 
There are several other factors/opinions that are usually not of importance in cost-
effectiveness trials and can not be measured in small studies with a short follow-up 
period, but may be very important when deciding which treatment strategy to use. 
The most important of these factors are: 
1. Early diagnosis of gastro-oesophageal cancer; 
2. H. pylori and gastric cancer; 
3. H. pylori eradication in H. pylori positive patients on maintenance proton pump 
inhibitor therapy; 
4. H. pylori and ASA/NSAIDs; 
5. H. pylori eradication and gastro-oesophageal reflux disease; 
6. Side effects of H. pylori eradication. 
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1. Early diagnosis of gastro-oesophageal cancer 
One of the major concerns of treatment strategies without early endoscopy is that 
gastro-oesophageal cancers may be missed. Therefore, it is usually advised to refer 
patients with alarm symptoms or over a certain age for prompt endoscopy.36-40 In 
line with this, these patients are usually excluded from studies investigating 
empirical treatment strategies. However, is this rational? Can one feel safe using 
these exclusion criteria? 
First let us turn to the alarm symptoms. Alarm symptoms are used in all dyspepsia 
guidelines and in most study protocols, even although there is little evidence 
supporting their use. In fact, as shown in chapter 2 of this thesis,41 alarm symptoms 
are of little use for selection of patients with gastro-oesophageal cancer because 
more than a third of patients with gastro-oesophageal cancer had no alarm 
symptoms, while only very few of the patients with alarm symptoms actually had 
cancer. In fact, alarm symptoms did not even prove to be useful for selection of 
patients with any gastro-oesophageal pathology. This is further substantiated by 
several studies showing no differences in findings at endoscopy between selected 
and unselected patients. Therefore, the presence of alarm symptoms does not 
necessarily have to lead to upper gastrointestinal endoscopy, certainly in patients 
under the age of 55 chances of finding gastro-oesophageal cancer are minute, while 
in elderly patients the risk is higher but still low. However, alarm symptoms should 
prompt physicians to make a thorough differential diagnosis, also considering 
disorders outside the upper gastrointestinal tract. Then, based on the unique 
characteristics of each individual patient an adequate diagnostic trajectory should be 
chosen. 
Furthermore, in symptomatic patients with cancer, the cancer usually is in an 
advanced stage and delay in diagnosis would rarely have changed prognosis. In fact, 
curable malignant lesions are often coincidental findings, before the onset of 
symptoms. Therefore, if one would like to detect gastro-oesophageal cancers in a 
curable stage, a screening program would be necessary. However, this is not feasible 
because of the lack of a treatable precancerous lesion, and the low incidence of 
gastro-oesophageal cancer in most populations. 
Secondly, let us discuss the use of an age cut-off. In chapter 2 of this thesis it is 
shown that there is no safe age cut-off below which no patient has gastro-
oesophageal cancer at all. However, there is a clear relationship with age and gastro-
oesophageal cancer is extremely rare in patients under the age of 55, even in the 
presence of alarm symptoms. Therefore, it seems practical not to perform endoscopy 
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in patients under the age of e.g. 55 years. And indeed most guidelines and protocols 
use age cut-offs between 45 and 55 years of age, which seems plausible. 
However, rigid use of such an age cut-off implicates that patients over the defined 
age should automatically have prompt endoscopy. But even in patients over 70 years 
of age gastro-oesophageal cancer is still rare in most populations, certainly in the 
Dutch population. And again, in symptomatic patients gastro-oesophageal cancer is 
rarely curable. Therefore, endoscoping symptomatic patients usually detects cancers 
in a late stage.42 Therefore, one could defend not using an age cut-off at all. This 
would (by deduction based on the previously mentioned arguments) worsen 
prognosis only in a very small sub group of patients, while tremendously reducing 
the number of endoscopies, leading to conservation of funds and endoscopic 
capacity that may be used for more effective interventions, such as colon cancer 
screening. 
 
2. H. pylori (eradication) and gastric cancer  
H. pylori has been classified by the World Health Organization as a carcinogen43,44. 
According to data from a meta-analysis the odds ratio for gastric cancer among H. 
pylori infected people ranged from 9.3 (95% CI 3.4–34.0) in 20–29 year olds to 1.05 
(95% CI 0.7–1.5) in the elderly (> 70 years old) reflecting the change in prevalence 
of H. pylori in relation to age.45 
A Japanese cohort study showed that gastric cancer occurred in 36 (2.9%) of 1246 
H. pylori positives, but in none of 280 H. pylori negative persons and also in none of 
253 subjects who had received H. pylori eradication early during follow-up.46 
In a Chinese study randomizing 1,630 H. pylori infected participants to H. pylori 
eradication or placebo treatment no statistically significant reduction in the number 
of patients who developed gastric cancer was observed in participants who received 
H. pylori eradication treatment (n=7) compared with those who did not (n=11) 
(p=0.33). However, the population comprised a large sub group of patients who had 
already developed precancerous lesions. And when looking only at the subgroup of 
patients without precancerous lesions on presentation, eradication of H. pylori 
significantly decreased the development of gastric cancer during a follow-up of 7.5 
years (0 vs. 6 patients, p=0.02).47  
Besides its relationship with gastric cancer H. pylori infection is also strongly 
associated with MALT lymphoma of the stomach. And in a large proportion of 
patients with low-grade, early stage, gastric MALT lymphoma, H. pylori eradication 
alone is sufficient to induce regression.48 
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Therefore, even although the risk of developing gastric cancer/MALT lymfoma for a 
H. pylori infected individual is very low, an H. pylori eradication campaign on a 
population level will lead to a decrease in the incidence of gastric cancer (and 
probably also MALT lymphoma). Results from other prospective randomized trials 
will become available soon. If these further substantiate the preventive effect of H. 
pylori eradication on the development of gastric cancer, a search-and-treat policy 
may be cost-effective.49 
 
3. H. pylori and maintenance proton pump inhibitor treatment 
During the past years there has been much debate whether or not there is an 
increased risk of developing gastric cancer during maintenance proton pump 
inhibitor therapy in H. pylori infected patients. Although there are no data 
prospectively showing this there is ample evidence for the individual steps of the 
underlying cascade. 
It has been shown that during maintenance proton pump inhibitor therapy the pattern 
of gastritis in H. pylori infected patients shifts from antrum-predominant to corpus-
predominant.50 Furthermore, it has been shown that the corpus-predominant gastritis 
pattern is an unfavourable gastritis pattern; it is associated with the accelerated 
development of gastric atrophy,51 which, in turn, is associated with the development 
of gastric cancer.52 Thus, by deduction, maintenance proton pump inhibitor 
treatment may be associated with the development of gastric cancer in H. pylori 
infected individuals. However, this statement is subject to heavy debate, because 
there are no prospective data directly proving this. In order to gather such data, a 
large group of H. pylori infected people would have to be followed for a very long 
period of time, without having H. pylori eradication, which is not feasible in clinical 
practice (and also unethical). Fortunately, the solution is simple, H. pylori 
eradication before starting maintenance proton pump inhibitor treatment resolves  
the gastritis, thus preventing the development of unfavourable gastritis patterns, and 
interrupting the whole cascade, without reducing the efficacy of proton pump 
inhibitor therapy.53 Therefore, it seems wise to search for H. pylori and treat the 
infection in patients on long-term proton pump inhibitor therapy. 
 
4. ASA/NSAIDs and H. pylori 
Non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (ASA, 
aspirin), are widely used. They are associated with dyspeptic symptoms (in up to 
50% of users), peptic ulcer disease (in 15-25% of users), and serious complications 
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(in up to 5% of users). These adverse effects can occur with any formulation and 
even at low doses such as the doses for prevention of cardiovascular thrombotic 
events. When NSAIDS and ASA are used together the risk increases even further. 
Therefore, ideally, patients with dyspeptic symptoms should stop using these drugs, 
but that usually is not feasible. 
As already established H. pylori is another important risk factor for developing 
peptic ulcer disease. Together, ASA/NSAIDS and H. pylori account for more than 
90% of peptic ulcers. This was illustrated in a meta-analysis of case-control studies 
showing that NSAID use was associated with an odds ratio of 19 for developing 
peptic ulcer disease, which increased 3.5 fold in case of concomitant H. pylori 
infection. Similarly, H. pylori infection was associated with an odds ratio of 18, 
which further increased 3.6 fold in case of concomitant NSAID-use. In H. pylori 
infected NSAID users the risk of peptic ulcer disease was 61 times higher than in H. 
pylori negative patients not using NSAIDs. Furthermore, H. pylori infection and 
NSAID use increase the risk of peptic ulcer bleeding 1.8 and 4.9 fold, respectively, 
and 6.1 fold when both factors are present. Thus, NSAIDs and H. pylori 
independently and synergistically increase the risk of developing peptic ulcer 
disease and peptic ulcer bleeding.54  
H. pylori infection is also important in potentiating the development of low-dose 
aspirin-induced mucosal injury. In a study of healthy volunteers taking low-dose 
aspirin, gastric mucosal injury scores were fourfold greater in H. pylori-infected vs. 
uninfected volunteers.35 And a case-control study showed that H. pylori infection 
was an independent risk factor for bleeding in low-dose ASA users for 
cardiovascular prevention (odds ratio 4.7, 95% CI: 2.0–10.9).55 
Treatment of H. pylori infection before starting long-term NSAID therapy reduced 
the risk of developing peptic ulcer disease (12% vs. 34%) and ulcer complications 
(4% vs. 27%) after 6 months of NSAID therapy in H. pylori infected patients.56,57 
And for H. pylori positive low-dose ASA takers with a history of bleeding peptic 
ulcer disease, it was shown that H. pylori eradication and maintenance proton pump 
inhibitor therapy were comparably effective for prevention of recurrent bleeding.58 
Although is has not been proven, it seems reasonable to assume that the same goes 
for patients already taking NSAIDs, since H. pylori eradication removes one of the 
risk factors. 
Therefore, H. pylori eradication decreases the risk of developing peptic ulcer disease 
and ulcer complications in ASA/NSAID takers, although in high-risk patients (with 
a history of or active peptic ulcer disease or ulcer complications) taking NSAIDs 
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eradication treatment alone is insufficient and concomitant proton pump inhibitor 
treatment should be considered.59Thus, in general, the data available suggest that 
ASA/NSAID use is safer in H. pylori negative patients than in H. pylori positive 
patients and eradication of the infection makes future use of these drugs safer.60 
 
5. H. pylori (eradication) and GERD 
Theoretically, H. pylori infection (and H. pylori eradication) may indeed influence 
acid production. In H. pylori infected patients with severe corpus gastritis, acid 
production is decreased, because the acid producing cells are involved in the 
inflammation. In contrast, in H. pylori infected patients with severe antrum gastritis, 
acid production may be elevated due to high levels of circulating gastrin, produced 
in the inflamed antral epithelium. 
H. pylori eradication heals inflammation and restores normal acid production (at 
least if performed before atrophy becomes irreversible) and normalizes gastrin 
levels. Therefore, in patients with severe body gastritis H. pylori eradication may 
unmask/aggravate pre-existing gastro-oesophageal reflux disease, while in patients 
with severe antrum gastritis, GERD symptoms may decrease after H. pylori 
eradication. 
Epidemiological data show that at population level there is a negative association 
between H. pylori and GERD. Raghunath et al.61 performed a meta-analysis of 20 
observational studies examining the association between H. pylori and GERD 
(defined as presence of heartburn and/or acid reflux in association with either 
endoscopic oesophagitis or a 24h pH examination indicative of GERD), including 
4,134 patients. They found a mean prevalence of H. pylori infection of 38% in 
GERD subjects, compared with 50% in subjects without GERD (pooled OR for H. 
pylori in GERD symptoms 0.60 [95%CI: 0.47-0.78]). This protective effect may be 
caused by the tendency for H. pylori infection to lower gastric acid secretion with 
advancing age due to the development of atrophic gastritis. This protective effect of 
H. pylori may be more marked in patients infected with more virulent H. pylori 
strains.62 However, other factors such as smoking, body mass index, adult height etc. 
may have a more significant impact on GERD than H. pylori.63 
This negative association between H. pylori and GERD may translate through to an 
effect on GERD complications such as Barrett’s metaplasia and adenocarcinoma, 
but case-control studies showed conflicting results64,65 and a prospective Chinese 
study found a no clear relationship between H. pylori infection and Barrett’s 
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metaplasia.66 Therefore, a causal relation has not been proven, while again other 
factors such as smoking may be more important. 
In line with the above mentioned findings many studies focused on the effect of H. 
pylori eradication on GERD. Studies in patients with existing GERD have failed to 
show any worsening of GERD symptoms and studies in patients with functional 
dyspepsia showed that development of oesophagitis was rare and not significantly 
more often in patients having H. pylori eradication vs. placebo. Two meta-analyses 
investigated GERD symptoms in duodenal ulcer patients with successful H. pylori 
eradication vs. failed eradication, showing that overall there was no association 
between post-treatment H. pylori status and GERD,67 while in patients with pre-
existing GERD symptoms worsening of GERD symptoms was less common in 
patients with successful H. pylori eradication. This is confirmed by Ragunath et al.68 
studying the effect of H. pylori eradication on GERD, showing that the presence of 
GERD was influenced by the prior presence of heartburn, and not by the final H. 
pylori status. Meta-analysis of 4 trials including 14,941 asymptomatic individuals 
showed that there was no overall difference in GERD symptoms following 
screening and eradication compared with either placebo or no screening (RR: 1.0, 
95% CI: 0.84–1.20).69 Therefore, even although H. pylori infection rates seem to be 
somewhat lower in patients with GERD on a population level, H. pylori eradication 
does, overall, neither seem to induce nor aggravate GERD. 
 
6. Side effects of therapy for H. pylori eradication 
Although many patients experience side-effects of therapy for H. pylori eradication 
these are usually mild and self-limited, rarely leading to cessation of treatment. As 
with any antibiotic therapy there are of course cases of severe anaphylactic reactions 
or other serious complications such as the development of pseudomembranous 
colitis, but fortunately sever side-effects are very rare. 
 
 
Personal view 
 
In the previous paragraphs many aspects of treatment strategies for dyspeptic 
patients were discussed. First, the various strategies were described, then pitfalls 
when interpreting study results, followed by studies comparing treatment strategies, 
and finally other factors of influence on the choice for a treatment strategies that are 
not of importance in short-term comparative studies, but do matter in real life. Based 
on these data I will now come to a personal opinion regarding the optimal treatment 
 217 
of patients with dyspeptic symptoms. The following aspects will be taken into 
account: short term symptomatic effectiveness, cost effectiveness, additional factors 
of influence, and the population the strategy can be applied to. 
 
Short term symptomatic effectiveness 
There do not seem to be large differences in patient-related outcomes between the 
various strategies. On the short term, symptom reduction, proportions of symptom-
free patients, patient satisfaction, and quality of life are comparable. However, in 
general relapse rates tend to be lower in H. pylori positive patients having had H. 
pylori eradication.  
 
Cost-effectiveness 
Although the various treatment strategies produce comparable effectiveness 
outcomes, there are considerable differences in costs. One of the most important 
costs is that of upper gastrointestinal endoscopy. As mentioned, prompt endoscopy 
does not provide better symptom reduction, often does not change therapy, and does 
not identify the cause of the symptoms in the majority of patients. On the other 
hand, endoscopy, is associated with considerable cost, is usually experienced as 
troublesome, while the reassuring effect of a negative endoscopy is debatable and 
may not be higher than that of a negative H. pylori test. Both clinical trials and cost-
effectiveness modelling show that starting with prompt endoscopy is not cost-
effective. Therefore, starting with endoscopy does not seem to be a viable approach. 
Rather, the available capacity for endoscopic examinations should be used for more 
effective interventions such as screening for/prevention of colon cancer, or for 
interventions such as placement of stents, ligation of oesophageal varices, or 
treatment of severe upper gastrointestinal bleeding. 
Therefore, treatment strategies without prompt endoscopy such as H. pylori test-and-
treat, empirical acid suppression, or treat-and-test should be used. Unfortunately, 
there are few comparative studies, and again these studies are simplified strategies 
usually investigating only the initial treatment step, while there are large differences 
in study outcome definition, in handling of treatment failure, prevalence of H. pylori 
infection, and costs associated with the various procedures, making it difficult to 
compare the results. Overall, differences in cost-effectiveness between these 
strategies seem to be limited. 
Others studied cost-effectiveness with computer models. However, these studies are 
also difficult to interpret. First of all they rely heavily on assumptions, although this 
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can be tackled by sensitivity analysis in which the assumptions are varied in order to 
investigate the effect on the outcome. Secondly, it is difficult to make long term 
predictions, especially in case of dyspeptic symptoms which tend to run a relapsing 
course. Furthermore, in many studies endoscopy is used for patients with treatment 
failure, or repeated relapses but this is just a matter of definition. In fact, treatment 
failure is associated with a higher prevalence of functional dyspepsia. Moreover, the 
timing of the evaluation-point is very important in cost-effectiveness analyses: in 
short term studies the influence of costs that are made only once tends to be 
exaggerated in comparison with repeated costs. Because dyspepsia is a chronic 
condition, a 1-year time horizon may be inadequate to realistically portray the 
natural history of dyspeptic patients. The longer the study period, the less important 
the occasional costs become. This is important since after H. pylori eradication re-
infection rates are very low. Therefore costs associated with H. pylori tests and H. 
pylori eradication are usually only incidental costs. Finally, there are other factors, 
such as prevention of gastric cancer, the value of early detection of gastro-
oesophageal malignancy, the risks of maintenance proton pump inhibitor treatment 
in H. pylori infected patients, the prevention of future peptic ulcer disease, or future 
NSAID gastropathy, etc. that are difficult to incorporate in short-term cost-
effectiveness analyses. 
 
Spiegel et al. compared 4 treatment strategies (H. pylori test-and-treat, proton pump 
inhibitor therapy, H. pylori test-and-treat followed by proton pump inhibitor therapy 
in case of persisting/relapsing symptoms, and proton pump inhibitor therapy 
followed by H. pylori test-and-treat in case of persisting/relapsing symptoms) in a 
computer model. They concluded that H. pylori test-and-treat was most costly and 
least effective compared with the other strategies. However, differences in cost and 
effectiveness were relatively small and there were several biases. First of all cost-
effectiveness was estimated after 1 year, which, as mentioned above, has a negative 
impact on strategies associated with incidental costs such as H. pylori test-and-treat. 
Furthermore, it is a very cheap intervention. In terms of cost-effectiveness, once in a 
lifetime a simple non-invasive test, short treatment, in comparison with all costs for 
a much longer period of time. Furthermore, all patients with persisting/relapsing 
symptoms proceeded to endoscopy, which is costly but not very effective. 
Moreover, this practice handicapped the test-and-treat strategy, because in case of 
symptomatic response during proton pump inhibitor therapy patients were continued 
on maintenance proton pump inhibitor therapy, while H. pylori positive patients 
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with persisting or relapsing symptoms after successful H. pylori eradication 
immediately had endoscopy. A true H. pylori test-and-treat strategy would resemble 
the combination of H. pylori test-and-treat followed by proton pump inhibitor 
therapy in case of persisting/relapsing symptoms after successful H. pylori 
eradication. Such a “hybrid” strategy appears to be very effective and cost-effective 
in Spiegel’s analyses. 
Indeed, Spiegel concluded that hybrid strategies, i.e. combinations of H. pylori test-
and-treat and proton pump inhibitor therapy may be most cost-effective. Spiegel 
suggests that with a high H. pylori prevalence, and a high likelihood of underlying 
peptic ulcer disease, starting with H. pylori test-and-treat followed by proton pump 
inhibitor therapy in case of persisting/relapsing symptoms (i.e. true H. pylori test-
and-treat) would be most cost-effective, while in case of a low prevalence of H. 
pylori and a high likelihood of underlying gastro-oesophageal reflux disease, proton 
pump inhibitor therapy alone would be more cost-effective than the sequential use of 
proton pump inhibitor therapy and H. pylori test-and-treat. However, we already 
mentioned that calculating such a cut-off H. pylori prevalence is highly debatable 
and subject to many assumptions and biases. Furthermore, there are many other 
factors besides short-term symptomatic response which may influence the choice of 
treatment strategy. 
 
Other factors influencing the choice of treatment strategy 
In this chapter it was established that H. pylori is a definite pathogen, one of the few 
objectively measurable factors in the aetiology of dyspepsia. It is associated with 
dyspeptic symptoms, peptic ulcer disease, gastric atrophy, and gastric cancer. 
Therefore, H. pylori eradication may have symptomatic benefit, cures H. pylori 
positive peptic ulcer disease, and prevents future ulcer disease, ulcer relapse and 
ulcer complications. Additionally, timely eradication prevents development of 
gastric atrophy and gastric cancer, and eradication prevents future NSAID-
gastropathy. Furthermore, concerns regarding the development of GERD after H. 
pylori eradication do nont seem evidence-based. 
In turn, proton pump inhibitor therapy is associated with a good symptomatic 
response in patients with GERD, peptic ulcer disease, and functional dyspepsia, 
although in the latter the placebo response rate is also high. However, although 
proton pump inhibitor therapy heals peptic ulcers, relapse rates are high after 
cessation of therapy. And in case of relapse patients may (in a worst case scenario) 
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return with ulcer complications such as bleeding or perforation. Therefore, H. pylori 
positive ulcers are not adequately treated with proton pump inhibitor therapy only. 
Furthermore, many patients will need maintenance proton pump inhibitor therapy 
(especially those with GERD), and maintenance proton pump inhibitor therapy 
induces unfavourable gastritis patterns in H. pylori positive patients. This can easily 
be prevented by timely H. pylori eradication. Finally, relapse rates and reassurance 
seem better in the H. pylori test-and-treat strategy and many studies show that 
endoscopy can safely be omitted in H. pylori negative patients. Therefore, starting 
with an H. pylori test followed by H. pylori eradication in those who test positive 
seems easiest, safest, and prevents future disease. Proton pump inhibitor therapy 
should be used for those testing negative and for initially H. pylori positive patients 
with persisting/relapsing symptoms after successful eradication. 
 
Which population can be treated with this treatment strategy? 
Selection based on symptoms 
First of all, type and severity of dyspeptic symptoms are not useful to guide 
treatment since they very poorly correlate with the type and severity of the 
underlying pathology. Furthermore, in many protocols patients with predominant 
reflux symptoms are excluded from H. pylori test-and-treat strategy and treated with 
acid suppression. However, reflux symptoms are an integral part of dyspepsia: even 
patients with only reflux symptoms can have peptic ulcer disease, and patients often 
report a complex of several symptoms. Furthermore, even although H. pylori 
positive patients with solely reflux symptoms will in general not have symptomatic 
benefit from H. pylori eradication, it reduces the risk of developing corpus gastritis 
with its associated sequelae, prevents future ulcer disease, and decreases the risk of 
NSAID associated gastropathy. Therefore, first eliminating H. pylori, is of benefit to 
patients with reflux symptoms too, while it delays acid suppressive therapy only for 
a very short period of time. In fact, acid suppression is an important component of 
H. pylori eradication regimens. 
 
Selection based on alarm symptoms 
The value of alarm symptoms seems to be very limited. Their sensitivity and 
specificity is disappointing, and by the time gastro-oesophageal cancer becomes 
symptomatic it usually has become incurable. In combination with the very low 
prevalence of gastro-oesophageal cancer in most Western countries, and certainly in 
The Netherlands, patients should not proceed with prompt endoscopy solely on the 
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basis of alarm symptoms. In young patients with alarm symptoms endoscopy can be 
omitted. And in elderly patients, other patient factors should be taken into account, 
and a thorough differential diagnosis should be established, including disease 
outside the upper gastrointestinal tract. Better, more specific selection tools for 
patients with gastro-oesophageal cancer should be developed. 
 
Specific age groups 
Even although the prevalence of gastro-oesophageal cancer increases with age, there 
need not be a strict age cut off, above which patients should have prompt endoscopy, 
since in most Western populations, and certainly in the Dutch population, even in 
elderly patients the prevalence of gastro-oesophageal cancer tends to be very low. 
Furthermore, in patients with symptomatic cancer some delay usually does not 
worsen prognosis… On the other hand it may be practical to establish an age, not 
particularly to encourage performing endoscopy in patients over that age, but more 
importantly to discourage endoscopy in patients under that age. 
 
H. pylori infection rate 
There are concerns that H. pylori test-and-treat is not viable any more in the light of 
the declining prevalence of H. pylori infection. Cost-effectiveness studies suggest 
cut-offs of 10 or 20% H. pylori prevalence while others report even higher figures. 
However, H. pylori is far from extinct, not even in the area around Oss, the 
Netherands. In many countries the prevalence still is very high, and in The 
Netherlands, H. pylori infection rates are on average 30%, with higher figures for 
elderly patients and patients of foreign ancestry. Furthermore, given the relatively 
low cost, and incidental character of both an H. pylori test and triple therapy for H. 
pylori eradication, combined with the secondary advantages of being H. pylori 
negative (low risk of peptic ulcer disease, lower risk of gastric cancer, abolishment 
of developing corpus gastritis during maintenance proton pump inhibitor therapy, 
and reduction of the risk of NSAID gastropathy) H. pylori test-and-treat will 
probably be viable until H. pylori becomes almost extinct, which is by far not the 
case nowadays. Only in young patients (e.g. below 30 years of age) of Dutch (or 
other Western European or United States) ancestry H. pylori has become nearly 
extinct, turning the H. pylori test-and-treat strategy into proton pump inhibitor 
therapy for this population. 
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Overall conclusion 
 
Dyspepsia is not a disease but a complex of symptoms thought to originate in the 
upper gastrointestinal tract. Traditionally, the underlying pathology is divided in 
peptic ulcer disease, gastro-oesophageal reflux disease, gastro-oesophageal 
malignancy, and functional dyspepsia. Each of these has its own treatment options: 
in case of H. pylori positive peptic ulcer disease H. pylori eradication, in case of 
GERD acid suppression, in case of functional dyspepsia both acid suppression and 
H. pylori eradication have some symptomatic effect, and in case of cancer other 
therapy is necessary according to the disease stage. 
Unfortunately, type and severity of symptoms can not be used to determine the 
underlying pathology. Even the widely used alarm symptoms proved not to be 
helpful, since they poorly discriminate between patients with and without gastro-
oesophageal cancer, or even between patients with or without pathology detected at 
upper gastrointestinal endoscopy. Therefore, alarm symptoms should not lead to 
prompt endoscopy, although they should prompt the physician to make a thorough 
differential diagnosis, including disease outside the upper gastrointestinal tract. 
In Western patients under the age of e.g. 55 years the risk of gastro-oesophageal 
cancer is extremely low, and endoscopy is rarely necessary. Even in elderly 
(Western European) patients the risk of having gastro-oesophageal cancer is very 
low, while patients with symptomatic cancer usually have late stage disease, 
implicating that treatment delay does not alter prognosis. Therefore, elderly patients 
should not automatically be endoscoped either. The endoscopic capacity should 
rather be used for more effective intervention and other strategies for detection of 
treatable gastro-oesophageal cancers should be devised. 
Dyspeptic symptoms are not useful for making treatment decisions, which is proven 
by the fact that individualized symptom-based treatment can not outperform a 
uniform strategy for all patients. Several treatment strategies have been developed, 
the most important are: prompt endoscopy followed by targeted treatment, H. pylori 
test-and-treat, and empirical acid suppression. These all provide similar short term 
symptom reduction rates, but endoscopy based strategies are more costly. Therefore, 
strategies without endoscopy should be preferred. 
Starting with an H. pylori test and H. pylori eradication if infected, or acid 
suppression if not infected or in case of symptom relapse after successful H. pylori 
eradication is the strategy of choice. This is associated with lower relapse rates in H. 
pylori positives than proton pump inhibitor therapy. Furthermore, such a strategy is 
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simple, safe, practically feasible, understandable to the patient, and may prevent 
future disease. Only in young patients (<30 years of age) of Western/Northern 
European or United States ancestry H. pylori has become almost extinct, implicating 
that in this patient group the H. pylori could be postponed until symptom relapse (or 
even omitted entirely). 
 
Excluding patients from a H. pylori test-an-treat strategy based on alarm symptoms 
or age does not seem rational or cost-effective in the Dutch population. 
Overall, H. pylori prevalence is still 25-35% in the Dutch dyspeptic population, and 
even higher in subgroups of elderly patients or patients of non-Dutch ancestry. 
Given the relatively low cost and incidental character of H. pylori testing and 
treatment in comparison to long term use of acid suppressive medication during 
long-term dyspepsia, H. pylori test-and-treat can be cost-effective even in light of 
the declining H. pylori prevalence. 
 
In conclusion, H. pylori test-and-treat should be used in all Dutch patients with 
dyspeptic symptoms (including heartburn). This simple and safe strategy adequately 
treats patients with peptic ulcer disease or functional dyspepsia, as well as patients 
with GERD after they are proven H. pylori negative. Furthermore, it prevents future 
ulcer disease and complications, prevents the development of unfavourable gastritis 
patterns during maintenance proton pump inhibitor therapy, decreases the risk of 
future ASA/NSAID gastropathy, and decreases the risk of developing gastric cancer, 
while it does not decrease the effectiveness of proton pump inhibitor therapy and 
does not induce gastro-oesophageal reflux disease. Overall, H. pylori prevalence is 
still 25-35% in the Dutch dyspeptic population, and even higher in subgroups of 
elderly patients or patients of non-Dutch ancestry. Given the relatively low cost and 
incidental character of H. pylori testing and treatment in comparison to long term 
use of acid suppressive medication over a prolonged period of time, H. pylori test-
and-treat can still be cost-effective even in light of the declining H. pylori 
prevalence. Only in patients of Dutch ancestry under the age of 30 years, H. pylori is 
virtually extinct, and an H. pylori test could be postponed or even omitted. In future 
this age cut-off will further increase due to the cohort effect in thye prevalence of H. 
pylori infection. Alarm symptoms rarely indicate gastro-oesophageal malignancy 
and should not by definition lead to endoscopic examination. An age criterion is not 
necessary per se, because even in elderly (Western European) patients the risk of 
having gastro-oesophageal cancer is very low. Definitely in young Western patients 
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under e.g. 55 years the risk of gastro-oesophageal cancer is extremely low, and 
endoscopy is rarely necessary. 
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Summary and conclusions 
 
In chapter 1 it is explained that dyspepsia is not a diagnosis, but merely a cluster of 
symptoms thought to arise in the upper gastrointestinal tract. Dyspeptic symptoms 
are common and are associated with considerable health care consumption. Usually 
upper gastrointestinal pathology is divided into: gastro-oesophageal reflux disease 
(some 10-40%), peptic ulcer disease (5-15%), gastro-oesophageal cancer (0-2%), 
and, by exclusion of these diagnoses, functional dyspepsia (50-70%) (average 
prevalences in Western countries). Unfortunately, symptoms poorly predict findings 
at upper gastrointestinal endoscopy. Acid suppression (with proton pump inhibitors 
or H2-receptor antagonists) and H. pylori eradication are the mainstays of treatment. 
Their effectiveness depends on the underlying pathophysiological mechanism. 
Although much research has been done in the field of dyspepsia and despite the 
formulation of several guidelines for treatment of patients with dyspeptic symptoms 
many important questions remain unanswered. 
 
Chapter 2 questions the (widespread) use of alarm symptoms such as 
melena/hemathemesis/anemia, disturbed food passage, weight loss, and vomiting, 
for selection of patients at risk for gastro-oesophageal malignancy. This is important 
because in treatment strategies without endoscopy one does not want to miss 
diagnosis in patients with gastro-oesophageal malignancy. However, because of the 
low prevalence of these malignancies it is difficult to investigate the value of alarm 
symptoms. Therefore we performed a meta-analysis using individual patient data. 
For the combined population of more than 13 thousand patients (of whom 1.2% had 
gastro-oesophageal cancer) it is shown that alarm symptoms are far from ideal for 
selection of patients with gastro-oesophageal cancer because more than a third of 
patients with gastro-oesophageal cancer had no alarm symptoms, while only few of 
the patients with alarm symptoms had gastro-oesophageal cancer. In fact, the 
presence of alarm symptoms only marginally increased the prevalence of organic 
disease in general. Therefore, other patient factors such as age, H. pylori status, and 
gender must be taken into account when estimating each individual’s risk. This 
study also shows that in two thirds of endoscopies in primary/secondary care 
patients no organic pathology was detected at all. Furthermore, it is shown that 
although there is no absolutely safe age cut-off, although gastro-oesophageal cancer 
is extremely rare in patients less than 55 years of age. Moreover, our data suggest 
that ASA/NSAIDs may protect against gastro-oesophageal cancer. 
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In chapter 3 the role of mucins in the aetiology of H. pylori infection is investigated. 
H. pylori resides in the mucus gel layer lining the gastric epithelium. The most 
important constituents of this layer are mucins, large glycosilated proteins, with 
gelforming capacities. It is shown that the size of these mucin molecules varies 
considerably due to a special type of polymorphism, knowingly VNTR (=Variable 
Number of Tandem Repeats) polymorphism in the genes encoding for these mucins. 
VNTRs consist of repeated DNA sequences and the number of these repeats is 
highly variable. We studied the association of mucin allele length (determined by 
the number of repeats) with H. pylori infection for mucins 6 (MUC6) and 5AC 
(MUC5AC) in a population of 160 Vietnamese patients. 
For mucin 6 a single tandem repeat is large: 507 bp. The MUC6 allele was found to 
be highly polymorphic with allele fragment lengths ranging from 7 to 19 kbp. Our 
data suggest that H. pylori infection is more frequent in patients with short MUC6 
alleles. 
For MUC5AC the number of repeats was also highly polymorphic (ranging from 
170 to 380 repeats) but due to the small size of a single repeat (24bp) allele fragment 
length range varied much less than for MUC6 (from 6.2 to 11.2 kbp with the 
majority of measurements between 7.0 and 9.0 kbp). No association of MUC5AC 
VNTR polymorphism and H. pylori infection was found. 
 
In chapter 4 the prevalence of antibiotic resistant H. pylori strains is studied. H. 
pylori can be or become resistant against especially clarithromycin and nitro-
imidazoles and most patients are treated without prior culture and susceptibility 
testing. Therefore, it is very important to have recent data on local resistance 
patterns in order to guide the choice of antibiotics for H. pylori eradication. It is 
shown that primary metronidazole resistance is stable at a low level (14%), while 
primary clarithromycin resistance is virtually absent in a population of over a 
thousand H. pylori positive cultures in Doetinchem. Similar results were found for 
overall resistance in almost a thousand H. pylori positive cultures from ‘s-
Hertogenbosch. After failed H. pylori eradication the prevalence of antibiotic 
resistance is considerably higher. 
 
In chapter 5 two widely used therapies for treatment of H. pylori infection are 
compared, knowingly triple therapy with clarithromycin and either amoxicillin, or a 
nitro-imidazole. Triple therapies using ranitidine bismuth citrate (RBC) or a proton 
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pump inhibitor are considered separately. In a meta-analysis of eight RBC- based 
comparative studies combination with a nitro-imidazole seemed somewhat more 
effective. In a meta-analysis of 40 proton pump inhibitor based studies both 
combinations of antibiotics were equally effective, although in case of 
clarithromycin resistance, the combination with a nitro-imidazole was more 
effective, while in case of nitro-imidazole resistance it was the other way round. 
 
In chapter 6 the influence of pre-treatment with a proton pump inhibitor on H. pylori 
eradication is investigated. In the past there have been reports about both positive 
and negative effects of pre-treatment. Pre-treatment is quite common, either 
deliberately in an attempt to increase cure rates of H. pylori eradication, or 
accidentally, because patients already use a proton pump inhibitor because of 
symptoms or proven peptic ulcer disease. Chapter 6A describes a pilot study 
showing that 3-day proton pump inhibitor pre-treatment certainly does not increase 
(and in fact may even decrease cure rates) of a very short (2-day) quadruple therapy 
regimen. Overall, this very short treatment reached a 75% cure rate. Chapter 6B 
describes a meta-analysis including almost eight hundred patients showing that pre-
treatment does not seem to influence H. pylori eradication rates at all. 
 
In chapter 7 an open-access UBT facility and associated H. pylori test-and-treat 
protocol in and around the city of Oss, The Netherlands, are evaluated. The figures 
show that the open-access UBT facility was frequently used and highly appreciated 
by GPs. Of over eight hundred patients with a primary screening test about one third 
were infected with H. pylori. H. pylori prevalence was highest in elderly patients in 
patients of Turkish/Moroccan ancestry. In patients of Dutch ancestry under the age 
of thirty H. pylori infection was virtually absent. The H. pylori eradication rate in 
routine clinical practice was almost 90%. Although after the introduction of the 
open-access UBT facility the proportion of young patients referred for endoscopy 
decreased, still many patients under the age of 55 were endoscoped, which suggests 
that the proposed guideline was not yet properly implemented. This is confirmed by 
the GP questionnaires showing that many GPs did not adhere with the proposed 
protocol. 
 
In chapter 8 results from two large studies investigating the effectiveness of proton 
pump inhibitor therapy with esomeprazole are reported. The first study investigated 
almost three thousand patients with upper gastrointestinal symptoms selected by 
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their GPs for esomeprazole treatment and showed that 46% of patients were 
completely symptom free during the last week of esomeprazole treatment. A second 
study investigating a similar group of almost three thousand patients, investigated 
the influence of ASA/NSAID co-medication, both notorious for their upper 
gastrointestinal side-effects, on the effectiveness of esomeprazole for treatment of 
upper GI symptoms. This study showed that almost a quarter of patients used 
ASA/NSAIDs, but that this did not decrease the effectiveness of esomeprazole 
therapy. Furthermore, in this second study 40% of patients were symptom-free 
during the last week of treatment, similar to the result of the previous study. 
Both studies show that nearly all included patients reported a complex of several 
upper gastrointestinal symptoms, and that the majority of patients could not be 
included in a specific symptom sub group. Furthermore, symptom sub grouping was 
of little value for prediction of the response to treatment. Other factors such as 
duration of esomeprazole treatment, severity of symptoms and number of symptoms, 
and baseline use of dyspepsia-related medication (especially prokinetics) were more 
important predictors of treatment success. 
 
In chapter 9 testing for H. pylori infection (and eradication of the organism if 
present) and proton pump inhibitor therapy are combined into two multi-step 
treatment strategies without endoscopy, one starting with treatment based on the 
result of the H. pylori test (if positive H. pylori eradication, if negative proton pump 
inhibitor therapy), followed by proton pump inhibitor therapy for patients with 
persisting/relapsing symptoms, the other starting with proton pump inhibitor therapy 
irrespective of H. pylori status, followed by H. pylori eradication (if infected) in case 
of persisting/relapsing symptoms. In a population of 182 primary care patients with 
an almost 54% H. pylori infection rate (due to the inclusion of a large sub group of 
patients of Turkish/Moroccan ancestry with a high prevalence of H. pylori infection) 
we found no differences in proportions of “symptom-free”/”sufficiently treated” 
patients, both after the first treatment step and at the end of the 6 month follow-up 
period. In both strategies some 50% of patients were symptom-free and some 60% 
felt sufficiently treated after the first treatment step. However, in the (high H. pylori 
prevalence) sub group of patients of Turkish/Moroccan ancestry cure rates were 
higher in the test-first group. Furthermore, the relapse rate was much lower in the 
“test first” strategy, and this difference was seen only in (initially) H. pylori positive 
patients. The patients with persisting/relapsing symptoms proceeded with the second 
treatment step and at the end of the 6 month follow-up period, again there were no 
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differences between the strategies: some 50% of patients were symptom-free, and 
some 80% felt sufficiently treated, while only a few patients had had endoscopy 
during the study period. The H. pylori eradication rate of 7-day therapy with 
esomeprazole, clarithromycin, and amoxicillin was 98%. 
 
Finally, chapter 10 provides a personal view on the management of patients with 
dyspeptic symptoms, based on data from the literature as well as on data from this 
thesis. The various treatment strategies, results from comparative studies, pitfalls in 
interpreting study results and various factors not captured in study protocols that are 
important when deciding which strategy to use are discussed. When taking all these 
data into account I conclude that H. pylori test-and-treat should be used in all Dutch 
patients with dyspeptic symptoms (including heartburn). This simple and safe 
strategy adequately treats patients with peptic ulcer disease and functional 
dyspepsia, as well as patients with GERD after has been documented that they are 
H. pylori negative. Furthermore, it decreases the risk of developing future ulcer 
disease and complications, prevents the development of unfavourable gastritis 
patterns during maintenance proton pump inhibitor therapy, decreases the risk of 
future ASA/NSAID, and decreases the risk of developing gastric cancer, while it 
does not decrease the effectiveness of proton pump inhibitor therapy and does not 
induce gastro-oesophageal reflux disease. Overall, H. pylori prevalence is still 25-
35% in the Dutch dyspeptic population, and even higher in subgroups of elderly 
patients or patients of non-Dutch ancestry. Given the relatively low cost and 
incidental character of H. pylori testing and treatment in comparison to long term 
use of acid suppressive medication during the long-term dyspepsia, H. pylori test-
and-treat can be cost-effective even in light of the declining H. pylori prevalence. 
Only in patients of Dutch ancestry under the age of 30 years, H. pylori is virtually 
extinct, and an H. pylori test could be postponed or even omitted. Alarm symptoms 
rarely indicate gastro-oesophageal malignancy and should not by definition lead to 
endoscopic examination. An age criterion is not necessary per se, because even in 
elderly (Western European) patients the risk of having gastro-oesophageal cancer is 
very low. 
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Samenvatting en conclusies 
 
In hoofdstuk 1 wordt besproken dat dyspepsie geen duidelijke diagnose is, maar 
slechts een complex van symptomen dat afkomstig lijkt te zijn uit de slokdarm, 
maag, of twaalfvingerige darm. Dyspeptische klachten komen veel voor en leggen 
een behoorlijk beslag op de gezondheidszorg. Meestal worden de aandoeningen van 
slokdarm, maag en twaalfvingerige darm onderverdeeld in een aantal categorieën, te 
weten: gastro-oesofageale refluxziekte (bij ongeveer 10-40% van de mensen met 
dyspeptische klachten), ulcuslijden, d.w.z. een of meer zweren in maag of 
twaalfvingerige darm (5-15%), maag- of slokdarmkanker (0-2%), en zogenaamde 
functionele “dyspepsie” (dyspeptische klachten zonder een van de hiervoor 
genoemde oorzaken bij aanvullend onderzoek (50-70%) (de genoemde getallen 
betreffen gemiddelde prevalenties in Europa en de Verenigde Staten). Helaas kan op 
basis van de symptomen nauwelijks worden voorspeld wat er bij gastroscopie zal 
worden gevonden. Zuurremming (met proton pomp remmers of H2-receptor 
antagonisten) en H. pylori eradicatie vormen de belangrijkste behandelopties. De 
effectiviteit van deze behandelingen hangt af van het onderliggend 
pathofysiologisch mechanisme. Hoewel er veel onderzoek is gedaan op het gebied 
van dyspepsie, en hoewel er verschillende richtlijnen zijn opgesteld voor de 
behandeling van patiënten met dyspeptische klachten zijn nog veel belangrijke 
vragen niet beantwoord. In dit proefschrift worden een aantal van deze vragen nader 
bestudeerd. 
 
In hoofdstuk 2 wordt het wijd verbreide gebruik van alarmsymptomen voor selectie 
van patiënten met een hoog risico op maag- of slokdarmkanker (te weten 
melaena/bloedbraken/anemie, verstoorde passage van voedsel, gewichtsverlies, en 
braken) in twijfel getrokken. Dit is een belangrijk thema omdat men in 
behandelstrategieën zonder gastroscopie de diagnose maag- of slokdarmkanker niet 
wil missen. Door de lage prevalentie van deze maligniteiten is het echter moeilijk 
om de waarde van alarmsymptomen te onderzoeken. Om dit probleem te omzeilen 
hebben we een meta-analyse verricht op basis van individuele patiënt gegevens. 
Voor de gecombineerde populatie van meer dan 13 duizend patiënten (waarvan 
1,2% maag- of slokdarmkanker had) laten we zien dat alarmsymptomen verre van 
ideaal zijn voor de selectie van patiënten met een hoog risico op maag- of 
slokdarmkanker, omdat meer dan een derde van de patiënten met deze maligniteiten 
geen alarmsymptomen had, terwijl slechts een gering deel van de patiënten met 
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alarmsymptomen maag- of slokdarmkanker had. Het hebben van alarmsymptomen 
verhoogde zelfs nauwelijks de kans om überhaupt afwijkingen te vinden bij 
gastroscopie. Daarom moeten andere factoren zoals leeftijd, H. pylori infectie en 
geslacht in overweging worden genomen bij het inschatten van het risico van de 
individuele patiënt. Onze gegevens laten ook zien dat bij tweederde van de 
gastroscopieën in de eerste en tweede lijn geen afwijkingen worden gevonden. 
Verder blijkt er geen volledig veilige leeftijdsgrens te zijn (waaronder maag- of 
slokdarmkanker helemaal niet voorkomt), hoewel maag/slokdarmkanker zeldzaam is 
in patiënten onder de 55 jaar. Daarnaast laten onze gegevens zien dat het gebruik 
van ASA en/of NSAIDs de kans op kanker aan maag of slokdarm mogelijk verlaagt. 
 
In hoofdstuk 3 wordt de rol van mucines in de etiologie van H. pylori infectie 
onderzocht. H. pylori voelt zich thuis in de slijmlaag die de binnenkant van de maag 
bedekt. De belangrijkste bestanddelen van deze slijmlaag zijn de zogenaamde 
mucines: grote geglycosileerde eiwitten, met gelvormende eigenschappen. De 
grootte van deze mucine moleculen kan behoorlijk variëren ten gevolge van een 
bijzonder polymorfisme, het VNTR (=Variable Number of Tandem Repeats) 
polymorfisme, in de coderende genen. VNTRs bestaan uit herhaalde DNA-
sequenties, waarbij het aantal herhalingen erg variabel is. Wij onderzochten het 
verband tussen de lengte van het mucine allel (bepaald door het aantal herhalingen) 
en H. pylori infectie voor mucines 6 (MUC6) en 5AC (MUC5AC) in een groep van 
160 Vietnamese patiënten. 
Bij MUC6 is de herhaalde sequentie lang: 507 baseparen (bp). De allellengte van 
MUC6 bleek fors te variëren: van 7 tot 19 kbp. Onze gegevens suggereren dat H. 
pylori infectie vaker voorkomt bij patiënten met korte MUC6 allelen. 
Bij MUC5AC varieert het aantal herhalingen ook sterk (van 170 tot 380) maar door 
de geringe lengte van de herhaalde sequentie (24 bp) is de invloed op de allellengte 
veel beperkter dan bij MUC6 (6.2 tot 11.2 kbp met de meerderheid van de lengtes 
tussen 7.0 en 9.0 kbp). Er werd geen verband gevonden tussen de lengte van het 
MUC5AC allel en H. pylori infectie. 
 
In hoofdstuk 4 worden gegevens over de prevalentie van antibioticum-resistente 
stammen gepresenteerd. H. pylori kan resistent zijn/worden tegen o.a. metronidazol 
en clarithromycine. De meeste patiënten worden behandeld zonder voorafgaande 
kweek met gevoeligheidsbepaling. Daarom is het belangrijk om actuele gegevens te 
hebben over lokale resistentiepatronen zodat gekozen kan worden voor de meeste 
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geschikte combinatie van antibiotica. Onze gegevens laten zien dat de prevalentie 
van primaire metronidazol resistentie laag is (14%), en dat primaire clarithromycine 
resistentie zelfs vrijwel niet voorkomt in een populatie van meer dan duizend 
patiënten in Doetinchem. In de regio ’s-Hertogenbosch vonden we vergelijkbare 
resultaten voor primaire en secundaire resistentie samen, ook in een populatie van 
bijna duizend patiënten. Na falen van H. pylori eradicatie is de prevalentie van 
antibioticum-resistentie aanzienlijk hoger. 
 
In hoofdstuk 5 worden twee veel gebruikte therapieën voor H. pylori eradicatie 
vergeleken, te weten tripel therapie met als antibiotica ofwel de combinatie 
clarithromycine en metronidazol, ofwel clarithromycine en amoxicilline. Hierbij 
wordt onderscheid gemaakt tussen proton pomp remmer tripel therapie en 
ranitidinebismutcitraat (RBC) triple therapie. In een meta-analyse van 8 RBC 
gebaseerde vergelijkende studies leek de combinatie met metronidazol net iets 
effectiever. Bij meta-analyse van 40 proton pomp remmer gebaseerde studies bleken 
beide combinaties van antibiotica even effectief, echter voor metronidazol gevoelige 
stammen was de combinatie met metronidazol effectiever en voor metronidazol 
resistente stammen was de combinatie met amoxicilline effectiever. 
 
In hoofdstuk 6 wordt de invloed van voorbehandeling met een proton pomp remmer 
op de effectiviteit van H. pylori eradicatie beschreven. Van voorbehandeling werden 
zowel positieve als negatieve effecten gerapporteerd. In praktijk komt 
voorbehandeling vaak voor, hetzij expres in een poging de effectiviteit van H. pylori 
eradicatie therapie te verhogen, hetzij onbedoeld als patiënten al een proton pomp 
remmer gebruiken vanwege dyspeptische klachten of bewezen ulcuslijden. In 
hoofdstuk 6A worden de resultaten beschreven van een pilot studie die laat zien dat 
3 dagen voorbehandeling met een proton pomp remmer het succespercentage van 
een ultrakorte (2-daagse) intensieve quadrupel-therapie zeker niet verhoogt, en 
mogelijk zelfs verlaagt. Gemiddeld werd met deze korte intensieve therapie 75% 
van de patiënten genezen van zijn/haar H. pylori infectie. In hoofdstuk 6B laat een 
meta-analyse met bijna acht honderd patiënten zien dat voorbehandeling met een 
proton pomp remmer waarschijnlijk geen enkel effect heeft op het slagen van H. 
pylori eradicatie. 
 
In hoofdstuk 7 wordt een vrij toegankelijke ureum ademtest faciliteit in Oss met een 
bijbehorend H. pylori test-en-treat protocol geëvalueerd. De ureum ademtest 
 239 
faciliteit werd veel gebruikt en werd erg gewaardeerd door de huisartsen in de regio. 
Van de ruim acht honderd patiënten die werden verwezen voor een screening op H. 
pylori bleek ongeveer een derde besmet te zijn. De prevalentie van H. pylori infectie 
was het hoogst in oudere patiënten en in patiënten van Turkse/Marokkaanse 
afkomst. Bij autochtone Nederlanders onder de dertig werd vrijwel nooit een H. 
pylori infectie gevonden. In de alledaagse praktijk bleek bijna 90% van de patiënten 
die een H. pylori eradicatie ondergingen daarna ook daadwerkelijk genezen van de 
infectie. Hoewel na de invoering van de ureum ademtest faciliteit de proportie jonge 
patiënten die een gastroscopie onderging afnam, ging het in absolute zin nog steeds 
om een grote groep, hetgeen suggereert dat het voorgestelde test-and-treat protocol 
slechts gedeeltelijk werd nageleefd. Dit wordt ondersteund door de resultaten van 
enquête onder de huisartsen die laat zien dat velen van hen zich niet aan het protocol 
hielden. 
 
In hoofdstuk 8 worden twee grote studies betreffende de effectiviteit van de proton 
pomp remmer esomeprazol beschreven. De eerste studie beschrijft de effectiviteit 
van esomeprazol bij de behandeling van bijna drieduizend patiënten met 
dyspeptische klachten die door de huisarts waren geselecteerd voor behandeling met 
een proton pomp remmer. Zesenveertig procent van deze patiënten was volledig 
klachtenvrij gedurende de laatste week van de behandeling. In een tweede studie met 
een vergelijkbare populatie werd de invloed van gelijktijdig gebruik van ASA en/of 
NSAIDs, medicijnen die beide dyspeptische klachten kunnen veroorzaken, op de 
effectiviteit van behandeling met esomeprazol voor dyspeptische klachten 
beschreven. Bijna een kwart van de geïncludeerde patiënten gebruikte ASA en/of 
NSAIDs. Dit leidde echter niet tot een verlaging van de effectiviteit van 
esomeprazol. In deze studie was 40% van de patiënten klachtenvrij gedurende de 
laatste week van de behandeling, vergelijkbaar met het resultaat van de vorige 
studie. 
Beide studies laten zien dat vrijwel alle geïncludeerde patiënten een complex van 
meerdere dyspeptische klachten presenteerden, en dat de meerderheid van de 
patiënten niet in een specifieke symptoom-subgroep kon worden ingedeeld. 
Bovendien had het indelen in symptoom-subgroepen weinig zin wat betreft het 
voorspellen van de respons op therapie. Andere factoren zoals de duur van de 
therapie, de ernst van de symptomen, het aantal symptomen, en het gebruik van 
dyspepsiegerelateerde medicatie ten tijde van de inclusie (m.n. prokinetica) bleken 
betere voorspellers te zijn voor behandelsucces. 
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In hoofdstuk 9 worden H. pylori test (en behandeling) en proton pomp remmer 
therapie gecombineerd in twee meerstapsbehandelstrategieën zonder gastroscopie; 
de ene beginnend met behandeling op basis van de uitslag van de H. pylori test (als 
positief: H. pylori eradicatie, als negatief: proton pomp remmer therapie), gevolgd 
door proton pomp remmer therapie bij aanhouden/terugkeren van de klachten, de 
andere beginnend met proton pomp remmer therapie ongeacht de uitslag van de H. 
pylori test, gevolgd door behandeling afhankelijk van de H. pylori test bij aanhouden 
of terugkeren van de klachten. In een populatie van 182 eerstelijnspatiënten waarvan 
meer dan de helft geïnfecteerd was met H. pylori (ten gevolge van de inclusie van 
een grote groep patiënten van Turkse/Marokkaanse origine met een hoge H. pylori 
prevalentie) vonden we geen verschillen tussen beide strategieën wat betreft de 
proportie patiënten “zonder klachten” / ”met afdoende behandelde klachten” zowel 
na 1 als na 6 maanden. Na 1 maand was in beide strategieën ongeveer de helft van 
de patiënten klachtenvrij, terwijl ongeveer 60% de klachten voldoende behandeld 
vond. Echter in de subgroep van patiënten van Turkse/Marokkaanse afkomst waren 
de uitkomsten beter in de groep patiënten die behandeld werd op basis van de H. 
pylori test. Verder kwamen de klachten minder vaak terug bij patiënten die eerst 
werden behandeld op basis van de test, en dit verschil werd alleen gezien bij de 
(initieel) met H. pylori geïnfecteerde patiënten. De patiënten met 
persisterende/recidiverende klachten gingen verder met de tweede behandelstap, en 
aan het einde van de 6 maanden durende follow-up waren de uitkomsten wederom 
gelijk voor beide strategieën: ongeveer de helft van de patiënten was klachtenvrij, en 
ongeveer 80% van de patiënten vond de klachten afdoende behandeld, terwijl slechts 
enkele patiënten een gastroscopie hadden ondergaan tijdens de studie. Ver was na 
behandeling van H. pylori infectie met 7 dagen esomeprazol, clarithromycine en 
amoxicilline was bij 98% van de patiënten de infectie verdwenen. 
 
Tenslotte wordt in hoofdstuk 10 een persoonlijke visie op de behandeling van 
patiënten met dyspeptische klachten gegeven, gebaseerd op gegevens uit de 
literatuur en op gegevens uit dit proefschrift. De verschillende behandelstrategieën, 
resultaten van vergelijkende studies alsmede problemen bij de interpretatie van 
studieresultaten worden beschreven. Daarnaast worden verschillende aspecten van 
de behandeling van dyspeptische klachten die niet goed tot hun recht komen in 
studieprotocollen maar die wel belangrijk zijn bij het kiezen van een 
behandelstrategie besproken. Al deze gegevens overwegend kom ik tot de conclusie 
dat H. pylori test-en-treat zou moeten worden gebruikt voor patiënten met 
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dyspeptische klachten (inclusief zuurbranden). In deze eenvoudige en veilige 
strategie worden patienten met ulcuslijden en functionele dyspepsie adequaat 
behandeld, evenals patiënten met gastro-oesophageal refluxziekte (zodra bewezen is 
dat zij H. pylori negatief zijn). Bovendien wordt zo de kans op toekomstig 
ulcuslijden en ulcusgerelateerde complicaties verlaagd, wordt de kans op het 
ontwikkelen van maagkanker verlaagd, terwijl de effectiviteit van zuurremmende 
therapie niet nadelig wordt beinvloed en gastro-oesofageale refluxziekte niet wordt 
geïnduceerd. De algemene prevalentie van H. pylori infectie is nog steeds zo’n 25-
35% in de populatie van Nederlandse patiënten met dyspeptische klachten, en nog 
hoger in oudere patiënten en niet-Westerse allochtonen. Alleen in autochtone 
patiënten onder de dertig, komt H. pylori vrijwel niet meer voor, zodat in deze 
populatie een H. pylori test kan worden uitgesteld of achterwege gelaten. 
Alarmsymptomen wijzen zelden op maag- of slokdarmkanker en hoeven niet per 
definitie te leiden tot endoscopisch onderzoek. Een leeftijdscriterium is niet erg 
praktisch gezien de lage prevalentie van maag- en slokdarmkanker, zelfs in oudere 
patiënten. 
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Dankwoord 
 
Nu dit proefschrift klaar is, is het goed nog eens terug te kijken op de afgelopen 
jaren en iedereen die heeft bijgedragen aan dit proefschrift expliciet te bedanken. 
 
Allereerst wil ik jou, Wink (de Boer), bedanken want zonder jou zou ik nooit aan dit 
proefschrift zijn begonnen. We leerden elkaar kennen tijdens mijn 
wetenschappelijke stage bij jou in Oss. Jouw enthousiasme voor alles wat met 
Helcobacter pylori te maken heeft werkte aanstekelijk, evenals je herhaalde advies 
om ons onderzoek uit te bouwen tot een proefschrift. Ik wil je bedanken voor de 
prettige samenwerking, de snelheid en nauwgezetheid waarmee je ondanks je drukke 
werkzaamheden in Oss altijd mijn manuscripten doorlas (zelfs tijdens je vakanties in 
het buitenland), voor alle Kerst- en vakantiekaartjes die je me stuurde, en de 
onderzoeksavondjes bij jou thuis. 
 
Wink had mij de richting gewezen, maar het zou niets zijn geworden zonder Robert 
(Laheij) en Jan (Jansen). Jullie zorgden voor salaris, een werkplek (eerst samen op 
de prekliniek bij MTA, en al snel in de kelder onder de poli Oogheelkunde) en een 
wetenschappelijk, maar vooral ook gezellig werkklimaat. Jan, ik heb genoten van de 
laagdrempelige manier waarop je aanspreekbaar bent en van de gezellige uitjes naar 
Orlando, Praag, Kopenhagen, en Berlijn. 
Robert, jij was mijn grote leermeester in de wetenschap, mijn werkgever, maar meer 
nog dan dat was (en ben) je mijn vriend. Ik heb genoten van je wetenschappelijke 
enthousiasme en creativiteit, van de goede werksfeer, van de barbecues bij jou thuis 
in Liempde (al laat ik volgende keer de rosé staan). Ik heb veel geleerd door de 
zelfstandige rol die je me gaf, niet alleen wat betreft de invulling van mijn werk, 
maar ook in het contact leggen met subsidieverstrekkers en sponsors. Daarnaast 
vond ik het erg plezierig hoe je al je medewerkers betrok bij je privé leven en je 
gezin. Ik vond het jammer dat je nadat je aan je co-schappen begon weinig tijd meer 
had voor actieve kennisoverdracht en het lezen van mijn manuscripten, maar ik 
besef dat je het toen erg druk had. Jammer dat je stopt met Medical Science; ik ben 
benieuwd wat je nu gaat doen. 
 
Wat betreft de financiering heeft ook Andrea Sellink van AstraZeneca BV een 
belangrijke rol gespeeld, door middel van het sponsoren van de studies “ORDER”, 
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“NEXT”, en “eXtreme”. Andrea, bedankt voor de goede samenwerking, en voor alle 
cursussen die je voor me geregeld hebt! 
 
Natuurlijk wil ik ook al mijn collega’s van Medical Science (Leo, Martijn, Corine, 
Suhreta, Lieke en Saskia) bedanken, voor de goede sfeer, voor de vriendschap, voor 
alle hulp en vooral ook voor de gezelligheid. Soms was het zo gezellig, en 
discussieerden we zo veel dat er pas echt goed gewerkt kon worden vóór 9u en ná 
18u. Ik waardeer heel erg dat we alles met elkaar konden bespreken en dat iedereen 
elkaar altijd hielp. 
Martijn wil ik nog even speciaal bedanken. Onze promotietrajecten verliepen zo 
ongeveer parallel, en ik heb veel geleerd van onze onderlinge dicussies over 
wetenschap en statistiek. Ik geloof ook dat we elkaar stimuleerden om steeds beter te 
schrijven, te presenteren en om van alles te ondernemen. Daarnaast konden we ook 
onze frustraties bij elkaar kwijt en werden we al snel ook goede vrienden. Ik kan me 
dan ook geen betere paranymf voorstellen en ben blij dat je me bijstaat. Ik ben 
benieuwd wat je allemaal gaat doen in de toekomst en ik hoop dat van dichtbij mee 
te maken. 
 
Daarnaast wil ik iedereen bedanken die met een wetenschappelijke stage heeft 
bijgedragen aan dit proefschrift. In chronologische volgorde: Jorn Bovenschen, 
Suzanne Ligthart, Paulien Gritters, Linde Hendrikse, Sanne Steffens, Suzanne 
Monden. Bedankt voor jullie bijdragen en voor de gezellige samenwerking. 
 
Verder wil ik alle medewerkers van de afdeling Maag-, Darm-, Leverziekten 
bedanken. In het bijzonder wil ik noemen Wim Hopman en Karin van Hoven-van 
Loo die mij werkruimte en een helpende hand boden bij het behandelen van de 
patienten die deelnamen aan de diverse onderzoeken. Daarnaast natuurlijk ook René 
te Morsche die met elke DNA-analyse raad weet en die ervoor zorgde dat het 
VNTR-polymorfisme in de mucines 5AC en 6 kon worden gemeten. 
 
Ook de huisartsen van Gezondheidscentrum Lindenholt in Nijmegen hebben in 
belangrijke mate bijgedragen aan een van de studies uit dit proefschrift door mij 
toestemming te geven om in hun praktijk mensen met maagklachten in kaart te 
brengen en te behandelen. Bedankt voor jullie gastvrijheid! 
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Of course, I would also like to thank you, Thai, for teaching me about health care in 
Viet Nam, and showing me a glimpse of another culture. I will never forget the 
weeks we spent in the laboratory, extracting DNA from the samples you brought 
with you on the plane. And I will always remember the Vietnamese saying: “Lady is 
like tiger: beautiful but dangerous…” (Was that really a Vietnamese saying or did 
you make that up yourself?) I wish you all the best in Viet Nam with the 
improvement of both the research climate and the patient care at the University of 
Can Tho, as well as with the defense of your own thesis this fall. 
 
Natuurlijk wil ik ook mijn ex-collega’s van de afdeling Interne Geneeskunde van het 
Slingeland Ziekenhuis bedanken. Ik heb met veel plezier in het Slingeland gewerkt, 
veel geleerd, en erg genoten van onze “Slingeland Science” bijeenkomsten waarin 
we hebben laten zien dat je samen veel kan en dat ook in de periferie leuk onderzoek 
kan worden gedaan. Onze samenwerking is nog lang niet voorbij, en ik hoop dat we 
elkaar nog vaak zullen zien, op en buiten het werk. 
 
Verder wil ik Frans Corstens en Wim Oyen bedanken voor de kans die zij mij boden 
om te starten met de opleiding Nucleaire Geneeskunde. De eerste maanden bij jullie 
op de afdeling zijn mij uitstekend bevallen, en hebben mij laten zien dat 
patiëntenzorg, wetenschappelijk onderzoek en een prettige werksfeer uitstekend 
samen kunnen gaan. Ik hoop dat de toekomst nog veel moois zal brengen. 
 
En dan is er natuurlijk nog een persoon die ik niet genoemd heb maar die ik heel 
speciaal wil bedanken: Gerdine. Wij hebben elkaar leren kennen op het werk, tijdens 
het begin van onze promotietrajecten. We hebben elkaar veel geholpen, niet alleen 
wetenschappelijk (zie onze gezamenlijke publicaties), maar veel meer nog met de 
problemen die het leven zo af en toe op ons pad brengt. Jij hebt van mij een beter 
mens gemaakt. Al snel waren we niet alleen collega’s maar ook minnaars en 
geliefden. Van begin af en aan is onze relatie onstuimig en onvoorspelbaar geweest, 
en zelfs nu terwijl ik dit schrijf weet ik niet precies hoe onze relatie zal zijn op 28 
juni, maar wat ik wel weet is dat je een heel bijzondere vrouw bent en dat ik van je 
hou. 
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Curriculum vitae 
 
Marcel Janssen werd geboren op 17 april 1974 in 
Weert, Midden-Limburg, als (op afstand) de 
jongste in een gezin met twee oudere zussen: 
Marianne en Toos. Hij werd geboren in het St. Jans 
Gasthuis omdat de huisarts dacht dat het wel eens 
om een tweeling kon gaan. Dit bleek echter niet het 
geval en de geleende extra wieg kon weer worden 
teruggebracht. 
Hij leidde een onbezorgde jeugd en genoot van 
kikkers vangen, zandkastelen bouwen, knutselen, 
vergeten kasteelruïnes ontdekken en met het hele 
gezin op reis gaan in een overbevolkte 
Volkswagen. 
Deze onbezorgdheid verdween op 11 november 1983 toen zijn moeder op 49-jarige 
leeftijd geheel onverwacht overleed, zonder duidelijke oorzaak. Daarna werd het 
leven serieuzer en bleek onbezorgdheid een steeds moeilijker te bereiken ideaal. 
De vele logeerpartijen bij zijn zussen Marianne (in Weert), en Toos (in Nijmegen) 
vormden daarop positieve uitzonderingen. Zo leerde hij al op jonge leeftijd 
Nijmegen met zijn herenhuizen, bioscopen en eetcafés goed kennen en dit verklaart 
misschien zijn latere keuze voor Nijmegen om te studeren, werken en (liefst ook) 
wonen. 
Tijdens zijn VWO-tijd op de Philips van Horne scholengemeenschap werd het halen 
van de hoogste cijfers een doel op zich, echter geen oplossing. Het streven naar 
zekerheid en veiligheid maakte het steeds moeilijker om gevoelsmatige keuzes te 
maken, om lekker te leven. 
Daarna ging Marcel Chemische Technologie studeren aan de Technische 
Universiteit Eindhoven. Hoewel de chemie interessant was, maakte het streven naar 
veiligheid, zekerheid en controle het studeren lastig. Het kostte veel energie om dat 
te veranderen, maar uiteindelijk lukte dat uitstekend, waarna het leven weer 
ontspannen werd. 
Bij een ander leven hoorde ook een andere studie. In 1996 koos Marcel voor 
Geneeskunde, vanwege de combinatie van techniek en wetenschap met sociale, 
psychologische, emotionele en zorgzame aspecten. Waarschijnlijk speelde hierbij 
het voorbeeld van Marcels vader, die als directeur van de Weerter verzorgingshuizen 
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instellingsmanagement wist te combineren met veel persoonlijke aandacht voor de 
mensen die aan zijn zorgen waren toevertrouwd, een belangrijke rol. 
De studie Geneeskunde verliep voorspoedig en bij het begin van de co-schappen 
ontmoette Marcel bij toeval Wink de Boer. Winks enorme enthousiasme voor 
dyspepsie en m.n. voor alles wat met Helicobacter pylori te maken heeft werkte 
aanstekelijk en leidde tot een leuke wetenschappelijke stage afgerond met een 
artikel. Dat dit artikel ook nog eens zonder commentaar werd geaccepteerd 
stimuleerde Marcel om verder te gaan met onderzoek. 
Tegen het einde van de co-schappen werd het tijd om een carrière te kiezen. Tijdens 
de co-schappen was Marcel het meest enthousiast over gynaecologie, en in 
aansluiting op een keuzeco-schap gynaecologie in het Rijnstate Ziekenhuis bleef 
Marcel daar werken op de kraamafdeling. Daar was het prettig werken, in een goede 
sfeer, met een team dat gezamenlijk verantwoordelijkheid nam voor de patiënten. 
Dat leek een goed begin voor een toekomst in de gynaecologie. Helaas ging op dat 
moment ook Marcels relatie uit zodat hij even behoefte had aan een wat rustigere 
baan. Tegelijkertijd hadden Robert Laheij en Jan Janssen budget voor een extra 
onderzoeker, en toen was de keuze snel gemaakt. 
De onderzoekstijd bij “Medical Science” was erg leerzaam en gezellig. In de kelder 
van het Radboud heerste een goed onderzoeksklimaat, er werd hard gewerkt in een 
goede sfeer en iedereen hielp elkaar met het opzetten en uitwerken van de diverse 
projecten. Daarnaast bleek het ook nog een goede voedingsbodem voor nieuwe 
liefde... 
Toen de laatste hoofdstukken van dit proefschrift in zicht kwamen kwam er opnieuw 
een belangrijk keuzemoment. Marcel wilde graag klinisch specialist worden om 
onderzoek en patiëntenzorg te kunnen combineren, maar op wel gebied? In eerste 
instantie viel Marcel terug op zijn oorspronkelijke plan, gynaecologie, maar het 
beviel hem niet zo goed om als enige beginnende assistent-gynaecoloog te werken 
temidden van een massa ervaren collega’s. 
Toen kwam een relatief onbekend specialisme op zijn pad: modern, met veel nieuwe 
ontwikkelingen en talloze onontgonnen gebieden, waarin patiëntenzorg, techniek en 
onderzoek bij elkaar komen: nucleaire geneeskunde. Als eerste onderdeel van de 
opleiding nucleaire geneeskunde heeft Marcel het afgelopen jaar met veel plezier 
gewerkt op de afdeling Interne Geneeskunde van het Slingeland Ziekenhuis. Sinds 1 
april 2007 werkt Marcel in het UMC St Radboud op de afdeling Nucleaire 
Geneeskunde, voor het vervolg van de opleiding. 
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